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ABSTRACT
During the 20th century many clinical tests have been developed for the assessment of
digestive function or diagnosis of gastrointestinal disease. Many of these tests are
based on the analysis of faeces, which is readily available and for which the only
obvious disadvantage is aesthetic.
Reliable, reproduceable tests depend on the biological stability of the substance during
passage through the gut, and unfortuneately pancreatic and intestinal proteases in gut
contents destroy many proteins in faeces which otherwise could yield valuable
diagnostic and mechanistic information.
Recently the potential of the analysis of whole gut lavage fluid (WGLF), a clear
effluent obtained following routine bowel preparation with a polyethylene glycol based
isotonic solution, has been recognised, and has already been shown to be of value in
assessing protein loss in inflammatory bowel disease. The fluid can be processed
rapidly, to prevent proteolytic degradation enabling its use for accurate protein
measurements for protein loss determination and research in gut immune function.
Furthermore such analyses can be readily standardised since they are not confounded
by biological variables such as diet or transit time which would limit their value.
The object of this thesis is to investigate the value of analysis of WGLF hi the
asessment of gastrointestinal pathology, specifically in the measurement of blood and
protein loss from the gut.
The method for haemoglobin measurement was selected on the basis of a need for
sensitivity and the need to detect metabolites of haemoglobin as well as the parent
molecule. The measurement ofhaemoglobin in WGLF has been assessed in a series of
patients with clinical conditions known to result in anaemia and which may be related
to blood loss from the gut.
in
The relationship between the subjective assessment of inflammatory bowel disease
activity and the measurement ofWGLF proteins arising by leakage from plasma has
been examined with a view to establishing more objective activity indices.
The specificity of WGLF protein measurements for the diagnosis of active
inflammatory bowel disease has been assessed in a large group of patients with a
variety of gastrointestinal pathologies.
Gut clearance measurements of plasma proteins and haemoglobin have been
undertaken to evaluate quantitative protein and blood loss in normal and pathological
groups.
Many workers have used alpha-1-antitrypsin in faeces as an indicator of inflammatory
bowel disease, and different molecular weight forms have been described. The
molecular weight of alpha-1-antitrypsin hi WGLF has been investigated in controls
and patients with inflammatory bowel disease.
Flyaluronic acid , a structural glycoprotein found in the submucosa of the intestine has
been determined hi WGLF in control and patient groups in an attempt to find a direct
index of tissue disruption during active disease process in the gut.
This work has been supported by a grant from the Scotish Hospital Endownments
Research Trust and has been carried out while I have been employed by the Lothian
Health Board as a Clinical Scientist at the Gastrointestinal Laboratory. The research
has been compatible with my normal duties in the area of the development of novel
tests for the investigation ofgastrointestinal diseases.
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A wide range of functional tests are available for use in clinical gastroenterology
which have been well validated and yield valuable information. Many of these tests are
based on the analysis of faeces which can reveal:
a. residues of dietary substances or other molecules used to test absorption
b. endogenous substances normally found in the gut lumen eg enzymes
c. various materials which may exude or leak into the gut from blood or tissues, in
inflammatory or malignant disease.
d. labelled substances given systemically and which have leaked into the gut lumen as
a result of disease.
Practical issues of sampling are important. Although quantitative, timed collections
are ideal, in practice one or more random aliquots are used for routine diagnostic use
and screening. Reliable, reproducible tests depend on the biological stability of the
substance during passage through the gut, and unfortunately, pancreatic, intestinal
and bacterial proteases in gut contents destroy many proteins in faeces which
otherwise could yield valuable diagnostic and mechanistic information.
During the last seven years, our research group has developed and exploited a whole
gut lavage method for the study of gut immunity. Whole gut lavage fluid , essentially
a gut perfusate, is the clear effluent passed per rectum after completion of bowel
cleansing, when patients or volunteers take a polyethylene glycol-based isotonic
solution. The fluid can be processed rapidly to prevent proteolytic degradation and
thus is suitable for assays of immunoglobulins and other proteins. A recent
publication from this department has recognised increased levels of both IgG and
albumin in patients with active inflammatory bowel disease and so it seemed likely
that measurement of protein loss from the gut using whole gut lavage fluid would be
feasible. In theory, blood loss into the gut lumen could also be studied with the same
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material. Furthermore, with a standardised clinical protocol, the confounding effects
ofvariables such as diet, faecal water content or gut transit time, could be eliminated.
The overall aim ofmy research has been to investigate the value of analysis ofWGLF
in the laboratory assessment of patients with GI diseases and symptoms,
concentrating particularly on measurements ofblood and protein loss from the gut.
Bowel preparation with isotonic polyethylene glycol leads to the rapid evacuation of
solid faecal/intestinal contents and prolonged ingestion of this fluid leads to a
potential gut perfusion situation with possible steady state characteristics. This has
been confirmed by collecting and analysing several sequential aliquots ofWGLF after
the bowel effluent has gone clear.
The method for haemoglobin measurement was selected on the basis of a need for
sensitivity and the need to detect metabolites of haemoglobin as well as the parent
molecule. Haemoglobin in WGLF has been assessed in a series of patients with
clinical conditions known to result in anaemia and which may be related to blood loss
from the gut.
The relationship between subjective assessment of inflammatory bowel disease
activity and concentrations ofWGLF proteins has been examined, with a view to the
development of objective indices of disease activity. The specificity of high WGLF
protein concentrations for active inflammatory bowel disease has been assessed.
Gut clearance of plasma proteins and haemoglobin have been calculated to document
the GI protein and blood loss in normal and pathological groups.
In an attempt to examine in more detail the nature and sources ofproteins in WGLF,
two further studies have been carried out. Since many workers have used alpha-1-
antitrypsin in faeces as an indicator of inflammatory bowel disease, and different
molecular weight forms have been described, I have studied the molecular weight of
alpha-1-antitrypsin in faeces and in WGLF in controls and patients with
inflammatory bowel disease.
Hyaluronic acid , a structural glycoprotein found in the submucosa of the intestine has
been determined in WGLF in control and patient groups in an attempt to find a direct
index oftissue disruption during active disease process in the gut.
xix
CHAPTER 1
INTRODUCTION AND REVIEW OF THE LITERATURE
BLOOD LOSS FROM THE GUT
Gastrointestinal (GI) bleeding occurs in various forms. An acute GI bleed is a
medical emergency, normally from the oesophagus, stomach or duodenum, but
occasionally colonic. Intermittent rectal bleeding, manifested by the passage of small
amounts of fresh blood per rectum, can be due to anal disease, such as haemorrhoids,
proctitis, diverticulosis, bleeding from a polyp or carcinoma of colon or rectum, and a
number of other rare causes, hi a study of 319 apparently healthy Australian war
veterans aged over 50 (Chapuis et al,1985) 15% had reported overt rectal bleeding
during the previous six months. Of this group sigmoidoscopy revealed no colorectal
cancers, and only four polyps greater than one cm. About 50% of these subjects had
haemorroids with/without other associated colonic disease. This study highlighted the
poor positive predictive value of overt bleeding (<10%) in otherwise healthy subjects
for colorectal polyps and cancer.
Occult GI bleeding is loss ofblood into the GI tract which cannot be observed by the
patient or detected by the physician on physical examination.
Occult blood loss may be suspected if a patient has an otherwise unexplained iron
deficiency, and is detected by analysis of the stool for blood by any one of a range of
techniques. The presence of occult blood is important because it may indicate
otherwise asymptomatic GI neoplasia, or another GI source of blood loss in the
patient with iron-deficiency anaemia. (Greegor,1967, Hardcastle et al,1989).
Both serious and apparently trivial diseases can lead to occult GI blood loss (Winawer
et al,1976, Herzog et al,1982, Simon 1988) and studies of the subject are confounded
by methodological limitations ofthe commonly available laboratory techniques.
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Normal Physiological Blood Loss
About 0.3 - 1.3 ml of blood is normally lost into the GI tract daily (Cameron 1960,
Herzog et al,1982). The precise source ofthe bleeding is not known.
Increased physiological blood loss has been reported in several situations. Pasteurised
cows milk fed to infants significantly increased faecal haemoglobin whilst formulae
feeds had no effect (Zeigler et al,1990). It is not known whether this is a toxic effect
or due to local damage associated with an immune response, although the fact that
milk feeds modified for infants do not seem to have this effect, suggests that it is
probably not immunological.
Blood loss has been reported in long distance runners and may be severe enough to
produce anaemia. 10-20% of marathon runners may have positive faecal occult tests
after a marathon (Fischer et al,1986, Stewart et al,1984). The mechanism of increased
physiologic blood loss is unknown, but it has been speculated to involve mesenteric
ischaemia. In some high performance runners, gastric and colonic erosions have been
identified and these improve with abstinence from running.
Physiologic blood loss does not appear to increase with anticoagulant therapy when
prothrombin time is controlled at normal therapeutic levels (Jaffin et al, 1987). When
faecal occult blood is detected in asymptomatic outpatients receiving anticoagulant
therapy with sodium warfarin in a normal therapeutic range, a pathologic explanation
for the occult blood is usually identified. This is not the case for patients with a
markedly elevated prothrombin time, in whom frank or occult bleeding may occur
without detectable pathology.
Iron Deficiency and Hypochromic Anaemias
Iron deficiency anaemia due to occult GI bleeding must be distinguished from
hypochromic microcytic anaemias due to bleeding from sites other than the GI tract,
iron malabsorption, or inadequate iron ingestion.
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Anaemias with similar morphologic abnormalities of red blood cells may be found
secondary to chronic disease.
Thalassemia and sideroblastic anaemia should also be excluded. These can usually be
distinguished from iron deficiency anaemia by the presence of Prussian-blue stainable
iron in the bone marrow or by measurement of total iron, transferrin and ferritin in the
serum.
Measurement of faecal occult blood (FOB)
1. Qualitative chromogenic testsfor FOB
Occult GI bleeding may be detected by a positive FOB test. A variety of simple
qualitative FOB tests have been used. Gum guaiac, benzidine, and o-tolidine were
used in the 19th and early 20th century by Dutch and German scientists as indicators
ofGI bleeding in simple colorimetric tests. Other chromogenic tests for haemoglobin
were based on the use of ferrocyanide, 3-aminophthalic acid hydrazide, pyramidon,
aloin, phenolphthalein and other chromogens. Each of these chemical tests depends
on the ability of haemoglobin to oxidise a chromogen, thus producing a coloured
product. Such oxidation can be enhanced by hydrogen peroxide, catalysed by the
haematin component of haemoglobin which exhibits a pseudoperoxidase activity
(similar to other naturally occurring peroxidases and catalases). The phenolic group of
guaiac is converted to a quinone structure, which hi turn changes colour to blue by an
intermolecular reaction.
The major advantages ofthese qualitative tests for occult blood are simplicity, ease of
performance, low cost, and widespread applicability.
There have been several commercial developments of these tests such as 'Hematest'
(Ames Co, UK) which uses o-tolidine as chromogen, 'Haemoccult' (Smith Kline
Diagnostics,US) which uses guaiac as chromogen; 'Haemoccult 2', 'Fecatest'
(Finnpipette Ky), 'Fecatwin' and 'Fecatwin S' ( Labsystems Corp, Finland.) are also
guaiac based tests which have been developed all with varying sensitivities.
The 'gold standard' for quantitative blood loss measurement is the ^ ^Cr-labelled red
cell test and there have been relatively few comparisons of qualitative tests with this.
(Morris et al ,1976, Hertzog et al ,1982, Macrae et al,1982a, )
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The occult blood reaction is not specific for haemoglobin but is affected by
peroxidases and catalases in various foodstuffs including meat, fresh fruits and
uncooked vegetables (Macrae et al, 1982b) and pubbshed studies vary in making
allowance for this factor. When GI blood loss does not exceed two ml per day,
approximately 10% of stool samples collected from patients not on dietary restriction
will be Haemoccult positive (Stroehlein et al,1976) which is reduced to 2% on dietary
restriction (Bassett and Goulston,1980). The amount of bquid in a faecal specimen
also markedly affects the rate of test positivity for any level of haemoglobin
concentration. In bquid stool there is enhanced lysis of red cebs and dissolution of
haemoglobin (Macrae et al, 1982b).
A number of drugs can affect the FOB test peroxidase reaction. Ascorbic acid acts as
an anti-oxidant and can produce false negative tests. Aspirin and non steroidal anti¬
inflammatory agents cause GI mucosal inflammation and increased occult GI blood
loss (Scott et al,1961, Bjamsson et al,1989) and should be stopped prior to screening
for colonic neoplasia using any FOB test.
Hih and Fyflfe (1990) have highlighted the need for quality control material which
would assist competent use of such tests.
2. Immunological tests ofFOB
hi order to improve the specificity of the FOB test, techniques using immunological
recognition of faecal human haemoglobin have been developed, some of which are
available commerciahy (Heme Select, Smith Kline Diagnostics, and FECA-EIA, Lab
Systems, Finland). These immunochemical tests are exquisitely sensitive, require no
dietary restriction and can detect small amounts of blood passed into the lower
digestive tract. However they may fab to detect much larger amounts of bleeding in
the upper digestive tract because of haemoglobin degradation by proteolytic and
bacterial enzymes. In the last 10-15 years many immunological tests have been
described which measure faecal hemoglobin (Songster et al, 1980, McDonald et al,
1984; Saito et al ,1985; Uchida et al, 1990; Nagata et al, 1992), but since metabobtes
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are not measured these can at best only be considered qualitative indices ofblood loss
from the lower bowel. Most studies have shown that immunological tests are superior
to guaiac based slide tests in the identification of patients with colonic polyps or
carcinomas despite yielding more false positive tests (Robinson et al, 1994).
Turunen et al (1984) have combined Fecatwin S (guaiac test) and FECA-EIA
(immunological test), when testing for colorectal cancer only using the more
expensive immunological test on those samples which are positive for Fecatwin S.
3. Quantitative measurement offaecal occult blood
a.^lCr-labelled red cells in faeces
Chromium labelled gamma-emitting red cells were initially used by Owen et al
(1954) to measure blood loss in faeces of dogs. Subsequently these were used by
Bannerman (1957) hi humans and the radioactivity was calculated in a weighed
aliquot from a 24 hour collection. However the method is malodourous and
cumbersome, and Cameron (1960) improved sensitivity and the practicality of the
technique by using freeze dried faeces. Because of the relatively long half life of 28
days for 5' Cr, each patient can be studied for four - six weeks after red cells have
been labelled.
Experiments were carried out which showed no absorption of orally-administered Cr-
labelled red cells, and insignificant elution of Cr from red cells to plasma. In 10
healthy control subjects the average daily blood loss was 0.6 ml, with a range from
0.3 - 1.3 ml. There are obvious practical limitations in this method which requires
complete faecal collections free from contamination with urine.
b. Whole body counting of ^Fe labelled red cells
A method using whole body counting of 5^Fe labelled red cells was used by Holt et
al (1967). When plasma is labelled with 59pe, the label is taken up into red cell
haemoglobin within 7-10 days. In normal males and post menopausal women the
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whole body radioactivity will remain stable and any loss in total body radioactivity
must represent loss ofblood. A knowledge ofblood volume is required (taken as 65.6
ml/kg body weight).
The method is insensitive for blood loss of one to three ml per day but as blood loss
increases so acccuracy of detection increases. GI or menstrual bleeding may occur
erratically and lead to fluctuations in the red cell content of ^Fe and blood volume. It
is not possible to make corrections for these. The principal source of error in
measurement is caused by minor variations in the patient's counting position on
different occasions. Another disadvantage is the delay of 7-10 days while iron is
being incorporated into haemoglobin, before counting can occur. The main advantage
of this method is the ability to measure intermittent blood loss, since the long half life
of the isotope allows measurements over two to three month periods.
c. Fluorometric determination of faecal haem and metabolites
Schwartz et al (1983) described 'Hemoquanf, a fluorometric assay which measures
haem and haem-derived porphyrin. This is affected by red meat in the diet but not by
vegetable peroxidases. By detecting haem metabolites, 'Hemoquanf is more sensitive
than other tests for detecting blood loss from upper GI tract sources and since
haemoglobin metabolites are also measured a quantitative assessment of blood loss is
made. Young et al (1990) have shown that most of the haem lost into the gut lumen
enters the colon and is converted by bacteria into a range of haem-derived porphyins,
lacking iron. This conversion is a slow and incomplete process and the amount
converted in this way depends on colonic transit rate, site of bleeding and amount of
luminal haem. As a result faeces contain variable proportions of haem and haem-
derived porphyrins. Ahlquist et al (1985) have shown that faecal haemoglobin levels
are less than 2 mg / g of stool in 98% ofhealthy volunteers.
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4. Plasma markers ofblood loss
Moran et al (1993,1995) have used faecal al-AT as an indirect index of faecal occult
blood loss and have shown that this gave a more accurate diagnosis ofGI blood loss
than both guaiac based FOB and immunochemical faecal haemoglobin measurements.
Uchida et al (1990), combined immunological measurement of haemoglobin with
transferrin to improve detection ofblood loss.
Comparison between quantitative techniques of FOB
Using three different quantitative methods, Leahy et al (1991) assessed blood loss in
faeces in five patients with recurrent Fe deficiency. Whole body counting of ^Fe
was relatively insensitive to small blood losses but allowed losses to be followed up
over longer periods. In short term studies (12 day) chemical analysis of complete
stool collections for haem-derived porphyrins (Hemoquant) gave results which closely
correlated with those obtained by measuring stool loss of ^Cr labelled red blood
cells (r=0.98), although absolute values were about 10% lower for Hemoquant than
for ^ 1 Cr studies.
Intestinal absorption of haem
None of the chemical or immunological tests for blood loss make allowance for
intestinal absorption of haem, and quantitation of GI bleeding derived from
measurement ofhaem and its metabolites hi faeces is therefore likely to underestimate
the amount ofhaem delivered into the gut lumen.
Young et al (1993) have shown that recovery of the haem of ingested red cells by
Hemoquant is only 63%, compared with 100% using the ^' Cr labelled red cell
method. Schwartz et al (1985) examined faecal recovery of ingested haemoglobm
haem in blood and compared this with ingested meat and fish. The average faecal
recovery of haemoglobin haem from 10-36 ml blood was 88% (n=13). All
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Haemoccult tests remained negative despite greater than 20-fold increases in faecal
haem. Up to 83% of the blood haem was converted in the intestinal tract to
protoporphyrins. Negligible amounts of haem were found in fish and fowl and their
ingestion led to no significant increase in faecal haem. An average of 25% of the haem
from ingested meat was subsequently recovered in faeces.
Causes of occult GI bleeding
Disease of the oesophagus, stomach and duodenum is a common clinical problem and
Sequent cause of occult bleeding. The high prevalence of these conditions makes
secondary iron deficiency relatively frequent. Cook et al (1986) in a study where GI
investigations were carried out in patients with iron deficiency anaemia, demonstrated
a large number with upper GI pathology (44% of diagnoses). The majority of these
patients had ulcerative oesophagitis, gastric or duodenal erosions, or were post
gastrectomy; large hiatus hernia, gastric cancer and angiodysplasia accounted for
most of the other diagnoses.
Non steroidal anti-inflammatory agents are perhaps the most common group of drugs
used, both by prescription and over the counter, and these frequently produce
gastroduodenal mucosal erosions and ulceration, and small intestinal inflammation.
Many patients using these drugs have an increased rate of GI blood loss, which may
be clinically apparent or occult, and may result in iron deficiency anaemia. For
example approximately 70% of people taking 2.5 g aspirin per day lose 2-5 ml blood
daily into the GI tract (Ahlquist et al, 1985).
On a global scale infections that cause occult GI bleeding are very common. In the
tropics and subtropics hookworm infection is endemic. Daily faecal blood loss
averaged about 12 ml per day and correlated with worm density in the gut (Roche et
al,1966). Other chronic GI infections such as tuberculosis, amoebiasis, ascariasis, and
acute infectious gastroenteritis, may also cause occult GI bleeding.
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Vascular malformations of the GI tract can lead to occult GI blood loss (Anon, 1981,
Howard et al, 1982). Angiodysplasia occurs in 0.5-2% of adults over age 50 and
occult blood loss may be the only symptom Blood loss may also occur in the
hereditary haemorrhagic telangiectasia syndrome, 'watermelon-stomach', radiation-
induced enteritis, and uraemia associated telangiectasias (Richardson et al, 1975;
Stafford et al,1970).
All inflammatory bowel diseases including Crohn's disease, chronic ulcerative colitis,
eosinophilic gastroenteritis, Whipple's disease, and solitary colonic ulcer, can result in
occult bleeding (Guiliani et al,1961). Usually these conditions present with other
symptoms referable to the digestive tract such as diarrhoea, weight loss, abdominal
pain or fever, but bleeding, although occult, may provide valuable discriminating
clinical information.
One of the major uses ofFOB measurements is in the diagnosis of colorectal cancer.
FOB and colorectal cancer
1. Sensitivity andpredictive value using chromogenic slide tests
Since it is well established that occult bleeding may be due to a colonic carcinoma
which is otherwise asymptomatic, tests for FOB have been used in several important
screening programmes in attempts to detect colorectal cancer (Winawer et al,1976,
Gilbertson et al,1980, Knight et al,1989, Ahlquist et al, 1990).
Initially, Greegor (1967,1971) used guaiac-impregnated slides for his patients and
reported the detection of several asymptomatic neoplasms. Subsequently this slide
test has been refined and marketed as the 'Haemoccult' test, the most commonly used
FOB test. Studies have suggested that neoplasias identified by screening for faecal
occult blood are found at an early stage, which may result in a more favorable patient
prognosis (Cummings et al 1984, Gilbertson et al 1980, dayman, 1989, Ransohoflfet
al, 1991). Nevertheless there are problems in relation to this topic also. Firstly not all
colorectal tumours bleed in quantities suitable for detection by presently available
FOB tests; many other GI conditions can result in positive FOB tests, and if the
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screening test is too sensitive large numbers of expensive, unpleasant and potentially
dangerous tests may be required to exclude a diagnosis of carcinoma; finally it is not
clear to what extent premalignant tumours (polyps) actually bleed, since because
these are extremely common, their presence, even in a patient with a positive FOB
may be coincidental.
The predictive value of a positive Haemoccult test for colorectal cancer is less than
10%, usually about 5% (Ahlquist et al,1989, Barry et al ,1987). Polyps are detected in
about 20% of people with positive Haemoccult tests. The majority of positive
Haemoccult results appear to be due to technical false positives, with no evidence of
GI disease or evidence of only benign disease such as haemorrhoids (Johnston, 1989).
Fecatwin S and Fecatest tests are reported to be more sensitive than Haemoccult
(Adlercreutz et al 1978, Turunen et al 1984).
The commonly used guaiac tests have low sensitivity for detecthig bleeding from the
proximal colon as they fail to detect haem that has been degraded by bacteria to
porphyrin during intestinal transit. Thus both guaiac FOB tests and sigmoidoscopy are
biased towards the detection of distal colorectal disease.
^'Cr-labelled erythrocytes have been used by Hertzog et al (1982) and Macrae et al
(1982) to quantitate blood loss from colonic polyps and colorectal cancer
respectively. The mean faecal blood loss per day was 1.3 ml per day for polyps
compared with 0.6 ml per day in controls; the mean blood loss per day for subjects
with caecal and ascending colon cancer was nine ml per day and between 1.5 - 2 ml
for all other areas. Ahlquist et al (1985) using Hemoquant and pooling six aliquots
taken from separate sites of the same stool showed that 43/44 patients with diagnosed
colorectal cancer had faecal haemoglobin concentrations of >2 mg/g stool, median
6.2 mg/g with ulcerated tumours having higher values (median 9.4), than non-
ulcerated tumours (median 3.2). Patients with polyps <2 cm had median faecal
haemoglobin of 1.6 mg/g , and with polyps >2 cm a median faecal haemoglobin of 3
mg/g.
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In a further study records were examined from 160 patients with both a new tissue
diagnosis of colorectal adenocarcinoma and a preceding stool blood test by
Hemoquant (Alilquist et al 1990). In this group 71% had suggestive colorectal
symptoms ( recent change in bowel habit, frank rectal bleeding, abdominal pain) or
anaemia at presentation, and 29% were asymptomatic; faecal blood levels were
normal in more than 40% of both symptomatic and asymptomatic patients. Faecal
blood levels were higher in more advanced, larger and proximal tumours and before
purgation.
The authors concluded that increased faecal blood loss alone is an uncommon
manner of colorectal cancer presentation in the clinical practice setting (16%).
However cancers so detected are likely to be at an earlier pathological stage.
Both asymptomatic and symptomatic cancers were not uncommon in patients with
normal faecal blood levels.
Overall the conclusion was that despite the widespread use of faecal blood tests in
case detection, most colorectal cancers present with clinical symptoms.
2. Comparison of chromogenic slide tests with other methods in the detection of
colorectal cancer
Ahlquist et al (1993) assessed the ability of both Hemoccult and Hemoquant as
screening tests in two patient groups likely to have higher than average prevalence of
colorectal neoplasia; patients who had undergone resection of colorectal cancer and
first degree relatives of patients with colorectal cancer. Overall sensitivity of either
test for cancer detection was only 26%. Haemoccult was positive with 21% of
intraluminal recurrences, 33% of all with new primary tumours and 29% of those with
Dukes A or B cancers: Hemoquant was elevated in 24%, 28%, and 29% of these
groups respectively. Sensitivity for polyps one cm or larger was 13% for Haemoccult
and 11% by Hemoquant. In relatives, estimated sensitivity for cancer at one and three
years of follow up was 25% and 33% by Haemoccult, 29% to 43% by Hemoquant.
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More recent work using immunoassays to measure FOB have produced much better
sensitivity for detection of colonic polyps and cancer than Haemoccult (Songster et
al,1980; Turunen et al,1984; Saito et al,1985; Uchida et al,1990; Robinson et
al,1994), but some studies show that a significant number of colonic cancers do not
bleed measureably.
The principal factors limiting FOB testing for the detection of colonic
neoplasia/carcinoma are poor patient compliance in providing faecal specimens, the
observation that as many as 30% of colorectal neoplasms do not shed sufficient
amounts of blood to be detected, and the large number of evaluations that must be
performed to identify test-positive patients in order to achieve the benefits of
screening (Griffith et al, 1981).
Rationale for the use ofwhole gut lavage fluid to investigate occult blood loss
7. Factors influencingfaecal composition
The biological nature of faeces can be influenced by several physiological/pathological
factors. There is great variation in the normal daily stool output varying between 50 -
280 g per day and whole gut transit time can vary between one to seven days.
(Eastwood et al,1984). Both these factors are strongly influenced by diet. The
consistency of faeces varies to an even greater extent in pathological conditions where
the proportion ofwater can vary between 60% in constipated patients to over 90% in
patients with diarrhoea, with an even greater range of stool weights and transit times.
With such natural and pathological variation excretion ofblood would be expected to
vary considerably if random samples of faeces were being analysed and such variation
might blur differences between normal and pathological blood loss, hi addition
Rosenfield et al (1979) have reported non uniform distribution ofblood in faeces.
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2. WGL as a gutperfusion system
Whole gut lavage has been used for several years to prepare the colon for
examination (Thomas et al,1982, Di Palma et al,1984), and recent work from this
department (Sallam, Brydon and Ferguson) has confirmed earlier work by O'Mahony
et al (1990) that the clear fluid which is passed per rectum, after bowel cleansing is
complete, is gut perfusion fluid, and can be used to investigate GI pathology.
Because this procedure can be standardised with respect to perfusion rate, problems
associated with faecal sampling do not occur.
Selection ofmethod likely to be suitable for measurement of Hb in WGLF
In much of the early literature on occult blood loss relating to iron deficiency
anaemia, the presumed site of bleeding has been established radiologically or
endoscopically, but without quantitative or qualitative assessment by detection of
FOB. In a few cases, radiolabeled red cells have been used (either 51cr or ^^Fe) to
measure gut blood loss. These either required several faecal collections or patient
monitoring over several weeks; ie these are complex tests and a rapid measurement
which might contribute to early diagnosis cannot be made.
Anaemia and GI diseases which may but do not necessarily lead to blood loss may
coexist and the link between the two is often assumed without good FOB data being
available. The development of a rapid quantitative test of GI blood loss would
facilitate investigation of patients with different clinical conditions associated with
occult GI bleeding.
The guaiac and tetramethylbenzidine tests give a qualitative index of faecal blood,
depend on the pseudoperoxidase activity of intact haematin and cannot detect haem
metabolites.
Immunological tests are even more fastidious in that these require an intact
haemoglobin molecule for detection, and their extreme sensitivity increases the chance
of false positives due to minor bleeds from trivial causes. These tests perform better in
the detection of large bowel bleeding rather than more proximal bleeding.
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The fluorometric Hemoquant assay quantitates both haem and metabohtes, and
performs well for both proximal and distal bleeding.
I have investigated the measurement of haemoglobin in WGLF in order to quantify
blood loss in GI disease.
PROTEIN LOSS INTO THE GUT.
Historical background
The GI tract plays a major role in the homeostasis of plasma proteins in health and
disease. The small intestine is a major site of synthesis of serum proteins, including
certain lipoproteins, complement components and immunoglobulins In addition the
mucosal epithelium absorbs the products of protein digestion and under certain
circumstances intact plasma proteins are absorbed. For example, IgG antibodies are
transported across the GI epithelium of neonatal rats by a saturable transport process
that involves binding by enterocyte surface receptors specific for IgG (Jones et
al, 1972).
For many years it was assumed that the hypoproteinaemia in patients with GI diseases
was due to impairment ofprotein synthesis.
Welsh et al (1937), in a study of three patients with chronic ulcerative colitis made
extensive measurements of the nitrogen composition of the faeces, urine and food.
They concluded that there was normal absorption from the small bowel (faecal fat
normal), increased loss of nitrogen in the faeces, unrelated to food intake, and
decreased urinary nitrogen excretion; the metabolic disturbance had a direct relation
to disease severity. This study introduced the concept that losses of proteins are
important contributing factors in ulcerative gut diseases.
Albright et al (1949) using infused albumin showed that excess catabolism rather than
decreased synthesis resulted in reduced plasma albumin in patients with idiopathic
hypoproteinaemia.
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Evidence for the site of protein catabolism was initially provided by Citrin et al
(1957), who showed that a patient with giant hypertrophy of the gastric mucosa and
associated hypoalbuminaemia lost excessive amounts of albumin into the lumen of the
GI tract. In their experiments an oro-gastric tube was used to collect the gastric
secretions from the patient after being given intravenous (IV) iodinated albumin.
Protein-bound radioactivity was detected in the gastric juice.
However there are many practical and theoretical difficulties with this approach.
Complete retrieval of GI secretions is difficult and furthermore there is rapid
catabolism of labelled proteins in the GI lumen with reabsorption of amino acids and
the iodine label. Also both salivary glands and the gastric mucosa secrete the free
label.
In 1959, Gordon, in an attempt to avoid these problems, used IV-administered
radioiodinated polyvinylpyrrolidone (PVP). This is a synthetic polymer with a
molecular weight (MW) in the same range as that of the smaller serum proteins, is
unaffected by mammalian or bacterial enzymes and poorly absorbed from the GI tract.
Since then many other labelled molecules have been used to assess leakage of proteins
from blood into the gut, including ^ 'Cr-labelled serum proteins (Rubini and
Sheehy,1961, Waldman,1966);95Nb-labelled albumin (Jeejeeboy et al, 1968); 59pe_
labelled dextran (Anderson and Jamum,1966); and ^Cu-labelled ceruloplasmin
(Waldman et al, 1967). These have proved to be superior to ' ^ 11-PVP for the study of
protein losing enteropathy (PLE).
Tests of GI protein loss have also been of value in determining the relapse and
remission of activity of disease and in monitoring effects of therapy.
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Physiology of protein turnover
Investigation of the normal metabolism of serum proteins, especially albumin and
immunoglobulins, has led to greater understanding of the disturbances of protein
metabobsm in patients with GI disorders (Berson et al, 1953; Rothschild et al,1972).
The protein that has been most studied in this context is albumin. Albumin is
synthesised by the liver (normal rate 10-14 g/day for a 70kg man) and then delivered
into the systemic circulation. Substantial amounts of albumin are distributed in
extracellular and extravascular spaces with only 36% to 53% of the body albumin
pool in the plasma compartment.
The site of catabolism of the plasma proteins has not been determined, and the role of
the GI tract in this process is thought to be minor. Nevertheless albumin, gamma
globulins and other serum proteins have been demonstrated in the GI secretions of
normal individuals by electrophoretic and immunological techniques (Gullberg and
01hagen,1959, Holman et al,1959, and Steiniield et al,1960).
The removal of the stomach, and small and large intestine of rats resulted in only a 0 -
10% increase in the survival time of iodinated albumin (Gitlin et al,1958, Katz et al,
1961). In addition, clearance studies performed using ^ 'Cr-albumin (van Tongeren,
1966, Waldman et al, 1969) and a variety of other labelled proteins showed that only
5 - 15% of the normal turnover of albumin and gamma globulin could be accounted
for by enteric protein loss.
Pathophysiology
Many GI diseases result in protein loss into the gut and this can occur by a variety of
mechanisms. Disorders of the GI lymphatics can lead to a loss of lymph fluid into the
gut lumen and inflammation and ulceration of the gut mucosa can result in exudation
of plasma proteins. In other conditions the mechanism of loss has not been
determined. The half-life of plasma albumin, IgG, IgA, IgM and ceruloplasmin are
markedly reduced (Strober et al ,1967, Waldman et al,1967). The fraction of IV pool
of these proteins catabolised per day is the same for each protein, which indicates
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bulk loss of the serum proteins irrespective of their size, which is in contrast with the
selective loss of proteins in the nephrotic syndrome where the sieving properties of
the glomerulus are partly retained and lower MW proteins are preferentially lost.
A rate of loss of protein across the gut exceeding the body's capacity to synthesize
that protein results in PLE and hypoproteinaemia. In these circumstances protein
synthesis rates are normal or can only be increased to a maximum of twice normal as
determined indirectly using radioiodinated albumin, or directly using '^C carbonate
(Wochner et al, 1968). The synthesis of gamma globulins is usually normal and the
serum concentration is reduced in enteropathies that are not associated with an
inflammatory disease process (Strober et al,1967).
Immediately after the onset of PLE, the amount of albumin and gamma globulins lost
exceeds that synthesised and the serum levels fall until new steady states are reached
at lower levels. At these new levels the absolute quantity of the protein degraded daily
(determined from the product of the lower than normal protein pool size and the
higher than normal fraction of that pool catabolised or lost per day) again equals the
daily synthetic rate of the protein.
The reduction in serum protein concentrations varies for individual proteins. GI
protein loss has a greater effect on the serum concentration of a protein with a low
fractional catabolic rate such as IgG (6%) compared with one with a high catabolic
rate such as IgE (92%) (Waldman et al,1972).
The loss of serum components in PLE is not limited to proteins. It has been shown
that iron, calcium, copper and lipids may be lost into the GI tract. Also loss of
lymphocytes into the GI tract, causing lymphocytopenia and abnormalities of cellular
immunity, is a major feature of patients with disorders of lymphatic channels of the
bowel (Strober et al,1967, Weiden et al,1972).
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Disorders associated with protein loss in the gut
Protein loss from the gut has been demonstrated in association with a large number of
disorders affecting the GI tract.
It is not only seen in diseases restricted to the GI tract but may be observed as a
significant feature in a number of generabsed disorders. Among these are congestive
heart failure, immunodeficiency diseases, connective tissue disorders, the nephrotic
syndrome and metastatic malignancy.
Diseases associated with PLE can be broadly classified into four groups:
1. Diseases with disorders of the intestinal lymphatics eg intestinal lymphangiectasia,
Whipples disease, neoplasms involving mesenteric lymphatics, congestive heart
failure.
2. Diseases with demonstrable pathology specific to GI tract, but in which the
mechanism of loss is not known eg coeliac disease, jejunal diverticulosis, giardiasis,
megacolon, chrome pancreatitis.
3. Diseases with demonstrable pathology (generalized) but in which the mechanism of
loss is not known eg cystic fibosis, dermatitis herpeteformis, scleroderma, toxemia of
pregnancy.
4. Diseases with ulceration of a region of the mucosa of the GI tract eg Crohn's
disease (CD), ulcerative colitis (UC), carcinoma of the large bowel.
It is this last group which has been investigated predominantly hi this thesis in relation
to protein loss.
Methods of measuring protein loss
Because most proteins are degraded in the GI tract with subsequent reabsorption of
constituent amnio acids, conventional nitrogen balance techniques cannot be used to
detect protein loss. Different approaches have been used.
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1. The magnitude of loss of serum into the GI tract is estimated by measuring the
faecal excretion of the radioactive label following IV administration of radiolabeled
macromolecules.
2. GI protein loss is quantitated by determining the faecal clearance of alpha-1-
antitrypsin (al-AT), a plasma protein that is relatively resistant to catabolism by
intestinal proteases.
3. specific protein loss into the gut has been measured using jejunal and colonic closed
loop perfusion studies.
Faecal excretion of radiolabeled molecules
The ideal label for GI protein loss measurement should fulfil the following
requirements:
a. the attached label should not alter the metabolic behaviour of the protein to which
it is bound.
b. no reabsorption of the label from the GI tract should occur after catabolism of the
protein.
c. there should be no excretion of the label into the GI lumen except when protein
bound.
If these requirements are all met, the labelled macromolecule can be used to determine
the fraction of the protein pool lost into the GI tract per day.
None of the radiolabeled molecules available fulfil all of these requirements but they
do provide much useful information.
The radioiodinated serum proteins were the first widely used radioactive molecules
for the detection of GI protein loss. Following catabolism of the labelled protein,
almost all the radioactivity is excreted into the urine and none is reincoiporated into
serum proteins. The radioactivity left in the serum is determined over the next 2-3
week period. In some studies the time course of decline of protein-bound
radioactivity in the whole body was measured. This was determined by whole body
counting or cumulative subtraction of daily urinary excretion of radioactivity from the
initially injected dose.
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Iodinated proteins had their limitations, partly because there was rapid reabsorption of
the radioiodide label after metabolism of the labelled protein in the GI tract and also
because active secretion of radioiodide into the intestinal lumen occurred in the
salivary glands, gastric mucosa, and certain other GI sites.
In order to overcome the problem of reabsorption of the free label Citrin et al (1957)
eliminated this problem by using direct gastric intubation in a patient with giant rugae
who had previously received IV iodinated albumin and identified significant amounts
ofprotein bound radioiodine in gastric secretions.
To avoid the problems inherent in the use of iodinated proteins other labelled
macromolecules have been proposed, and the most widely used of these are the ^ 'Cr
labelled serum proteins, including ^ 'Cr-albumin (Waldman,1961), 5 ^Cr-transferrin,
and serum proteins labelled in vivo by the IV administration of ^^CrCl3 (Rubini and
Sheehy,1961, van Tongeren and Reichert,1966). The ^' Cr label is neither
significantly absorbed from nor secreted into the GI tract and from 93-100% of an
orally administered dose of Cr-albumin appears in subsequent faecal collections.
To use this hi a simple screening test, approximately 25 microcuries of ^'Cr-albumin
is administered intravenously, and the stools collected over the next four days, in 24
hour lots, free of urine. Following homogenisation an aliquot is counted in a gamma
counter. Results are expressed as percentage of injected dose of radioactivity excreted
in the stool in the four days. Normal subjects excrete between 0.1 and 0.7% of the
administered dose in the stool during this period, whereas patients with excessive
protein loss excrete 2 - 40% of the dose (Waldman, 1961).
A more meaningful measure of enteric protein loss can be obtained if the clearance of
^' Cr-labelled serum protein is expressed as the fraction of the plasma pool or the
volume (ml) of plasma lost into the GI tract per day. This is accomplished by relating
the faecal excretion of ^Cr to the serum radioactivity curve. These studies require
faeces to be collected on several consecutive days and processed and counted
individually. Serum samples are obtained 10 minutes after injection and daily
thereafter, and likewise counted. The volume of plasma cleared into the GI tract per
day is then determined as follows:
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ml of plasma cleared ofprotein per day = 24 hour stool counts / counts in one ml of
the serum collected one day prior to stool collection.
This value assumes a one day transit time between secretion of protein into the GI
tract and its appearance in the stool.
The mean value between three and 12 days is calculated.
Normal individuals clear the protein from 5 - 40 ml ofplasma per day (Beeken, 1967;
van Tongeren and Reichert, 1966). This is equivalent to GI clearance of 0.2 - 1.6% of
the plasma pool of protein daily. Patients with excess protein loss clear from 50 -
1800 rnl plasma, which is 2 - 60% of the intravascular pool of proteins into the GI
tract daily.
One disadvantage of ^ ^Cr-albumin is the short half life of survival compared with
iodinated albumin. This is due to elution of chromium from albumin, with subsequent
association of the label with other serum proteins, especially transferrin. This does
not preclude its use for protein loss since it is assumed that the specific activity of
protein in plasma is the same as that lost into the GI tract.
Indeed, intravenous administration of sterile ^ 'CTCI3 with 'in vivo' labelling of a
number of serum proteins, has been suggested as an alternative technique for the
detection of GI protein loss (Rubini and Sheehy, 1961; van Tongeren and
Majoor,1966). Results of clearance studies using this approach are comparable to
those using ^ 'Cr-albumin, although a higher fraction of the administered radioactivity
may be cleared by the kidney and reticuloendothelial system.
Other radiolabeled macromolecules which are not normally secreted or absorbed
from the GI tract eg ^lj.pyp (Gordon, 1959), ^Fe-dextran (Anderson and Janium,
1966), have been used hi a manner similar to Cr-labelled proteins.
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Faecal alpha-l-antitrypsin
Because of the requirement to administer radioactive macromolecules and futliermore
to collect serial faecal samples, such techniques have not been widely used to assess
GI protein loss. Also, with the exception of ^ 'C1CI3, these materials are not
commercially available.
Because of this Crossley and Elliot (1977) assessed whether an endogenous marker,
faecal alpha- 1-antitrypsin (al-AT) could be used as an alternative approach, since this
protease inhibitor is a glycoprotein which is itself resistant to degradation, and is
present in significant amounts in serum (2-5 g/1). In their initial studies they
measured the al-AT concentration in saline extracts of random freeze-dried faecal
samples following centrifugation, using commercially available radial immune
diffusion plates; samples were first freeze-dried to eliminate the possibility that
excessive water content in some faecal samples might give falsely low results. Two
children with protein-losing enteropathies had much higher faecal al-AT
concentrations and faecal/serum al-AT ratios than did healthy adults or children.
Thomas et al (1981) confirmed these findings in a large group of children.
Haeney et al (1979) using an extraction procedure with distilled water did not get a
significant correlation between faecal al-AT concentrations and faecal ^ lCr-albumin.
Quigley et al (1987) showed a significant correlation between faecal al-AT and
faecal ^'Cr-albumin, but because of considerable overlap between controls and
patients, sensitivity and specificity of the test were only 58% and 80% respectively,
which made it an unreliable measure of enteric protein loss.
About the same time Best et al (1976) in a large national cooperative disease study
developed an index of degree of illness for Crohn's Disease (CD), the Crohn's Disease
Activity Index (CDAI) which combined eight subjective and objective clinical
predictors in a simplified, multiple regression equation, to give a figure which is an
index of CD activity. This has subsequently been used as a 'gold standard' when
evaluating other predictors of inflammatory activity. Faecal al-AT has been
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compared in several studies with the CDAI to assess its value as a measure of disease
activity.
Meyers et al (1985) have evaluated faecal al-AT as an index of CD activity in 34
patients, 24 with CD and ten controls. There was a significant correlation between
disease activity and faecal al-AT concentration (r=0.65, p<0.001), although the latter
could not be used independently to measure disease activity.
Other workers have determined the intestinal clearance of al-AT. (Bernier et al,
1978; Florent et al, 1981, Quigley et al,1987)
This is expressed as ml ofplasma cleared ofal-AT into the intestinal tract per day.
Florent et al (1981) had an upper limit of normal for al-AT clearance of 13 ml/day,
and there was a highly significant relationship between this and ^' Cr-protein
clearance (r=0.96, p<0.001) although a regression slope of 0.55 indicated some
degradation ofal-AT in the intestine. Gastric secretions virtually destroy al-AT, and
this test cannot be used to measure gastric loss of serum proteins. Quigley's study
showed considerable overlap in clearance results between controls and patients with
GI and hepatic diseases.
Karbach et al (1983) showed a weak correlation between faecal al-AT clearance and
5lCr-albumin clearance in ten cases. In all cases of active CD, faecal al-AT was
raised above control values but did not correlate with activity indices.
Kapel et al (1992) have shown that faecal clearance ofal-AT is increased hi subjects
with both inactive and active CD compared with controls but the increase was not
statistically related to the grade of the disease.
Strygler et al (1990) investigated plasma clearance of al-AT hi normal subjects and
in patients with chronic diarrhoea, malabsorption, or unexplained hypoalbuminaemia.
Normal subjects were also investigated following induction of diarrhoea secondary to
intake of different laxatives. They concluded that induced diarrhoea can cause an
increase in al-AT clearance (mean 28 ml per day compared with 14 ml per day
without diarrhoea); that there is a highly significant correlation between al-AT
clearance and serum albumin; that faecal al-AT concentration is not a reliable index
of abnormal al-AT clearance.
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Fischbach et al (1987) compared faecal al-AT (concentration and clearance) and
excretion of mIndium granulocytes, another putative index of disease activity, in
assessing disease activity in chronic inflammatory bowel disease (IBD). These authors
got a wide range of overlap for faecal al-AT clearance results between active and
inactive IBD , and a poor relationship between clearance results and CDAI. There
was however good correlation between 111 indium labelled granulocyte excretion and
CDAI. The authors concluded that assessment of inflammatory activity in an
individual patient cannot be based on faecal al-AT concentration and clearance
alone, since enteric protein loss depends not only on mucosal inflammation but may
also be influenced by prior resections, compbcations such as stenosis, extent and
location of disease and other factors such as bacterial overgrowth, and secondary
intestinal lymphangiectasia.
Faecal al-AT has also been shown to be raised hi coeliac disease (Bai et al 1991).
Mean clearance ofal-AT was 45 ml per day (n=83). Matoth et al (1991) have shown
increased concentrations of faecal al-AT in children recovering from burns.
To summarise, faecal al-AT clearance is increased hi most studies in patients with
IBD, although there is some overlap with control subjects, but does not distinguish
between active and inactive disease; faecal al-AT concentration alone is less
discriminatory.
I have followed up the principles of GI protein loss studies used by others by
measuring IgG, albumin and alAT concentrations in WGLF from patients with IBD
and the association with activity indices. The specificity of these tests for patients with
active EBD has also been measured.
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GI perfusion studies
Segmental perfusion of the jejunum has been described by Rambaud et al (1981),
using a four lumen tube with a proximal occluding balloon, which allows duodenal
fluid to be aspirated and discarded and pure jejunal fluid sampled without
contamination from other proteins or proteolytic enzymes. Albumin and IgA secretion
rates were studied and extrapolating results to the total length of the jejunum the
mean jejunal clearance of albumin for the ten subjects studied was 25 ml per day.
Jonard et al (1984) have measured secretion rates of albumin, IgG, IgA, and other
proteins in a segmental perfusion study in the human jejunum and a relative coefficient
of excretion (RCE), which is jejunum to serum concentration expressed relative to
that of albumin was determined for each protein. From radioisotopic studies in two
patients the specific activity of albumin in plasma compared with jejunal fluid was
0.9 and 1.1, which indicated that 100% of albumin hi jejunal secretion was derived
from plasma. RCE values for other proteins were as follows: 1.4 for orosomucoid,
0.83 for IgG, and 0.74 for IgE. This was inversely related to the MW of these
proteins and indicated mainly passive diffusion into the jejunum from plasma.
However transferrin (1.1), a2-macroglobulin (0.77) and polymeric-IgA (218) had
RCEs exceeding the value expected from simple seepage indicating local gut
synthesis and possible active transepithelial transport. Colombel et al (1992) have
done similar studies and showed that the RCE for IgG compared with albumin was
lower (about 0.5); when patients were on elemental diets, albumin secretion increased
approximately threefold and IgG secretion about fivefold. Based on these studies
clearance of IgG from the small bowel can be predicted to be between ten and 20 ml
per day in normal subjects. The influence ofMW on secretion into the gut should be
carefully considered when using different serum proteins for clearance studies across
the healthy and inflamed gut; the RCE differential may be different or abolished in GI
disease affecting the mucosa.
Prigent-Dedlecourt et al (1995) using a segmental perfusion technique have perfused
the colon in ten normal subjects and have studied secretion rates of immunoglobulins
and plasma proteins from the colonic mucosa and measured RCEs for various plasma
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and secretory proteins relative to albumin. The RCE for IgG was 1.17, with
intracolonic clearance of albumin extrapolated to 24 hours of 3.4 ml per day, and IgG
of four ml per day.
I have discussed protein loss and clearance in WGLF, in relation to previous
clearance and perfusion studies.
Faecal al-AT molecular weight heterogeneity
Mizon et al (1988) applied sodium dodecyl sulphate - polyacrylamide gel
electrophoresis and immunoblotting to analyse al-AT from healthy subjects and
patients with CD. A component with MW 38 kiloDaltons (kD) was identified in
normal faecal extracts as well as in six pathological samples, hi these cases the CDAI
was 170 (SEM 47). In contrast al-AT ofMW 51 kD was detected in faecal extracts
from eight patients with active CD (CDAI 287, SEM 39)
Mizon et al (1991) have sequenced the N-terminal end of the 38 kD molecular form
of al-AT, and have shown that it differs from the native plasma form by the loss of
17 N-terminal amino acids; carbohydrate analysis of this form demonstrated a total
lack of neutral sugars; in contrast the 51 kD form of al-AT is glycosylated and can
be differentiated by virtue of its reactivity with concanavilin A; furthermore analysis of
25 faecal extracts from patients with CD demonstrated that the presence of the
glycosylated form of al-AT was closely related to the degree of inflammation; the
authors interpretation of these findings was that in active CD there is inhibition of the
hydrolytic activity of some glycosidases.
I have extended this work by investigating al-AT MW and (3-galactosidase in faeces
and WGLF of patients with CD and UC.
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Hyaluronic acid
The lamina propria is characterised by a high concentration of hyaluronic acid (HA)
which is an essential component of extracellular matrix (Laurent, 1987, Gerdin et
al, 1991). The concentration of HA in intestinal lymph is much higher than in serum
and this suggests that there is local synthesis of HA in the intestinal mucosa and
considerable turnover of the intestinal HA pool (Tengblad et al,1986). HA can be
observed in the perfusate from isolated jejunal segments of healthy individuals
(Knutson et al,1989). The recovery is higher in the perfusate from isolated perfused
jejunal segments in patients with CD than in controls (Ahrnsted et al,1992, Colombel
et al, 1989).
Colombel et al (1992) using a segmental perfusion technique have studied the effect
of intrajejunal elemental diet perfusion on the jejunal secretion of immunoglobulins,
albumin, and HA in man, with albumin and immunoglobulin secretion increasing and
HA being unaffected. The increased secretion rate was thought to be caused by
hyperemia associated with the presence ofnutrients in the gut lumen.
I have measured HA in WGLF from normal subjects and patients with GI disease as




BLOOD LOSS IN GASTROINTESTINAL DISEASE
SELECTION OF METHOD TO MEASURE GI BLOOD LOSS INWGLF
For the current investigations the faecal 'Hemoquant' method of Schwartz et al
(1983) has been adapted to measure blood loss in WGLF; this measures GI blood loss
from any level of the gut ; using WGLF removes the main disadvantage of red meat
haem and the variable amount of faeces per day which may contribute to the
unreliability of faecal haemoglobin (Fib) concentrations for FOB detection.
Other methods for measuring FOB have been discussed in the thesis introduction.
WGLF haemoglobin by 'Hemoquant'
See chapter 2 appendix for full description ofmethod.
The changes from the method as described by Schwartz et al (1983) are as follows:
1. the use of 0.1 ml WGLF as sample for assay instead of 8 mg faeces.
2. adjustment of concentration of oxalic acid reagent constituents to give same final
concentration after addition of 0.4 ml to 0.1 ml WGLF as in method described by
Schwartz et al (1983).
3. the use of 600 nM instead of 650 nM as the emission wavelength.
Validation of technique for WGLF Haemoglobin measurement
1. Sensitivity of the method
Schwartz et al (1983) quote sensitivity for faecal method to <0.01 mg/g using an 8
mg sample of faeces, ie a detection limit of<0.1 ug per sample.
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Assuming that the instrument used here is of equivalent detection ability/stability the
sensitivity level should be similar ie <0.1 ug per sample or <1.0 ug/ml for a 0.1 ml
sample.
2. Analytical Precision
Coefficients of variation for results witlrin and outwith the reference range are less
than 10% (between batch variation).
For WGLF Fib of 3 ug/ml, coefficient ofvariation is 6.3 (n=29)
For WGLF Hb of 27 ug/ml coefficient ofvariation is 7.2 (n=29)
3. Use of 600 nm rather than 650 nm as emission wavelength
650 run was used by Schwartz et al (1983) as the emission wavelength, but from their
published work it was apparent that there was also a strong emission peak at about
600 nm.
Van den Berg (1988, 1989) using two simpler variations of this assay, where the
faeces are extracted in isopropanol/ HC1 before the reaction to convert to
protoporphyrins, used the emission wavelength of 597 nm and 599 nm.
(Measurement at 650 nm would have required the installation of a red filter in the
fluorimeter for my work).
600 nm appeared to have further advantages in that chlorophyll which is a possible
interferent in the assay in faeces while being strongly measured at 650 nm is not
measured at 600 nm.
625 nm is the peak wavelength at pH 4, and was used by Schwartz et al (1983) in an
F1PLC comparison with their assay at 650 nm. Their comparison using 150 different
faecal samples gave a correlation coefficient of 0.97.
To further validate the use of 600 11m rather than 650 nm, 40 samples were analysed
after the second extraction (ethyl acctatc/butanol) using an emission wavclenghth of
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625 run and also measured using the 'Hemoquant' procedure using 600 run as the
emission wavelength.
The results gave a correlation coefficient of 0.99, with the mean at 600 nm (7.9) being
slightly higher than the mean at 625 nm (7.6).
The method of van den Berg et al is simpler than the original description of
Schwartz in that it involves fewer liquid/liquid extractions, and heating at only 60°C .
This method was attempted for WGLF haemoglobin analysis omitting the initial
isopropanol/HCl extraction step and directly treating 50 ul WGLF with acetic acid (1
ml) and ferrous sulphate/FlCl reagent (50 ul). However results were unsatisfactory
and the method was not pursued.
4. Recovery of haemoglobin when added as red cells to WGLF (Table 2.1)
50 ul ofwhole blood of known haemoglobin value (Haematology quality control) was
added to 10 ml of three patient WGLF samples which were assayed after freezing
overnight at -70°C, and centrifuging.
Blood haemoglobin concentration was 123 g/1.
5. Recovery of disodium protoporphyrin when added to WGLF (Table 2.2)
Haemoglobin has a MW of 67000, with four haem groups each equivalent to a
porphyrin.
Disodium protoporphyrin has a MW of 606.6, and each porphyrin has an MW
equivalent of 562.6 mg
Therefore an I lb standard of 67 ug/ml is equivalent to 2.25 ug/ml protoporphyrin.
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About 40 mg disodium protoporphyrin (Sigma Cliem Co Ltd, UK) were weighed out
dissolved in 10 ml 6M HC1 and made up to 100 ml with distilled water to give a stock
solution of about 400 ug/ml.
The molar extinction coefficient ofprotopoiphyrin at 407 nm is 275 x 10A
Dilute stock solution x 200 and read OD
OD at 407 run = 0.883, ie stock solution is 0.642 rnrn/1 or 361 ug/ml protoporphyrin
Take 1.0 ml stock solution and dilute to 10 ml with distilled water to give a working
standard of 36 ug/ml
0.1ml WGLF samples from 2 patients were assayed with and without addition of
0.01 ml 36 ug/ml protopoiphyrin in duplicate and recoveries determined.
6. Linearity of Assay
50 pi of red cells were added to 5 ml WGLF solution and haemolysed by freezing
overnight at -70°C. After centrifugation at 1500g in a Mistral 3000i centrifuge the
supernatant was double diluted x8 with lavage fluid and the samples assayed as for
WGLF.
readings were as follows:
•9999, 9500, 4620, 2450, I 150, 620, 300, 150, 70
The first standard (>9999) was diluted x5, and gave a reading of 4100 (20500 when
collecting for dilution). This standard has not been included on the dilution curve
(Figure 2.1)
The correlation coefficient was 0.999.
The assay is linear up to full range ie 990 pg/ml, with dilutions required beyond this.
Calculation of blood loss
The blood loss was calculated as clearance of blood from whole blood into the gut in
ml per day.
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WGLF Hb (ug/ml) x 28.8 / Blood Hb concentration (g/1)
Tliis assumes a perfusion rate of20 ml/min = 28.8 1 per day.
Reference range for WGLF haemoglobin
Assays were performed in WGLF from 22 healthy volunteers and 58 patients with
simple constipation or trivial, functional GI symptoms.
Values for WGLF Fib ranged from 0-9 ug/ml The 95% percentile range was 1-5
ug/ml. This has been set as the reference range.
This is equivalent to blood loss of0.2 - 1 ml blood per day.
These results are shown in Figure 2.2
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ANAEMIA AND GI BLOOD LOSS IN PATIENTSWITH IBD
Introduction
EBD of small intestine and colon is associated with anaemia.
The anaemia ofCD was recognised when the condition was first described (Crohn et
al, 1932) and has been described and investigated by many groups since then. For
example anaemia was shown to occur in 79% males and 54% females with
exacerbation ofCD (Dyer et al, 1972).
Since it was established that erythrocytes were often hypochromic, iron deficiency
was considered an important cause. This could be due to low iron in the diet, blood
loss from the gut, or malabsorption of iron; in addition iron uptake by activated
macrophages and inhibition of bone marrow haematopoeisis in response to a chronic
inflammatory condition may contribute.
Also macrocytic anaemia occurs due to malabsorption of folate and vitamin B12.
Anaemia has been described in UC for many years. Garvin and Bargen (1937) in a
series of 100 cases found a mean blood haemoglobin of 11 lg /l. Subsequently many
authors have investigated anaemia in UC. Ormerod et al (1967) have shown, in
common with other series, that the anaemia is mainly due to iron deficiency.
The technique of whole gut lavage now makes it possible to measure the role of any
occult GI blood loss as a factor in the anaemia of IBD patients.
I have assayed Hb and IgG in WGLF in patients with both inactive and active CD
and UC to assess blood loss on the one hand and disease activity (objectively) on the
other. Hie use of IgG to assess disease activity is described in chapter 3. Results have
been compared with blood Ub to assess to what extent the presence of anaemia is
related to blood loss on the one hand and inflammatory disease activity on the other.
Patients receiving iron supplements or who had a macrocytic anaemia as assessed by
MCV >98(fl) were excluded from this study.
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Patients
93 patients with CD (49 males, 44 females) and 43 patients with UC (19 males, 24
females) were investigated prospectively over two years. 58 had active CD, and 26
had active UC as assessed byWGLF IgG > lOug/ml.
Blood Hb, and WGLF IgG and Hb were measured in all patients and GI blood loss
calculated from blood and WGLF Hb measurements.
Reproduceability of the assay was assessed indirectly by examining results ofWGLF
Hb measurements in pairs of samples which had been collected from 40 patients or
healthy volunteers in the course of other research projects, or as part of their routine
clinical care, including ten pairs of specimens from patients with active IBD before
and after initiation of treatment.
Results
28/58 patients with active CD and 11/26 patients with active UC had blood Hb
below the accepted reference ranges for males and females (<130 and <115 g/1
respectively). See Table 2.3 .
GI blood loss results are shown in Figure 2.3.
21/58 patients with active CD and 6/26 with active UC had GI blood loss within
reference range (<1.0 ml/day).
The median GI blood loss per day in patients with active CD was 1.5(0 - 12.8) nil
per day and was significantly less than patients with active UC, median 4.4(0.3 - 36)
ml per day (p<0.005).




There were significant differences between active and inactive disease groups for
both blood Hb and GI blood loss (p<0.05, and p<0.0005 respectively).
However 6/35 patients with inactive CD were anaemic (low Hb) and 7/35 had GI
blood loss, although in all cases this was less than 2 ml per day.
For patients with active disease:
There was a significant correlation between blood loss and WGLF IgG (r = 0.34,
p<0.01); see Figure 2.4a.
There was no significant correlation between blood Hb and WGLF IgG (r=-0.19,p=
0.15), or between blood Hb and blood loss (r=-0.19, p=0.16).
There was a weak significant relationship between blood Hb and blood loss in females
(n=22) p<0.05, but not in males; see Figure 2.5b.
UC patients
There was a significant difference between GI blood loss hi patients with active and
inactive disease (p<0.0001), but no significant difference between blood Hb levels
(p=0.053).
3/17 patients with inactive UC were anaemic and 2/17 had GI blood loss (2 and 4
ml/day).
For patients with active disease:
There was a significant relationship between blood loss and WGLF IgG (r = 0.54,
p<0.005); see Figure 2.4b.
There was a weak significant correlation between WGLF IgG and blood Hb (r = -
0.40, p<0.05); See Figure 2.5a.
There was no significant relationship between blood Hb and blood loss (r = -0.05, p =
0.6).
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WGLF haemoglobin reproduceability (biological)
Thirty sets of duplicate samples were obtained from individuals with normal values
for WGLF Hb at the first test. In all cases the value for the second sample was also
normal; mean difference in duplicate values was 1.0 ug/ml (range 0-3). There were
ten pairs of specimens from patients with EBD, one sample collected at relapse and
one after a variable clinical improvement on treatment. As shown in Table 2.4,
concentrations ofWGLF Hb and IgG in WGLF paralleled disease activity; Hb
concentrations were lower in the specimen collected after treatment, but in most cases
the values were still above the reference range.
Discussion
More than 50% ofpatients with active CD and UC had no evidence of anaemia based
on blood Hb , and about 40% patients with active CD , and 20% with UC had no
evidence ofGI blood loss.
In neither group was there a significant relationship between blood Hb and blood loss,
and this was also the case when subjects with low Hb were considered separately.
This indicates that factors other than gut blood loss contribute to anaemia in patients
with active IBD.
In patients with active UC WGLF IgG correlated with both fall in blood Hb and GI
blood loss. This may indicate that inflammation causes mucosal and systemic effects
with both blood loss and decreased Hb synthesis contributing to anaemia.
Teahon and Bjarnason (1993) used faecal 111 indium labelled neutrophils and faecal
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Cr labelled red cells as indices of intestinal inflammation and blood loss, and showed
a significant relationship between intestinal inflammation and blood loss in patients
with UC (n=12) but not in patients with CD (n=15).
Their patients with UC had significantly greater blood loss (median 6.5, range 1.8 -
29.2 ml per day) than patients with CD (median 2.1, range 0.7 - 5.3 ml per day) which
is in agreement with my results.
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However whilst WGLF IgG reflects altered permeability of the gut to serum proteins,
due to tissue damage, neutrophils may be involved in the inflammatory process per se
with the parameters used by Teahon and Bjarnason measuring different stages of
active inflammation than WGLF IgG.
Others in our group have developed methods to measure luminal neutrophilia by
assay ofneutrophil elastase inWGLF and further studies of this issue are planned.
Blood loss values were greater in Teahon's study which may reflect the greater
recovery of intestinal blood using the 51Cr-labelled red cells procedure and possibly
the detection of intermittent blood loss which would be facilitated by timed faecal
collections. Also they used in-patients whereas many of our patients studied were out¬
patients and the severity of illness may have been less in our group.
In conclusion in this group of patients with active UC and CD anaemia was not
related to GI blood loss. Only in patients with active UC was there a relationship
between a fall in blood Hb and the inflammatory parameter WGLF IgG. Tlie degree
of GI blood loss correlated weakly with WGLF IgG in patients with both active CD
and UC, but blood loss was not a consistent feature of active inflammation. Factors in
addition to inflammation, such as duration of illness with resulting macrophage
uptake of plasma iron and reduced bone marrow haematopoiesis (Fuchs et al, 1991),
and poor diet may be important in causing the degree of anaemia in these patients.
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ASSESSMENT OF BLOOD LOSS BYWGLF HAEMOGLOBIN IN
PATIENTS WITH UNEXPLAINED FE-DEFICIENCY ANEMIA
Introduction
Iron deficiency anaemia may be the only clinical manifestation of ulcerative
oesophagitis, benign or malignant gastric ulcer, duodenal ulcer, vascular
malformations, large benign colonic polyps or colonic cancer. Thus it is normal
clinical practice to examine the upper and lower GI tract by radiological or
endoscopic procedures in patients with unexplained iron deficiency; high detection
rates for lesions capable of causing blood loss are reported - eg 57%, 60%, 70% in
recent series from the USA (Rockey et al,1993), Australia (Cook et al,1986) and
England (Mclntyre and Long, 1993). However accurate measurements of the amounts
of blood lost into the gut in such patients have not been performed, and so the
cause/effect relationships between the lesions detected and the anaemia remain
uncertain.
WGLF Hb has been measured in a series of patients with Fe deficiency anaemia to
assess which of the GI lesions detected are chronically bleeding.
Patients and Methods
42 patients referred to GI physicians with unexplained iron deficiency were
investigated over an 18 month period. 26 were women aged between 40 and 85
(median 66) and 16 were men aged between 43 and 86 (median 72). Entry criteria
were a low blood Hb concentration (<130 g/1 in men, <115 g/1 in women) together
with two of the following: low MCV (<76 11), low serum ferritin (<10 ug/1), low
serum iron (<14 umol/1), reticulocyte response with rise in Hb after oral iron therapy.
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Clinical Assessment
As part of the initial clinical interview and examination, as well as GI symptoms and
clinical signs, quality of diet, current or recent use of NSAUDs, aspirin or
anticoagulants were also recorded.
Upper GI endoscopy, rigid sigmoidoscopy, barium enema and/or colonoscopy were
performed on 40 patients. In two patients, when the first endoscopy examination
showed a carcinoma (one gastric, one colonic) other investigations were cancelled.
These patients have not been excluded from the series since examination of the GI
tract was completed at laparotomy. Although the planned protocol included
endoscopic duodenal biopsies for the diagnosis of coeliac disease, these were in fact
obtained from only 25 patients. Thus, as a supplementary method to rule out coeliac
disease, serum IgA class and WGLF IgM class antibodies to gliadin (AGA) were
measured by ELISA in patients who had not had a small bowel biopsy (O'mahony et
al 1991b). The four with positive results (serum AGA IgA >20, WGLF AGA
IgM>15) were recalled and jejunal biopsy performed in three. One patient declined
further tests.
Results
These are shown in Table 2.5 and Figures 2.6a and 2.6b.
Initial Hb values in the 16 men ranged from 61 - 119 g/1 (mean 90 g/1), and in the 26
women ranged from 45 - 114 g/1 (mean 85 g/1). Many patients had symptoms of
anaemia, such as tiredness, lethargy and breathlessness, but few had significant GI
symptoms.
One woman developed dysphagia while being investigated; five patients reported
dyspepsia, three heartburn, one constipation and two diarrhoea.
There were ten patients whose diet was clearly deficient in iron containing foods ( as
judged at clinical interview; formal dietary assessment was not performed.) Nine
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patients had been taking NSAIDs when the anaemia was diagnosed, but at the time of
their GI investigations the drugs had been withdrawn from eight of the nine. Four
patients had been on long term anticoagulant therapy, which had been discontinued in
one case; there was a further patient with a bleeding diathesis due to idiopathic
thrombocytopenic purpura, and one woman with alcoholic liver disease also had
abnormal coagulation.
Malabsorption
Twelve patients had gastric pathology likely to lead to iron malabsorption. Of these,
seven had had a partial gastrectomy for peptic ulcer disease many years previously,
and the other five had atrophic gastritis.
There were two patients in whom it is likely that small bowel disease with
malabsorption was present. One woman, with no GI symptoms and a diet deficient in
iron, had small bowel biopsy pathology typical of coeliac disease. Coeliac disease was
probable in one other patient. She gave a history of pernicious anemia 25 years ago
and was receiving regular injections of neo-cytamen. Endoscopy had shown an
oesophageal carcinoma, and a duodenal biopsy was not taken. When EL1SA results
were found to be positive for serum and WGLF antibodies to gliadin, her old case
irotes were retrieved and examined and it emerged that she had had a macrocytic
anaemia; at clinical reassessment she was noted to be of short stature with signs of old
rickets, strongly suggestive of coeliac disease. Because of her failing health further
tests were declined.
Other GI diseases detected
Standard X-ray and endoscopic investigations produced many positive results,
including six carcinomas (Table 2.5). Indeed there were only seven patients in whom
no lesion was found; two of these had iron deficient diets, one had alcoholic liver
disease, one had previously taken NSAIDs, leaving only 3/42 patients for whom there
were completely negative findings (Fig 2.6).
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Measurement of GI blood Loss
25/42 patients with iron deficiency had values for WGLF Hb within the reference
range, and there were a further seven with marginally elevated levels (6-8 ug/ml,
calculated daily GI blood losses 1.2 - 1.7 ml per day), including two patients with
malignant disease (gastric cancer, 6 ug /ml, 1.2 ml/day, oesophageal cancer 6 ug/rnl,
1.3 ml per day). Two patients had WGLF Hb concentrations of 10 and 12 ug/ml, with
calculated blood losses of borderline clinical significance at 2 and 2.1 ml per day, and
there were only eight patients with unequivocally high values ( taken as WGLF >10
ug/ml, and blood loss > 2 ml per day) (Figure 2.7). This group included all four
patients with colon cancer (blood losses 5-132 ml per day).
Discussion
In view of the very high rates of detection of GI diseases in anaemic patients, it has
been entirely reasonable to assume that chrome blood loss from the gut is the
commonest cause of iron deficiency anaemia in men and post menopausal women
(Beveridge,1965). Lack of correlation with FOB tests has generally been attributed to
deficiencies in the guaiac based FOB methods, which are relatively insensitive and
preferentially detect blood loss from the distal GI tract. A further factor is that
bleeding may be in the form of multiple intermittent episodes, rather than a
continuous ooze.
Review of the results of WGLF Hb measurements highlights the complexity of
possible aetiologies in the 42 iron deficient patients studied. Altogether there were 73
clinical, dietary or iatrogenic factors recorded - poor diet (10), gross GI pathology
(34 in 28 patients), malabsorption (14), coagulation problems (6), and NSAID use
(9). However WGLF haemoglobin test detected only eight patients who were losing
>2 ml blood daily into the gut, including all six patients with lesions generally
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recognised to be important causes of occult bleeding four with colonic cancer, one
with diffuse gastric vascular ectasia, and one with severe, ulcerative oesophagitis.
There are several possible explanations for the findings. In some patients with low or
normal values for WGLF Hb, GI bleeding may be intermittent rather than a
continuous ooze, as discussed above. The lesion responsible for blood loss might have
healed in the interval between diagnosis of anaemia and investigation; this may well
have been the case in NSAID treated patients, eight of whom had the drugs
discontinued as soon as anaemia was recognised. However it seems likely that in
many instances, GI lesions detected by standard investigations are coincidental and
are not bleeding. In these patients, iron deficiency is due to poor diet, malabsorption,
chronic blood loss from a site other than the gut, or a combination of these (Sayer and
Long, 1993). The emphasis which has been placed on the development of better tests
for GI bleeding has led to relative neglect of these other clinically important features.
Absorption and bioavailability of dietary iron, and iron malabsorption , are partially
interrelated. Tire amount of inorganic iron which is absorbed is greatly influenced by
the nature of other foods taken at the same time (Charlton et al,1983). A much higher
proportion of haem iron than inorganic iron is absorbed (Bjorn-Rasmussen et
al,1974) and malabsorption syndromes may affect one and not the other; for example,
in coeliac disease there is malabsorption of ferrous but not haem iron (Anand et
al,1977). Optimal inorganic iron absorption requires healthy gastric and small bowel
mucosae, and so will be compromised after gastric surgery, and probably also in
patients with atrophic gastritis and hypochlorhydria. There were seven (17%) of the
patients in our series who had had a partial gastrectomy many years before. Coeliac
disease may be expressed as a single nutrient deficiency, and some form of small
bowel bioppsy should be included in the work up of all iron deficient patients. Free
iron loss into the gut in association with high rates of epithelial cell proliferation and
loss, is another potential factor in patients with coeliac disease or gastritis (Sutton et
al,1970).
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In iron deficient patients reported in recent literature, serious diseases detected vary
somewhat because of different aims of the studies, entry criteria, age and sex.
However hi all reports, a significant minority ofpatients with unexplained anaemia are
found to have completely asymptomatic colonic cancer - hi our study 9.5% of 42
patients, a good yield of potentially curable serious disease. There is no reason to
change current clinical practice, that such patients merit colorectal endoscopy or
imaging, and probably upper GI endoscopy at the same time. But in the majority who
do not have colorectal cancers, more attention needs to be given to the completion of
the diagnostic process: separate recognition of bleeding and non bleeding lesions, of
dietary iron deficiency, and of iron malabsorption due to hypochlorhydria or coeliac
disease.
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A COMPARISON OF FAECAL AND WGLF HAEMOGLOBIN
MEASUREMENTS
Introduction
WGLF has several theoretical advantages over faeces for quantitating analytes.
With regard to haemoglobin in the gut the 'Hemoquant' method quantitates both Hb
and metabolites and so bacterial degradation does not result in loss of quantitative
measurement in either faeces orWGLF.
However there is a possible dietary interference from haemoglobin and myoglobin
present in meat, which can significantly increase faecal Hb.
In addition unless daily collections of faeces are made blood loss cannot be quantified.
Since the normal stool weight can vary from 50 - 300 g/day, and since this range
widens with pathological conditions leading to diarrhoea/constipation, random stools
from such patients can only give a semi quantitative measure of blood loss and
concentrations determined may be misleading.
Furthermore it has been reported that faeces are non homogeneous and that there is
variation in constituents in the same stool sample at different sites. This can happen
when the bleeding site is the distal colon or rectum.
Subjects
Faecal samples were obtained from 70 subjects who were having the lavage
procedure. Both faecal samples and WGLF were assayed for Hb.










In a separate study faecal samples were obtained from 15 healthy laboratory
volunteers. Faecal samples were taken from three sites on the same stool from each
volunteer to determine the sample site variation in faecal haemoglobin results.
Figure 2.8 shows distribution of faecal Hb for control subjects (including patients with
IBS) and patients with IBD and colorectal cancer.
Results
Reference range for Faecal Hemoquant determined from control subjects and patients
with IBS was 0.1 - 1.8 mg/g (95 percentile range, n = 30).
The coefficient of variation (CV) of results for triplicate samples taken from a single
stool in 15 normal subjects was 18% .
There was a significant correlation between WGLF and faecal haemoglobin. ( r=0.82,
p<0.0001, Figure 2.9).
39 patients had both WGLF Fib and Faecal Hb within the reference ranges.
20 patients had both WGLF Hb and Faecal Hb outwith reference ranges.
This included patients with Ca colon (5) CD (2), UC (6), diverticulitis (2), polyp (1),
and anaemia (3).
11 patients had raised WGLF Hb (median 9, range 6 - 28) and faecal Fib within
reference range . Ofthis group 5 patients had CD, 2 had UC and 1 had colon cancer.
1 patient had WGLF Hb within the reference range with slightly raised faecal Hb.(2.5
mg/g)
Median(range) WGLF Hb = 19 (3 - 2640) ug/ml
Median(range) faecal Hb = 2.7 (0.2 - 129) mg/g
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Results for patients with either a raised WGLF or faecal Hb were further expressed as
multiples (M) of the respective upper limits of normals in order to compare the
relative sensitivities of these tests. See Figure 2.10.
The median and range ofM values for WGLF and faecal Hb were 3.7 (0.6 - 528) and
1.5 (0.1 - 72).
The M values for WGLF Fib were significantly higher than faecal Hb M values.
(p<0.01, Wilcoxon Signed Rank Test for paired data).
This indicates that the WGLF Hb test is more sensitive than random faecal Hb in the
detection ofFOB.
Discussion
Use ofWGLF samples for Hb measurement eliminates two major problems caused by
faecal samples.
1. sampling error is minimised by using a steady state perfusate (WGLF) aliquot for
analysis which can be quantified. To achieve this the rate of ingestion of gut lavage
solution must be controlled and monitored.
2. interference from dietary constituents is eliminated.
Additional knowledge of blood haemoglobin can enable quantitative measurement of
blood loss. This is important since in many cases blood haemoglobin concentration
may be low which will 'increase' calculated blood loss.
Such problems with faeces can be eliminated by making timed faecal collections over
several days, mixing and taking an aliquot; however in practise this is rarely done.
Rose et al (1989) have shown that the mean Hb concentration in faecal samples
increased from 0.65 (SD 0.42) on a meat free diet to 2.44 (SD 2.15) when consuming
250 g or more of rare red meat per day.
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This variable will increase the normal scatter of results within the reference range for
faecal Hb concentration, and hence reduce the sensitivity of the test. This influence
can be reduced by avoidance ofmeat in the diet for 3 days prior to the test.
The stool site sampling study gave a CV of 18%. Variation within samples from
normal subjects was minimal and analytical variation will contribute to this.
Several patients with active IBD had normal faecal and raised WGLF Hb; this may
have been due to dilution of Hb by the greater faecal mass which is typical of this
patient group.
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WGLF HAEMOGLOBIN IN PATIENTS WITH COLONIC POLYPS AND
COLON CANCER
Introduction
The most widespread use of faecal testing for blood is to assist in the diagnosis of
colonic cancer.
Ahlquist et al (1990) in a study of 160 patients with a new tissue diagnosis of
colorectal carcinoma (CRC) and a preceding stool blood test (Hemoquant) showed
that bleeding was a feature in otherwise symptomless CRC in 16% of cases.
However these were detected at a more favorable stage.
Faecal blood levels remained normal in about 40% of both symptomatic and
asymptomatic patients.
Symptoms were present in most cases (about 70%) of colorectal cancer prior to
diagnosis: these were changes in stool pattern, overt bleeding, melena, abdominal
pain, and weight loss.
For the entire group the median faecal blood level was only 2.7 mg/g range 0.1 - 67.
Overall sensitivity was 59% for symptomatic patients and 56% for asymptomatic
patients.
Since right sided cancers tend to bleed more than left sided ones, the combination of
faecal blood testing and flexible sigmoidoscopy appears to be complimentary and in
this series would have detected 83% of cancers. In this respect the Hemoquant test is
superior to guaiac and immunological tests which are better suited for detection of
left sided and rectal tumours.
Because of the relatively high incidence of this disease in the general population over
50, and the high parallel mortality rate (20,000 deaths in the UK annually) methods
to improve early detection are constantly being sought and evaluated.
Screening ofhigh risk populations for FOB with 'Haemocculf cards has been reported
but the poor sensitivity and specificity of this test has limited its value.
Nevertheless Mandel et al (1993) randomly assigned almost 50,000 asymptomatic
subjects aged 50 - 80 to screening annually, biennially or to an unscreened control
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group. Participants who were screened submitted six guaiac impregnated paper slides
with two smears from each of two consecutive stools. The 13 year accumulative
mortality per 1000 from colorectal cancer was 5.88 in the annually screened group
8.33 in the biennially screened group and 8.83 in the control group. The annually
screened group mortality rate was significantly lower (33%) than the control group.
Reduced mortality in the annually screened group was accompanied by increased
survival in those with CRC and a shift to detection at an earlier stage of cancer.
The guaiac based Haemoccult (Rohm Pharma, Weiterstadt, Germany) which is the
most commonly used slide test, requires approximately 5 times the average daily loss
to give a positive result - sensitivity 51 - 68% for detection of CRC; animal
haemoglobin and vegetable peroxidases interfere with this assay and can cause false
positive results; rehydration of slides although increasing sensitivity decreases
specificity for CRC detection.
'flic globin moiety of haemoglobin molecule is specifically detected by immunological
techniques which as a result are very specific for human blood and more sensitive than
guaiac based methods for CRC detection. Some of these are now commercially
available.
Robinson et al (1994) compared guaiac and immunological FOBs for population
screening for CRC and found the immunological FOB (Hemeselect) to be much more
sensitive in the detection of CRC (9/9 with positive FOBs detected) than Haemoccult
(1/9 detected).
Many groups have reported that colonic polyps and neoplasms also bleed although
the frequency of such is less than for tumours.
Ransonoff and Lang (1991) have argued that the detection of small adenomas (<1.0
cm in diameter) through FOB screening is purely by chance.
Macrae and St John (1982) showed previously that only adenomas with a diameter of
>2 cm cause faecal blood loss of >2 ml per day.
Robinson et al (1994) have shown that Hemeselect is much more sensitive in the
detection of adenomatous polyps than Haemoccult. Hemeselect detected adenomas of
<1 cm in size in 19 patients, between 1 and 2 cm in size in 22 patients and > 2 cm in 7
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patients. Corresponding figures for Haemoccult were one, six, and one. Although this
paper gives no information on carcinomas/adenomas missed on the 90% of patients
who were FOB negative by either test, it clearly indicates the insensitivity of the
Haemoccult test.
An epidemiological comparison of the prevalence of adenomas and carcinoma in
Norway (Eide,1986) calculated the annual risk of an adenoma converting to a
carcinoma to be 0.25% for all adenomas, 3% for adenomas > 1 cm, 17% for villous
adenomas, and 37% for those villous adenomas showing severe dysplasia.
Subjects
In a period of two years 530 patients have undergone whole gut lavage for colonic
washout prior to colonoscopy, barium enema, IBD assessment or other
investigations. All these patients had WGLF Hb and many had blood haemoglobin
measured to assess blood loss.
Of these, 20 were diagnosed as having colonic cancer, one had a large benign rectal
adenoma, and 20 had colonic polyps;
Results
Results are shown in Figure 2.11
1. Colorectal cancer
WGLF Hb ranged from 5 - 990 (median 31) ug/ml for patients with CRC. Only 1/20
patients had a result within the reference range (5 ug/ml).
GI blood loss in this group ranged from 1 - 133 (median 6) ml per day.




WGLF Hb ranged from 1 - 69 ug/ml (median 3) for patients with colonic polyps, with
only three patients having results outwith the reference range (6, 20, and 69 ug/ml,
blood loss 1, 4, and 12 ml/day).
One patient with a large benign rectal adenoma had a WGLF Fib of 270 ug/ml.
Discussion
The WGLF haemoglobin test for the CRC indicates a high detection rate (95%) in a
hospital population undergoing GI investigation. This is higher than has been
previously reported by some groups who claim that up to 30% of tumours do not
bleed. The median blood loss in this group of patients was 6 ml per day, and it is
possible that about 50% of these patients might be negative for guaiac based tests,
since these require a blood loss of 5 - 10 ml per day to be positive.
WGLF proteins were also raised in some patients which may have been directly
related to blood loss in some cases where this was considerable or to inflammation at
the site of the tumour.
Including the subject with the rectal adenoma only 4/21 subjects with colonic polyps
detected by colonoscopy were losing pathological concentrations of blood from the
gut. This was disappointing for a test which otherwise was very sensitive. However
most of the polyps were <1 cm in diameter and this further confirms that the majority
of colonic polyps detected are small and bleed negligibly.
The greater sensitivity of the WGLF haemoglobin test may contribute to the increase
in detection rate of colonic tumours. Further experience is required to substantiate
this.
SPECIFICITY OFWGLF HAEMOGLOBIN FOR GI BLOOD LOSS
Introduction
A series of 530 patients was investigated forWGLF Hb over a period of two years.
Results
Raised WGLF haemoglobin was found in 15 of the series of 530 patients in whom the
diagnosis was not one generally associated with blood loss. See Table 2.6
Discussion
Only 15 of 530 patients had a raised WGLF haemoglobin which was associated with
a condition normally unrelated to GI blood loss and only four of these had blood loss
greater than 2 ml per day with radiation enteritis, coeliac disease and idiopathic
diarrhoea who are being followed up in case significant pathology emerges.
The specificity of this test for GI blood loss is thus very high (>95%) when used in
this population. Exclusion of dietary interference and the variability of stool weights
may well contribute to this.
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Table 2.1
Recovery of blood haemoglobin added to WGLF







Recovery of protoporphyrin added to WGLF






protoporphyrin standard (3.6 ug/ml ) read 1105,1150 (mean 1128)
haemoglobin standard (67 ug/ml) set at 670.
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Table 2.3
Blood haemoglobin, WGLF haemoglobin , blood loss, and WGLF IgG in
patients with IBD
CD UC
ACTIVE INACTIVE ACTIVE INACTIVE
(58) (35) (26) (16)
BLOOD HB 123 138 126 134
g/1 (92-165) (97-156) (88-156) (111-169)
WGLF HB 6 3 16 3
ug/ml (0-58) (1-9) (1-151) (0-16)
BLOOD LOSSi 1.5 0.7 4.4 0.7
ml/day (0-12.8) (0.2-1.7) (0.3-36) (0-4.2)
WGLF IgG 37 3 48 4




Concentrations of IgG (reflecting disease activity) and of haemoglobin in
WGLF from a series of patients with IBD who had gut lavage performed twice
within a four week period.
IgG (ug/ml) in WGLF Hb (ug/ml) in WGLF
Relapsed Treated Relapsed Treated
CD 55 24 10 5
93 60 22 9
144 82 162 145
137 54 58 14
27 9 12 9
216 41 15 9
44 34 9 8
101 11 14 4
UC 254 102 151 25
188 2 23 4
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Table 2.5




Partial gastrectomy without gastritis 4



















Idiopathic thrombocytopenic purpura 1
Alcoholic liver disease 1
Drugs
Previously taking NSAIDs 8
Currently on NSAIDs 1
Poor diet
Iron deficient diet 10
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Table 2.6
Patients with WGLF haemoglobin >5 ug/ml having a condition not associated
with GI blood loss.
Diagnosis No WGLF haemoglobin
(ug/ml)
Constipation 2 7,9
Idiopathic Bile acid diarrhoea 3 6,6,6
Radiation enteritis 1 143
Radiation strictures 1 6
Coeliac 1 15
Idiopathic diarrhoea 8,10,32
Travellers diarrhoea 1 8
Diabetic, renal transplant 1 6
Wt loss ofunknown cause 1 6





















































INACTIVE CD ACTIVE CD INACTIVE UC ACTIVE UC
Figure 2.3
60









































































BLOOD LOSS and BLOOD HAEMOGLOBIN
in FEMALES Kith ACTIVE CD
r=-0.44, p<0.05
2 3 4 5 6
GI BLOOD LOSS (ml/day)
Figure 2.5b
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Presence of gastrointestinal diseases and other aetiological factors in 42 patients
with iron deficiency anaemia.







In 28 patients, one or more GI disease was detected by imaging or endoscopy, or both; in 10 the diet
was judged by an experienced clinician to be deficient in iron; 14 patients had diseases associated
with iron malabsorption. As shown there was significant overlap between these groups and with the
presence of other relevant factors such as use of NSAIDs or coagulation abnormality
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Distribution (within the classification of Figure 2.(5) and diagnosis for the eight



























FAECAL HAEMOGLOBIN in CONTROL SUBJECTS
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WGLF and Faecal Flaemoglobin:
Multiples outwith reference range
WGLF Faeces
M = multilples outwith reference range
Figure 2.10
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APPENDIX : CHAPTER 2
1. Protocol for whole gut lavage solution administration to patients
Introduction:
The whole gut lavage procedure is carried out using 'Kleen-Prep' or 'Golytely' which
are highly effective, commercially prepared orally administered bowel cleansing
agents which produce a consistently high quality bowel preparation when used prior
to barium enema or colonoscopy tests. Gut lavage with these preparations involves
no dietary restrictions, no net loss of fluids or electrolytes and enables a patient to be
prepared in as little as four hours in complete safety even in those patients who are
elderly, poorly hydrated or have cardiac or renal impairment.
It is well tolerated by over 90% of patients and over three million doses have now
been given worldwide.
The composition of the whole gut lavage solution is designed to maintain fluid and
electrolyte balance while rapidly cleansing the GI tract.
Since the patient has to swallow a large amount of liquid it is very important that the
composition of the solution does not deviate from the tightly specified values which
otherwise may compromise patient safety.
Pharmacology and preparation of WGL solution:
Whole gut lavage solution contains sodium chloride, sodium bicarbonate, sodium
sulphate, potassium chloride, and polyethylene glycol 3350 (see below). The sodium,
potassium, chloride and bicarbonate counteract the absorption or secretion of these
major serum electrolytes. Sulphate ions inhibit the active absorption of sodium and
chloride when substituted for the latter. This allows the electrolyte balance ofthe
patient to be undisturbed. The inert, osmotically active PEG balances the osmolality
of the solution to that ofplasma which results in no water absorption or secretion so
that patients become neither dehydrated nor overloaded with fluid. The product
comes as sachets of dry powder which are reconstituted to 1 litre with tap water.
Each sachet contains the following:






The solution has a slightly salty taste but is still acceptable to the majority ofpatients.
The palatability is improved if the solution is chilled overnight before use.
Sugar or fruit juice must not be added to the solution as this would upset the osmotic
balance.
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Administration ofWGL solution to the patient:
It is recommended that the patient may have a normal diet up to midnight before
starting the procedure at 0900 hrs.
No food or fluids should be given during the procedure.
The patient should drink one glass of solution (200 ml) every ten minutes. It is easier
for the patient to drink this quickly rather than by sipping ( half a glass every five
minutes is typical).
Initially the patient may feel full and bloated but this will pass after the first bowel
movement wliich usually occurs after about 60 minutes.
If the patient feels very uncomfortable, it may be necessaary to reduce the rate of
drinking; in extreme cases the patient may feel very nauseated and will vomit if
pressed to continue; in such cases an injection of a suitable anti-emetic such as
metocloprarnide should be considered.
The patient should continue drinking the solution until they are passing clear faecal
fluid contahiing no solid faecal matter. This usually occurs between three to four
hours after commencing drinking the solution. After the patient has ceased to drink
the lavage solution, they will pass faecal fluid several more times. Most patients will
not experience the urgency and discomfort associated with purgatives.
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APPENDIX : CHAPTER 2
Measurement of haemoglobin and metabolites in WGLF
Principle of Method
Haemoglobin is converted to fluorescing porphyrins by the removal of Fe. Total
haemoglobin is determined by reaction with heated oxalic acid:FeS04 reagent which
converts haem to porphyrin without loss of preformed porphyrins. A 3 step
purification procedure eliminates other interfering fluorescent materials which may be
present.
Specimen Requirements
l.WGLF: 2 x 1.5 ml samples of WGLF (unfiltered) are aliquoted into 2 ml
microtubes with screw lids (Sarstedt, UK). 30 pi sodium azide (2 g/100 ml distilled
water) is added as preservative, and samples stored at -70°C.
Sample storage and stability
Samples ofWGLF should be kept stored at -70^C, and analysed within 2 months.
There is no data on stability of samples beyond this time.
Instrumentation
Fluorescence is measured using the LS-5B Luminescence Spectrometer (Department
of Medicine). Switch on main power (rear of instrument, rhs). Set excitation slit
width to 15 nm (lhs), and emission slit width to 5 mn (rhs). Set excitation wavelength
to 402 mn and emission wavelength to 600 nm in the following way
a. Press low high reset simultaneously.
b. Press 402 goto EX
c. Press 600 goto EM and leave instrument for 5 minutes to stabilise.
d. Place blank sample in cell carrier (nearest the instrument) and press AUTOZERO
(light on)
e. Place standard sample in the cell carrier set value eg 1000 for 100 pg/ml standard
and press AUTOCONC (light on).
f. Repeat steps 4 and 5 to finalise calibration.
g. Test samples can now be read.
Reagents
All reagents are analar grade and obtained from Merck (BDH) unless otherwise
stated. These are stored in room 7.
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a. Oxalic Acid Reagent: 4.0 g oxalic acid (analar) is made up to a 10 ml volume with
distilled water, and dissolved in a water bath at 100°C. 0.31 g FeS04 is added to the
oxalic acid reagent which is returned to 100 C. 0.10 g uric acid and 0.11 g mannitol
are then added with mixing, final volume adjusted to 10 nil and the reagent left at
100°C for 5 minutes. The suspension is pipetted while hot in the fume cupboard. The
reagent is prepared fresh before use. Dispose of excess reagent by washing down sink
immediately after use.
b. Ethyl acetate/acetic acid 10/1 v/v. Add 50 ml glacial acetic acid to 500 ml ethyl
acetate in a fume cupboard. Mix and store in solvent cupboard. Label
coitosive/inflammable.
c. 3M Potassium Acetate (294 g/1). Dissolve 29.4 g potassium acetate (BDH GPR)
in 100 ml distilled water. Store at room temperature.
d. 3M Potassium Acetate in 1M Potassium Hydroxide (56 g/1). Dissolve 147 g
potassium acetate in about 300 ml distilled water, add 28 g potassium hydroxide
(fume cupboard), dissolve with stirring and make up to 500 ml with distilled water.
Store at room temperature. Label corrosive.
e. N-butanol (Rathburn Chemicals Ltd, Walkerburn). Store in solvent cupboard.
f. 2M H3P04/Acetic acid 9/1 v/v. Dissolve 68 ml orthophosphoric acid in 300 ml
distilled water (fume cupboard). When cool, make up to 500 ml with distilled water
and add 58 ml glacial acetic acid. Store in corrosives cupboard. Label corrosive.
g. PEG 4000 reagent: Dissolve 60 g PEG 3350, 9 g NaCl, and 0.2 g sodium azide in
1 litre of distilled water. Use to make Drabkins reagent. Do not keep any excess
reagent. Flush down sink with copious water.
h. Drabkins Reagent: (Sigma cat. no. 525-2) 6 vials.
Each vial contains 1 g sodium bicarbonate, 0.2 g potassium ferricyanide, and 0.05 g
sodium cyanide.
Take 1 vial and reconstitute to 1 litre with PEG 4000 reagent.
Store at room temperature. Label poisonous.
Standard Material
a. Cyanomethaemoglobin Standard: Dissolve 50 mg haemoglobin (Sigma - H 7379)
in 100 ml Drabkins reagent. Leave at room temperature for 15 minutes. To calculate
actual haemoglobin concentration read OD at 540 run against Drabkins reagent
(blank).
Molar extinction coefficient (540 nm) = 44.0
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Dilute x5 in Drabkins reagent to give a standard value of about 100 ug/ml. Aliquot
(0.5 ml) and store at -70°C. Label poisonous. Stable for up to 6 months.
Procedure
a.WGLF samples should be frozen at -70°C before assay to allow haemolysis of any
intact red cells. After thawing these should be centrifiiged at 2000 rpm in the Mistral
3000i (Room 1), and supernatant used for assay.
b. Add 0.4 ml ofthe oxalic acid reagent to 0.1 ml WGLF supernatant, quality control,
haemoglobin standard, and blank (golytely) in a 10 ml stoppered quickfit tube. Mix
thoroughly and heat at 100°C for 30 minutes hi a water bath. Remove stoppers and
cool for 2 minutes
c. Add 1 ml of the 3M potassium acetate reagent, followed by 3 ml ethyl
acetate/acetic acid reagent. Vortex mix for 30 seconds. This extracts the porphyrin
analytes into the upper organic phase.
d. Transfer 2 ml of the upper organic phase to a 30 ml stoppered quickfit tube and
add 0.8 ml butanol and 6.0 ml of 3M potassium acetate in 1M KOH. Mix for 30
seconds. This removes coproporphyrin and other porphrins not derived from
haemoglobin haem (contain more than 2 carboxyl groups) - extracted into the lower
alkaline aqueous phase.
e. Transfer 1 ml of the upper organic phase to a 10 ml stoppered quickfit centrifuge
tube, and add 3 ml phosphoric acid/acetic acid reagent. Mix for 30 seconds. Remove
the top layer which contains chlorlorophyll. Read the fluorescence of the lower acid
extract.
f. For instructions in use of the spectrofluorometer see Instrumentation section.
Tests readings / 10 give results in pg/ml.
g. For faecal haemoglobin, weigh out about 0.1 g faeces, and add whole gut lavage
solution to this to make the final faecal concentration 0.1 g faeces per ml lavage fluid.
Break up the faeces into a fine suspension using wooden applicators and rotaxixer.
Use 0.1 ml faecal suspension as sample and then analyse as for lavage.
spectrofluorometer readmgs / 1000 give results in mg haemoglobin per g faeces.
Interferences and Limitations
Other haem containing proteins have the potential to interfere in this assay; eg
haemoglobin,myoglobin in meat, peroxidases in vegetables, although neither of these
should cause significant interference in lavage samples; WGLF still contaminated with
faecal material, where any blood cells may be concentrated should be avoided. Faecal
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haemoglobin values can be raised by up to 1 mg/g faeces for a daily red meat intake
of 100 g, given an average stool output of 150 g. Vegetable peroxidases will cause
no significant interference taken even in large amounts. WGLF haemoglobin will be
unaffected by dietary constituents as any intestinal dietary residues will be flushed
through by the lavage solution before samples are collected.
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CHAPTER 3
PROTEIN LOSS IN GASTROINTESTINAL DISEASE
PROCEDURES DEVELOPED TO MEASURE WGLF PROTEINS
Introduction
Most previous studies of protein loss from the gut involve the measurement of
radiolabeled proteins in faeces after intravenous administration or the measurement
of faecal components which are stable during gut transit.
However the vast majority of proteins excreted in faeces have been partially or
completely degraded.
The WGL procedure allows proteins secreted into or diffusing across the gut lumen
to be obtained quickly, before significant degradation occurs and procedures which
inhibit protein degradation allow more accurate measurement of potentially labile
proteins.
Gaspari et al (1988) inhibited proteases in WGLF using gauze filtration and a two
stage centrifugation procedure in combination with addition of a series of reagents ,
and the success of this procedure was assessed using a non specific protease reagent.
This procedure was considered protracted and labour intensive and an alternative
using a one step filtration procedure has been developed.
O'Mahony et al (1990,1991a) have previously shown in preliminary studies in
patients with active inflammatory bowel disease that both IgG and albumin are raised
in WGLF, and that IgA levels decrease with time unless proteases are inhibited.
Since plasma may be a source of IgG in the gut and is almost certainly the major
source of albumin in patients with intestinal disease, both these proteins as well as al-
AT, which is known to resist proteolysis in gut contents, have been measured.
Methods have been developed to measure al-AT and albumin in WGLF which have
potential as rapid first line indices of inflammatory bowel disease.
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Depending on the site of lesion in the bowel, proteins once leaked or secreted into
WGLF may be in the gut lumen for between 5 and 120 minutes approximately before
being passed per rectum. Hence it is important to assess the biological stability of
such proteins, as this will affect the reliability of their measurement.
Development of a simple, rapid method for processing WGLF samples.
In order to protect immunoglobulins and other proteins in WGLF from degradation
by pancreatic, intestinal and bacterial proteases, Gaspari et al (1988) devised a
relatively complex and time consuming procedure involving both filtration,
centrifiigation, and reagent addition and although suitable for research into a small
number of samples it was felt that a simplified version would facilitate the procedure
and make it more suitable for wider use with the potential for increased protein
protection ifmore rapid.
As a result a single filtration stage was undertaken using Whatman GFA/A glass fibre
filter papers with a nominal cut off size of 1.6 uM which retains cells and cell debris.
Protease inhibitors and preservatives were added in the same order and
concentrations as used by Gaspari et al, and the procedure was completed within 15
minutes. Both WGLF processing procedures are described in chapter 3 appendix.
Comparison of processing procedures
In order to validate the new processing procedure WGLF samples which had been
simultaneously processed by the original and new procedures were assayed for
protease activity using a non specific protease assay (chapter 3, appendix) and WGLF
proteins. See Table 3.1 for results.
Two groups of patients were used for 1. IgG and protease inhibition and 2. albumin
and al-AT measurements since these were carried out at different stages of method
development.
There was no signigicant difference between IgG, albumin, al-AT or percent
protease inhibition when processed by either procedure - Spearmans Rank Sum Test
for paired data.
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Comparison of filtration processing procedure with protease inhibition by
addition of PMSF reagent only
The serine protease inhibitor phenyl methyl sulphonyl fluoride (PMSF) has been used
to treat aspirates of gut contents(Hohmann et al, 1983). For this reason it was
decided to compare the processing procedure as devised with the simple addition of
PMSF reagent alone to WGLF as this would further facilitate sample collection and
also collection tubes could be prepared in advance.
Ten WGLF samples were collected and processed as per normal using the filtration
procedure, and also by addition ofPMSF alone to a final concentration of 2 mmolar.
WGLF samples were also retained to which sodium azide alone was added which
provided baseline protease values.
All samples were then assayed for non-specific protease (Asacoll) activity and
chymotrypsin (chapter 3, appendix).
Results for non specific protease percent inhibition are shown hi Figure 3.1. In all
cases the full processing procedure resulted in a >95% inhibition of protease activity.
Although PMSF gave >70% inhibition in all cases the inhibition was less complete for
each sample (Spearmans Rank test p<0.001).
CT results ranged from 0.8 - 3.4 u/ml before and between 0 - 0.02 u/ml after the
different processing procedures. Inhibition of CT was similar by both procedures
(>99%)
Development of techniques for the measurement ofWGLF albumin and al-AT
Simple manual procedures based on immunoturbidimetric measurement have been
developed according to Whicher et al (1983) to measure both albumin and al-AT in
WGLF. The main advantage ofthese assays is that they can be performed in less than
1 hour.
Turbidimetry involves the measurement of fight scattering species in solution by
means of the decrease in intensity of the incident beam as it passes through the
sample. The fight has been lost due to absorption, reflection and scatter. Turbidimetric
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measurements can be made with a spectrophotometer and the signal will be a function
of several factors including monochromator wavelength, spectral band width, stray
light, cuvette path length and geometry, light source and detector stabihty.
Optimal concentrations of polyethylene glycol (PEG) 6000 and antibody, and time
course of turbidity development were determined.
PEG concentrations of 2,3 and 4% were chosen for turbidity enhancement and
turbidity development of 100 ug/ml standard ofboth albumin and al-AT fohowed for
60 minutes at 340 nM.
Calibration curves for albumin and al-AT were followed using 1-3% antibody
concentration.
For standardisation human serum was used (SPS-01, PRU, Sheffield). This was
diluted in isotonic saline containing 48 g/1 PEG 3350 and 1 g/1 sodium azide prior to
preparing standard curves for both tests.
Results
Results are presented in Figures 3.2 and 3.3. Turbidity development was complete
within two minutes using 4% PEG 6000 concentration, for both albumin and al-AT
assays, and remained constant for at least 60 minutes
2.5% concentration of antibody gave a standard cuive for both assays with antigen
excess at least twofold beyond the expected possible pathological values for the
assays.
Calibration curves for albumin and al-AT are shown in Figures 3.4a and 3.4b.
Recovery Experiments
Standard serum was added to four different WGLF samples one processed and one
unprocessed. For al-AT 0.02 ml standard serum (1.38 g/1 al-AT) was added to 0.53
ml WGLF. For albumin 0.02 rul of a 1 in 20 dilution of standard serum (42 g/1
albumin) was added to 0.53 ml WGLF. Results are shown in Table 3.2.
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Recoveries ranged from 94 - 110% for unprocessed samples and 92 - 110% for
processed samples for al-AT and 96 - 104% for unprocessed samples and 97 - 110%
for processed samples forWGLF albumin.
Comparison of al-AT by immunoturbidimetric and radial immune diffusion
methods
WGLF al-AT was measured initially using a radial immune diffusion (RID)
procedure (LC-Partigen, Behring, France), which is commonly used to measure faecal
al-AT. This has a working range of 8 - 125 ug/ml. Many of the subjects with active
IBD were found to have values within this range. Subsequently parallel
immunoturbidimetric methods were set up for both al-AT and albumin.
WGLF samples (n = 62) have been analysed by both immunoturbidimetric and RID
procedures. The standard curve for the RID procedure is shown in Figure 3.5, and the
comparison in Figure 3.6b. Methods are described hi frill in Chapter 3, appendix.
Correlation coefficient was 0.97 and slope 1.17.
Comparison of albumin by immunoturbidimetric and centrifugal analyser
immunoturbidity
WGLF samples (n = 54) have been analysed by both procedures and results presented
in Figure 3.6a. Methods are described hi full in Chapter 3, appendix. Correlation
coefficient was 0.99 and slope 1.19.
Investigation of the stability of IgG, albumin, and al-AT in WGLF
In order to determine the stability of individual proteins in WGLF patient sera (0.5
ml), was added to WGLF (50 ml) on eight occasions and samples processed
immediately and after two hours at 37°C, prior to analysis forWGLF proteins.
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Concentrations of both IgG and al-AT were not significantly different before and
after incubation. Concentrations of albumin decreased in all WGLF samples after
incubation at 37°C. See Figure 3.7. Mean decrease in WGLF albumin was 49%.
From these results it can be concluded that both IgG and al-AT leaking into the gut
lumen will be recovered fromWGLF, whilst albumin will be lost to a variable degree.
Total Protein in WGLF
The total protein found in WGLF will reflect protein secreted in biliary and pancreatic
fluid, intestinal secretions and mucus, and in disease, any protein loss across the
mucosa. Much of this protein is normally metabolised and reabsorbed as amino acids
and peptides, and so total protein in WGLF is a measure of protein movement into
the gut rather than protein loss. However this information is not available from faeces,
and may be of significance in intestinal disease.
Total protein has been measured in WGLF in patients without or with minimal GI
disease (normal or constipated) and subjects with IBD, using the Bio-Rad protein
assay (chapter 3, appendix). Results are shown in Figures 3.8a,b.
Control subjects have protein concentrations median 205, range 110 - 380 ug/ml.
Much of this will be IgA which is present in WGLF at a concentration of 50 - 200
ug/ml. Subjects with EBD have significantly higher values: CD: median 410, range
210-1300 ug/rnl (p<0.001); UC: median 925, range 430 - 1800 ug/ml (p<0.02). This
may in part reflect leakage ofplasma protein across the gut lumen.
These results should be interpreted with caution as individual proteins react differently
with the protein reagent used for this measurement. A composite human serum
standard (SPS01, Sheffield, UK) was used to calibrate this assay.
Discussion
The WGL procedure has facilitated the measurement of proteins which are released
into the gut lumen. Adequate treatment of this fluid to prevent protein metabolism is
essential to quantify proteins present. The use of a simple filtration procedure, with
subsequent addition within minutes of stabilising reagents, has facilitated tins
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procedure. The filter selected GFA/A (Whatman,UK) allows a rapid flow ofWGLF
filtrate which can then be treated with the series of inhibitors. There was no
significant difference in a series of proteins measured when processed by the Gaspari
or filtration procedures which confirmed the efficacy of protein protection, with non
specific protease inhibition being >95% for both procedures.
The action of the various reagents is as follows: Soybean trypsin inhibitor inactivates
pancreatic trypsin; PMSF inhibits serine proteases, which includes chymotrypsin and
trypsin; ethylenediamine tetraacetic acid complexes calcium which is a co-factor for
some proteases; sodium azide inhibits bacterial growth; newborn calf serum may slow
down proteolysis by acting as an alternative substrate for any remaining proteases.
The use of PMSF alone to inhibit proteolysis was shown to be less effective than
addition of all reagents. Although PMSF inhibits the major proteases of the GI tract ie
trypsin and chymotrypsin, others such as aminopeptidases, and carboxypeptidases
will remain active and the full processing procedure was considered superior and
necessary for biological recovery ofgut proteins.
The method for measuring WGLF IgG is by enzyme linked immunosorbent assay
(ELISA-Gaspari et al, 1988) and has been established in the laboratory for some time.
Albumin measurements have been measured using a micro albumin centrifugal
analyser technique in the Clinical Chemistry Department, Western General Hospital,
Edinburgh. Manual immunoturbidimetric methods for the measurement of albumin
and al-AT have been developed. Their main advantage over other analytical
procedures eg ELISA or radial immune diffusion are simplicity and speed of analysis.
Sensitivity for these tests was reasonable in the pathological range and added standard
recovered well for both assays in a series of processed and unprocessed WGLFs.
Buffone and Shulman (1985) have compared radial immune diffusion and
nephelometry for measurement of al-AT in faecal extracts with both tests giving
comparable results although the RID test was more influenced by complexing with
elastase.
The stability of both IgG and al-AT in WGLF over a two hour period without
protease inhibition was satisfactory with no significant inhibition. Albumin was less





Comparison of results for WGLF proteins and protease when samples are
processed using filtration or centrifugation procedures
No IgGug/ml Protease Albumin al-AT
%inhibition
F C F C F C F C
1 0 0 100 98 40 36 16 15
2 2 2 98 99 3 2 0 1
3 2 1 98 99 3 3 2 2
4 222 160 96 98 15 17 5 6
5 0 0 100 95 220 205 36 33
6 1 1 99 99 25 25 4 5
7 4 4 99 90 56 58 9 7
8 37 38 97 98 3 3 0 1
9 37 30 98 97
10 7 6 99 90
F = filtration, C=centrifugation.
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Table 3.2
Recovery of added al-AT
Sample WGLF al-AT WGLF al-AT %recovery
no + added standard
ug/ml ug/ml
lu 4 59 110
1 2 48 92
2u 0 48 96
2 1 55 108
3u 35 85 102
3 31 85 110
4u 7 54 93
4 6 55 98
u = unprocessed
Recovery of added albumin
Sample no WGLF albumin WGLF albumin %recovery
+ added standard
ug/ml ug/rnl
lu 120 194 103
1 95 166 97
2u 59 134 101
2 58 138 108
3u 8 87 104
3 7 91 110
4u 7 79 96
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REFERENCE VALUES AND RELATIVE SPECIFICITY FOR
ACTIVE IBD OF WGLF PROTEINS
Introduction
Normally WGLF contains only trace amounts of IgG, but in two separate groups of
ten and 44 patients with active EBD CTmahony et al (1990,1991a), found
concentrations of IgG that were significantly higher than those of controls. High
concentrations ofWGLF albumin were also found with a positive correlation between
IgG and albumin content, suggesting that these tests are measuring plasma leakage
across inflamed mucosa.
WGLF from a further series of patients have been assayed, in order to determine
reference values for WGLF protein concentrations, and to establish to what extent
abnormally high values are found in diseases other than IBD.
Subjects and Methods
Patients and volunteers
WGL was performed on 263 occasions. The indications were as bowel preparation
for barium enema, colonoscopy or colorectal surgery; as a treatment for intractable
constipation; and, in volunteer members of staff and patients, as part of a research
project on secretory antibodies to food proteins.
Analytical methods
WGLF IgG, albumin, and al-AT were measured by methods described in chapter 3
appendix.
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The data presented below relate to 70 specimens processed by the Gaspari method
and 193 by filtration. Protein results have not been corrected for dilution with
processing reagents.
Results
Reference values forWGLF proteins
The WGL procedure has been carried out in 63 individuals who were classified as
"normal". There were 20 men, age range 15-80, mean 44 years, SD 22.3; and 43
women, age range 24 - 88, mean 51 years, SD 20.0. There were seven healthy
volunteers, 19 patients with simple constipation, eleven with small benign colonic
polyps, 18 who had had minor GI symptoms, and in whom no abnormality had been
found, and eight patients with minor, non-inflammatory GI conditions. All were
taking a normal diet, and none was being treated with immunosuppressive drugs or
NSAIDs.
Values for WGLF IgG, albumin and al-AT had a skewed distribution (Figure 3.9),
which was not normalised by using transformed data. The upper and lower values
which enclose 95% of the results (Altman 1991), have been taken as the working
normal ranges and are as follows: WGLF IgG 0-10 ug/ml, albumin 0-26 ug/ml, and
a 1 -AT 0-19 ug/ml.
WGLF proteins in patients with IBD
102 WGLs were performed in patients with IBD, 71 with CD, 31 with UC,
heterogeneous with respect to disease distribution, activity and treatment.
Abnormally high concentrations ofWGLF IgG were present in 64% of these (44 CD,
21 UC); of albumin in 52% (35 CD, 19 UC); and ofal-AT in 36% (28 CD, 9 UC).
See Figure 3.10.
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WGLF proteins in patients with colorectal cancer
Apart from IBD, colorectal cancer (CRC) was the only diagnostic category for which
a substantial number of patients had abnormal results. Data was available for ten
patients, and in seven of these, one or more abnormal results was obtained.
Concentration ofWGLF IgG was high in four cases, albumin high in six and al-AT
high in two. See Figure 3.10.
WGLF proteins in other diseases
Details of the diagnoses and WGLF results in 95 patients with other conditions, are
given in Table 3.3
Small bowel disease
Only four of 29 patients with small bowel disease had a high value for one or more of
the WGLF proteins studied; unequivocally abnormal findings in two patients - a man
with lymphangiectasia and protein-losing enteropathy, and a male coeliac with
enteropathy-associated T cell lymphoma, which was extensively ulcerated, with local
perforation and an abscess cavity communicating with the gut. Two of eight patients
with idiopathic diarrhoea (ie. severe watery diarrhoea with no diagnosis reached after
investigation by a consultant gastroenterologist) had high values for al-AT (21 and
31 ug/ml).
Colorectal disease
Three of 27 patients with various non-malignant colorectal disease had high values for
WGLF protein concentrations - a young man with immunodeficiency, several auto¬
immune diseases and lymphocytic colitis, whose diarrhoea was steroid responsive, a
patient with pouchitis, and an 81-year-old woman with severe diverticulitis, local
perforation, peri-diverticular abscess and a colo-vesical fistula.
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Other diseases
WGLF protein concentrations were normal in 41 of 42 patients with various other GI
and systemic disorders, the exception being a women with lung cancer and
widespread abdominal metastases.
WGLF proteins: analytical precision (reproduceability)
The coefficient of variation for measurement of patient samples for the proteins were
as follows: (n=30)
for IgG of 12 ug/ml =13%
for albumin of 87 ug/ml = 6%
foral-AT of 12 ug/ml = 13%
Discussion
This work has confirmed a high frequency of positive results for plasma derived
proteins in IBD patients.
When cases judged to be normal are excluded, there were 98 examinations in patients
without IBD. In 15 of these, a positive result was obtained for one or more of the
assays performed. In the majority of cases, and in all those with multiple abnormal
results, the existence ofGI protein loss was in keeping with the clinical picture - one
patient with lymphangiectasia, seven with malignant colorectal tumours, two with
intra-abdominal abscesses communicating with the gut, one pouchitis and one unusual
lymphocytic colitis. The phenomenon detected by WGLF protein assays clearly can
occur in a range of clinical situations, although the majority of positive results are in
IBD patients.
Further experience continues to give the same type of results, although healthy
volunteers have reference ranges which are lower than those given by hospital
controls. One further patient with the rare condition of lymphangiectasia has since
been investigated who also shows a disproportionate increase in WGLF al-AT with
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protein values of 78 for IgG, 15 for albumin and 120 for al-AT. The mechanism for




Diagnosis Number of WGLF proteins Values in abnormal
lavages normal cases (ug/ml)
IgG albumin cd-AT
Small bowel disease
coeliac disease 4 4
bacterial overgrowth 4 4
ileal resection 3 3
Lymphangiectasia 1 - 14 36 195
Giardiasis 1 1
Idiopathic diarrhoea 15 13 1 3 21
2 5 31
Enteropathy- associated
T cell lymphoma 1 - 41 70 19
Other benign colo-rectal disease
Colonic diverticulosis 10 10
(uncomplicated)
Perforated diverticulitis 1 - 85 18 10
Eosinophilic colitis 1 1
Microscopic colitis 1 1
Ischaemic colitis 1 1
Collagenous colitis 1 1
lymphocytic colitis and 1 - 18 68 29
common variable
immuno-deficiency
radiation proctitis 3 3
(treated)
solitary rectal ulcer 2 2
rectal prolapse 1 1
Pelvic ileal reservoir 4 4




Systemic 15 14 18 48 1*
* lung cancer with large intra-abdominal metastases
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WGLF PROTEIN CONCENTRATIONS: OBJECTIVE
MEASURES OF DISEASE ACTIVITY IN IBD
Introduction
Subjective indices of IBD activity
The Crohn's Disease Activity Index (CDAI), developed by Best et al (1976) has
proved a reliable and reproduceable measure ofhealth status in patients with CD. In
theory, the CDAI is vulnerable to criticism because it is heavily weighted by
subjective factors of general well-being and abdominal pain, and investigators have
argued that the CDAI is not so much a measure of disease activity as of general
disability. Many factors apart from intestinal inflammation will contribute to the
index, including infection, obstruction, malnutrition, psychological dysfunction and
the side effects of drugs. Nevertheless, the CDAI, and similar indices for UC activity
such as the Powell-Tuck Index (PTI), developed by Powell Tuck et al (1978) are
used almost exclusively as measures of remission in clinical trials and are recognised
as standards for the assessment of any new approach to the measurement of disease
activity in IBD.
The degree of illness in a patient with IBD is not directly related to the length of
bowel grossly affected. Factors such as the severity of local inflammation and non¬
specific "disease activity" are also relevant. There is an urgent need for simple and
objective indices of these separate components of overall disability, for use in clinical
practice and research.
WGLF proteins as potential objective indices of IBD
The aims were
1. to establish whether assay ofWGLF proteins could be used as a diagnostic test for
IBD
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2. to assess to what extent concentrations of proteins in WGLF parallel the global
indices, CDAI and PTI.
3. to determine whether it is possible to grade the severity within "active" disease, or
to detect minimal abnormalities in patients with CDAI at 150 or below, or PTI at 4 or
below (i.e. classified as inactive).
4. to determine whether WGLF proteins offer any advantage over conventional
clinical tests (ESR, C-reactive protein, platelet count), or a physician's global
assessment, for the purpose of this investigation, recorded on a visual analogue scale
(VAS).
In the present prospective study, the WGL procedure has been performed on 53
occasions in 45 well characterised patients with CD or UC, and WGLF
concentrations of IgG, albumin and al-AT measured. At the same visit the CDAI or
PTI as appropriate was calculated, blood taken for measurements of ESR, platelet
count and C-reactive protem (frequently used, single indices of activity), and the
physician's global assessment was quantified by using a VAS of 0-120.
Material and methods
Subjects
This study was undertaken in collaboration with Dr C.P.Choudari who took
responsibility for the clinical descriptions, and patient evaluation and collaborated in
result interpretation.
A total of 45 patients with IBD were studied, 27 with CD (11 male, 16 female), 18
with UC (8 male, 10 female). The diagnosis and disease extent in all patients were
confirmed by histology, endoscopy and radiology. Full details are given in Table 3.4 .
The patients were classified into various sub-groups by the nature of previous
resections and current macroscopic disease. Five CD patients and one UC patient
were studied twice, and one man with UC was studied three times. In 44 of the 53
studies, WGL procedure was being performed as bowel preparation for colonoscopy
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or barium enema examination; in four cases as preparation for surgery; and in five
cases, to empty the GI tract prior to treatment with an elemental diet.
Clinical assessments
Patients completed a diary card of symptoms for the week preceding the WGL
procedure. Haematological and biochemical indices measured included haemoglobin,
platelet count, ESR, serum total protein, albumin, al-AT, C-reactive protein, and
immunoglobulins, and were carried out in the Departments of Haematology and
Clinical Chemistry, Western General Hospital, Edinburgh.
All patients were clinically assessed, and the CDAI or PTI was calculated in the
standard fashion ( chapter 3, appendix). In addition, the physician's assessment of
overall disease activity for the day of lavage was recorded on a VAS, this being
based on symptoms, signs and results of the blood tests.
WGL protocol
<7
This was carried out as previously described. The procedure was supervised by an
experienced nurse and performed either in a general in-patient ward or in the
Gastrointestinal out-patient investigation area ofthe Western General Hospital.
Results
The patients studied were heterogeneous in disease distribution, and in their previous
and current treatment. In CD, the CDAI range was from 24 to 321; 24 lavages were
in patients with CDAI of>150 (described below as having active disease) and eight in
patients with a CDAI <150 (in remission). In patients with UC, the PTI ranged from
zero to 13; 13 lavages were in patients with active disease (PTI of >4) and eight
were in patients in remission with a PTI of < or = 4.
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WGLF proteins
Values forWGLF protein concentrations in CD and UC patients were plotted against
CDAI or PTI respectively and are shown in Figures 3.11 and 3.12. These results have
not been corrected for dilution with processing reagents.
Diagnostic potential ofWGLF proteins
If WGLF protein concentrations are always high when there is overt intestinal
mucosal inflammation (on radiological or endoscopic visualisation), this would
provide a means of screening patients for the presence or absence of EBD. This issue
has been considered by analysis of the results for WGLF IgG. High values for IgG
concentration were present in only 24 of the 27 lavages performed in patients who
had unequivocal macroscopic small bowel or colonic CD, and in 13 of the 15 lavages
in patients with UC who had positive X-ray or endoscopic findings. There was also
one patient with microscopic evidence of colonic CD, no macroscopic disease but
high WGLF IgG concentration.
Further experience is clearly showing that quite extensive disease, if inactive, gives
normal values for IgG and albumin, whilst active diffuse disease which cannot readily
be seen radiologically gives raised values for these proteins especially IgG.
WGLF proteins and disease activity
a. IgG
Values for WGLF IgG concentration were normal hi nine lavages in CD patients in
this study. Seven of these were in patients in remission and one in an 18-year old man
with a borderline CDAI of 168. He had ankylosing spondylitis, and his anorexia and
high ESR shortly after right hemicolectomy for CD were thought to reflect activity of
arthritis rather than of CD. There was one patient with WGLF IgG concentration of
10 ug/ml and CDAI of 185.
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Abnormally high concentrations ofWGLF IgG were present in 23 cases, ofwhom 22
had active disease. A 13 year-old boy with perianal CD and unexplained abdominal
pain had a CDAI of 119 and WGLF IgG of20 ug/ml. During the next six months his
growth stopped and pain became worse; both problems have resolved with systemic
steroid therapy.
In 21 lavages from patients with UC, values for WGLF IgG concentration were
normal in eight cases (of whom seven were in remission) and high in 13 cases (12
with active disease). Both discrepant cases were patients who had had unequivocally
active disease two weeks before and were in the early stages of sulphasalazine or oral
corticosterioid treatment respectively.
b. Albumin
hi 32 lavages from patients with CD, values for WGLF albumin concentration were
normal in 15 cases (of whom eight were in remission, CDAI in the others ranging
from 168 - 283).
Albumin concentrations were high in 17 cases, all with active disease.
In 21 lavages from patients with UC, values for WGLF albumin concentration were
normal in 12 cases, (of whom eight were in remission), and abnormally high in nine
cases, all with active disease.
c. al-AT
hi 32 lavages from patients with CD, values for WGLF al-AT concentration were
normal in 17 cases (ofwhom seven were in remission), and were high in 15 cases (14
with active disease).
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Ill 21 lavages from patients with UC, values for WGLF al-AT concentration were
normal in 14 cases (of whom seven were in remission), and high in seven cases, (six
with active disease).
Correlation ofWGLF protein concentrations with activity indices in active and
inactive disease
Correlation co-efficients for WGLF protein concentrations against activity indices are
detailed in Table 3.5. For both CD and UC, and for all three proteins studied, there
was a highly significant positive correlation between activity index and WGLF protein
concentration, with r values ranging from 0.44 to 0.72.
Since, as shown clearly in Figure 3.11, the relationship between activity index and
WGLF proteins is not linear but biphasic, correlations were separately calculated for
cases with active and inactive disease (as defined by CDAI and PTI). Calculations
were also performed for the subsets of CD patients with active colonic and active
small bowel disease.
The results show that only in active disease were there significant correlations; that
the highest r values were found for IgG versus CDAI in active CD (r=0.82), and
particularly in the subset with active small bowel CD (r=0.97); and that in active UC,
there was good correlation between WGLF IgG concentration and the PTI (p<0.01),
with the other two proteins correlating less well with the PTI (p<0.05) In inactive
CD and UC, WGLF protein concentrations were independent of activity indices.
Conventional laboratory indices of disease activity
As described above for the purposes of this analysis, patients with CD who had a
CDAI of >150, and those with UC who had a PTI of >4, have been designated as
having active disease. The numbers of cases with abnormal and normal values for
ESR, C-reactive protein and platelet count in the active and remission groups are
given in Table 3.6. This table also includes, for comparison, numbers with normal
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and abnormal WGLF IgG, albumin and al-AT values, and the physician's overall
assessment based on a VAS.
The three blood indices were normal in most patients with inactive disease. However
these were also normal in many patients with unequivocally active disease, and this
was particularly so in the group of 13 assessments in active UC - ESR was normal in
eight cases, C-reactive protein was normal in ten and platelet count was normal in
eight.
Discussion
There have been many attempts to develop a single index of illness in IBD (Best et al,
1976, Powell-Tuck et al,1978, Harvey et al,1980, Van Hees et al,1980, Myren et al
1984, Sandler et al,1988) by combining a few clinical and/or laboratory criteria, and
claims have been made for the significance of single laboratory determinations in
some situations (Sachar et al,1986, Fegan et al,1982, Jansen et al,1976, Meyers et al,
1985).
This prospective study is based on 53 lavages in patients with CD or UC, fully
characterised with regard to anatomical distribution of disease and investigated for
various single and composite activity indices at the time of the lavage.
The study demonstrates that WGLF protein concentrations, particularly IgG,
discriminate well between active and inactive IBD; and also, within the subsets of
patients with active disease, closely parallel disease activity as defined by CDAI and
PTI. Furthermore, these sensitive tests were completely normal in most patients with
CDAI <150 and PTI <5, strongly supporting the present clinical trials practice
whereby such values are taken as successful end-points, indicating that remission has
been achieved.
However WGLF protein assays cannot be used as screening or diagnostic tests for
IBD. Although high values are found in many patients, the data in this paper clearly
show that values are normal in clinically inactive disease, even when there are
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unequivocal radiological or endoscopic features of IBD such as cobblestone ulcers
and long, string-like strictures. Nevertheless in clinical practice the assay ofWGLF
IgG is proving to be a valuable aid to diagnosis in some clinical situations eg in
patients with microscopic CD, when IBD co-exists with severe diverticular disease,
and in separating the effects of intestinal and joint disease in IBD patients with
ankylosing spondylitis.
There is abundant evidence to implicate IgG in the pathological lesions of IBD,
particularly CD - immunohistochemistry reveals an excess of IgG-containing cells,
deep in the mucosa (Harries et al, 1983, Baklien et al, 1976); isolated intestinal
mononuclear cells from IBD patients spontaneously secrete high amounts of IgG
(Rosekrans et al, 1980, MacDermott et al, 1981); and there are differences in intestinal
plasma cell IgG subclass distribution between controls, UC and CD patients
(Verspaget et aL 1988). Thus, when the presence of IgG in WGLF was first noted, it
was thought that this was probably derived from the abundant IgG cells in diseased
mucosa. However the findings of high concentrations of two plasma proteins,
albumin and al-AT, in WGLF from patients with active IBD suggests that at least
some of the IgG is plasma-derived. Furthermore, all three protein concentrations
were low in WGLF from some inactive CD patients who have extensive chronic
ulceration of the intestine (diseased tissues known to be replete in IgG cells).
It could be argued that these sensitive tests are merely measuring plasma proteins
entering the gut lumen as a result of bleeding. However, in active IBD, when
abundant amounts of the three proteins are present in WGLF, their relative
concentrations sometimes differ from those in plasma. The three proteins differ in
molecular weight, IgG 150 kD, albumin 69 kD, al-AT 54 kD, and it could be that
there is a selective increase in mucosa-to-lumen permeability in active IBD, operating
either at the level of the capillary or the epithelial basal lamina. Although there is
blood loss in some patients with active inflammatory bowel disease in the majority
increase in WGLF protein concentration is not accompanied by a corresponding
increase in WGLF haemoglobin concentration (Chapter 2).
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Jonard et al (1984) and Colombel et al (1992) have shown greater plasma to jejunum
excretion of albumin compared with IgG in normal subjects. The lower clearance of
IgG in control subjects may contribute to the greater sensitivity of this test if the
excretion differences are abolished in disease state.
It has also been considered whether analytical factors could explain the different
results for the three proteins studied, in relation to discrimination between active and
inactive disease. Although fluids are processed within minutes of collection, proteins
leaking into the gut lumen proximally will have been exposed to pancreatic and
intestinal proteases during the transit of fluid along the gut (0.5-2 hours).
Experiments have shown that at 37°C, degradation of albumin by unprocessed
WGLF is significant (loss of 50% of measured albumin in two hours), whereas IgG
and al-AT are resistant to such proteolysis. This could explain the differences in
results for IgG and albumin in active disease. The relative insensitivity ofWGLF al-
AT concentrations may be due to the low plasma levels of this protein in relation to
IgG (x4-5) and albumin (xl5 - 20).
Various scientific approaches to the measurement of disease activity in IBD have
recently been reviewed (Kett et al 1987, Singleton, 1987). Laboratory tests such as
ESR, platelet count, and acute phase proteins are useful. However these may be
normal in active TBD, particularly in UC and in small bowel CD (Table 3.6) and will
be positive in situations of active inflammation or infection without gut involvement.
Other techniques such as labelled leucocyte studies (Camilleri et al, 1989, Saverymuttu
et al, 1986, and Crama-Bohbouth et al, 1988) and measures of GI protein loss by al-
AT clearance (Florent et al, 1981, Boirivant et al, 1991, Strygler et al,1990), have
advantages and disadvantages which are discussed later in this chapter. In general,
they have been developed and applied without being subjected to prospective
evaluation against the carefully developed standard activity indices such as CDAI.
Furthermore, labelled leucocyte studies are expensive, involve exposure to radio¬
activity, and depend on complete faecal collection. The findings with these tests
relate to events in macroscopically affected gut and thus differ from GI protein loss
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which appears to measure a more diffuse phenomenon. Work recently undertaken in
our laboratory ( L. Handy and S.Ghosh) suggest that leucocyte tests measure
different aspects of the inflammatory process compared with tests ofprotein loss.
There may be problems in interpretation of isotope-based or al-AT clearance studies
if the treatment used, such as elemental diet therapy, changes intestinal transit rate or
otherwise influences defaecatory function; this could either mask or mimic changes
due to specific anti-inflammatory effects of the test treatment. Since the standard
protocol for collection of WGLF is not influeuced by concurrent dietary or
pharmacological treatment, this method should lend itself to clinical trials.
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TABLE 3.4
Clinical details of 45 patients with IBD, undergoing WGL on 53 occasions
Parts of G1 tract Number Macroscopic Number
previously resected of disease at of






























no macroscopic disease 3
recto-sigmoid 9
no macroscopic disease 1
left sided 2





WGLF proteins in patients with active and inactive IBD:
correlations with CDAI and PTI
Number of IgG Albumin al-AT
lavages
r P r P r P
CD
(CDAI)
All 32 0.72 <0.0001 0.59 <0.0001 0.44 <0.01
Active 24 0.82 <0.0001 0.55 <0.01 0.29 NS
Inactive 8 0.22 NS -0.35 NS 0.16 NS
Active colonic 8 0.78 <0.05 0.51 NS 0.47 NS
Active SI 10 0.97 <0.0001 0.55 NS 0.36 NS
UC
(PTI)
All 21 0.71 <0.0001 0.70 <0.0001 0.53 <0.02
Active 13 0.74 <0.01 0.61 <0.05 0.60 <0.05
Inactive 8 -0.32 NS -0.38 NS -0.04 NS
NS - not significant, P>0.05
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TABLE 3.6
Presence of normal or abnormal values for conventional laboratory indices of
disease activity, global assessment, WGLF IgG, albumin, and al-AT in patients
with CD and UC arbitrarily subdivided into active or inactive IBD on the basis






































































































































INTESTINAL CLEARANCE OF PROTEINS IN
INFLAMMATORY BOWEL DISEASE
Introduction
The amount of plasma-derived protein lost into the gut (protein clearance per ml of
plasma per unit time) has usually been measured using faecal loss of chromium
labelled albumin or faecal a 1-AT.
When WGL solution is taken by the patient at the rate of 200 ml every 10 minutes,
which is equivalent to 20 ml per minute or 28.8 1 per day, knowledge of both the
serum protein concentration and the corresponding WGLF concentration should
allow an estimate of clearance values (ml/day), to be determined for these proteins,
and thus provide a measure ofprotein loss.
The data presented in the previous chapter from patients with 1BD in whom the
disease activity indices, CDAI and PTI, have been determined have been
reexamined to determine clearance values for the three proteins.
Additional patients with both active and inactive CD and UC have been included in
this group and 17 healthy volunteeers have been included as a control group.
The aim was to establish whether intestinal clearance of proteins correlated better
with activity indices than the simple measure of concentration in WGLF. Clearance
values using the three WGLF proteins have been compared with published results
based on existing methods described for faecal clearance of proteins.
Subjects and methods
42 patients with CD, 27 active and 15 inactive as assessed by CDAI; 23 patients with
UC, 13 active and ten inactive assessed by PTI; 17 control subjects (normal
volunteers). Clearance of protein per ml plasma per day was calculated from the
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concentration ofprotein in WGLF (ug/ml) x 28.8 / concentration ofprotein in plasma
(g/1).
For this study protein results have been corrected for dilution with processing
reagents to give absolute clearance values.
Serum proteins were measured by immunoturbidity at the Department of Clinical
Chemistry, Western General Hospital, Edinburgh.
Results
These are presented in Tables 3.7 - 3.10.
CDAI and intestinal clearance ofproteins is shown in Figure 3.13
PTI and intestinal clearance ofproteins is shown in Figure 3.14
Clearance values for al-AT are consistently higher for all groups including controls
compared with IgG which in turn gives clearance values about twofold higher than
albumin.
For IgG and albumin there is good separation between active and inactive CD
(p<0.0001) but there is greater overlap for al-AT clearance values (p<0.05).
Clearance of albumin gave a consistently better correlation with activity indices than
WGLF albumin concentration.
There was no significant relationship between activity indices and clearance of al-
AT.
There was a significant correlation between serum albumin and WGLF albumin
clearance in CD but not in UC patients (Figure 3.15, Table 3.9).
There were significant correlations between serum albumin and WGLF IgG clearance
in both CD and UC patients. (Figure 3.16, Table 3.9).
There was a significant correlation between serum albumin and both CDAI and PTI,
which may contribute to the stronger relationship between clearance of albumin and
activity indices (Figure 3.17, Table 3.10).
There was a significant correlation between serum al-AT and CDAI in CD patients,
but not PTI in UC patients (Table 3.10).
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Discussion
In order to measure protein loss into the gut from plasma the following criteria should
be fulfilled.
1. The protein in the gut only arises from leakage from blood plasma.
2. The protein is not metabolised in the gut lumen.
3. The protein is not reabsorbed from the gut lumen.
Criteria 2 and 3 are minimised by using the WGL procedure.
IgG clearance
Jarnum and Jensen (1975) compared the faecal excretion of 13 lj labelled albumin and
labelled IgG following intravenous injection in IBD patients. The ratio of
excretion of IgG to albumin was near to unity for patients with colonic disease whilst
in patients with small bowel disease the ratio was higher and significantly more
labelled IgG was excreted, and was highest in cases with jejunal involvement. These
results may have been caused by greater metabolism of albumin with release and
reabsoiption of the labelled iodine in the more proximal cases.
In my study median (range) clearance values were as follows : for non hospital
controls 4 (3 - 9); active CD 98(6 - 501); inactive CD 13(4 - 49); active UC 140(9 -
1054); inactive UC 9(4 - 88). These results are lower for controls as judged from
clearances reported for segmental perfusion studies (Jonard et al, 1984, Colombel et
al, 1992, Prigent-Delecourt et al, 1995) but similar for IBD patients when compared
with ^lCr-albumin measurements (Quigley et al, 1987, Fishbach et aL, 1987).
Albumin clearance
The clearance of albumin fr om plasma into the GI tract has been studied by several
groups using ^Cr-albumin. Van Tongeren et al,(1966) showed that there is a
redistribution of chromium between different plasma protein fractions especially
transferrin; ie this measurement gives a value for the clearance of plasma proteins
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rather than specifically albumin ; however in practice there is little difference, while
the specific activity of the labelled proteins does not change between plasma and gut.
Various control values have been reported:
van Tongeren et al (1966): 2 - 23 (mean 13); Waldman et al (1969) 6 - 35 (mean 16);
Beeken et al (1972) up to 35 ml. These are similar to values obtained in segmental
perfusion studies where Rambaud et al (1981) found a mean albumin clearance
(jejunum) of 25 ml per day, and Prigent-Delecourt (1995) found a mean albumin
clearance (colon) of 3.7 ml per day; ie a total of about 30 ml per day.
Several groups have used this test to assess protein loss in IBD. For Beeken et al
(1972), the median (range) clearance of ^Cr-albumin in active IBD was 78(18 -
750)
From studies ofQuigley et al (1987), and Fishbach et al (1987) median clearance was
estimated to be between 100 and 200 from published graphs.
Results from this study are lower possibly due to the lability of albumin in the GI
tract; however there is good diagnostic separation between active and inactive
disease.
Median and range of clearance of albumin for non hospital controls : 5(0 - 13); active
CD : 39 (4 - 218); inactive CD : 6 (1 - 20); active UC : 69(13 - 273); inactive UC :5
(1-99).
al-AT clearance
Many groups have investigated the clearance of al-AT in faeces . Median and range
of clearances of 6(0 - 46), 3(0 - 8), and 30(0 - 150), have been reported in control
groups (Quigley et al, 1987, Bernier et al, 1978, Fishbach et al,1987), with
corresponding figures for active IBD groups being 35(4 - 890), 92(17 - 218), 50(3 -
705).
Strygler et al (1990) had an additional control group with induced osmotic diarrhoea
with a mean clearance of 28 ml per day, which was significantly higher than the
control group without diarrhoea (mean 14 ml per day).
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In the study by Fishbach et al (1987) subjects with inactive CD had a higher median
clearance 80(30 - 320) than the corresponding active group. In most other studies
inactive IBD cases are not separated from active cases or are not studied.
Quigley et al (1987) showed al-AT clearance in faeces had poor sensitivity, with
many false negatives (10/18 with raised ^ 'Cr-albumin). Furthermore they showed
that the in-patient control population had a skewed distribution which raised the
upper limit of normal, reducing sensitivity.
The clearance ofal-AT compared with ^Cr-labelled albumin had a regression slope
0.55 (Florent et al, 1981) and 0.64 (Quigley et al,1987) indicating possible different
mechanisms of clearance of these two proteins. Florent et al (1981) showed good
separation between control and IBD patients with a strong correlation between 51Cr-
albumin and faecal al-AT but did not separate active and inactive IBD patients.
In my study the results were higher compared with most other studies. Median
clearance for non hospital controls: 38 (0 - 120), active CD: 198(0 - 1730); inactive
CD: 79(11 - 324); active UC: 260(24 - 764); inactive UC: 110(18 - 292).
The influence ofWGL procedure may be similar to that of induced osmotic diarrhoea,
where the control values approximate to those for Strygler et al (mean 28, range 10 -
100 ml) with reduced likelihood of digestion and/or absorption of al-AT, or
increased leakage or exudation of al-AT because of the increase in flow of fluid
through the intestine. This effect was not evident for albumin or IgG. Geboes et al
(1982) have identified al-AT in human small intestinal epithelia using
immunofluorescence techniques in both healthy subjects and patients with CD.
Molmenti et al (1993) using immunohistochemical procedures have shown that al-
AT is expressed in human and jejunal enterocytes and is also a product of Paneth
cells, and suggest that it is possible that al-AT detected in faecal al-AT may be
derived from sloughed enterocytes. It may be that the WGL procedure, which
involves the administration of a PEG 3350, a non absorbable osmotic agent, leads to
release of this protein in some normal subjects and to a greater extent in subjects with
1BD. This would explain the higher results for the clearance in WGLF compared with
that reported for faeces. No RCE values for al-AT have been reported but the
smaller MW compared with albumin and IgG ( 54 kD compared with 65 kD and 145
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kD) may lead to higher seepage from plasma to gut lumen in normal subjects
compared with albumin and IgG.
The separation between active and inactive 1BD cases was not clear. This is similar to
other reported studies, and may indicate a different mechanism for loss/exudation of
al-AT in these patients. Alternatively interaction between al-AT and elastase may
confound interpretation of these results (James et al 1978).
Preliminary studies using a more sensitive test for measurement ofWGLF al-AT, a
modification of the ELISA technique of Michalski et al (1985), gives a similar
reference range for normal subjects which confirms the increased clearance values.
Protein clearance and activity indices
The correlations between protein clearances and activity indices in patients with
active IBD in general are similar to corresponding correlations using protein
concentrations, although the correlation for clearance of albumin is consistently
better; this probably reflects the fact that serum albumin concentrations were
decreased in some of these cases, thus increasing the clearance values. (Table 3.10,
Figure 3.15)
To enable more accurate values of clearance to be determined timed collections of
WGL fluid would be required ; a study by Sallam et al (1995) from this unit
demonstrates that WGLF output rates are very similar to intake rates; further work
measuring sequential WGL collections is in progress.
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TABLE 3.7
WGLF proteins - concentrations and clearances.
PATIENT IgG Albumin al-AT







































































number ofpatients in brackets
median (range)
concentrations and clearances corrected for processing dilution
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TABLE 3.8
Correlations between activity indices and WGLF protein clearance and











IgG Albumin al-AT IgG Albumin al-AT
CD 0.84 0.63 0.36 0.69 0.66 0.24
ACTIVE (0.001) (0.001) (ns) (0.001) (0.001) (ns)
CD 0.96 0.65 0.38 0.73 0.70 0.44
SI ACT (0.001) (0.01) (ns) (0.003) (0.005) (ns)
CD 0.85 0.59 0.42 0.68 0.63 0.22
COL ACT (0.001 (0.03) (ns) (0.01) (0.02) (ns)
UC 0.74 0.61 0.60 0.82 0.72 0.44
ACTIVE (0.004) (0.03) (0.03) (0.001) (0.005) (ns)
figures in brackets = significance (p<) levels
SI ACT = small intestinal active; COL ACT = colonic active
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TABLE 3.9
Correlation between serum albumin and VVGLF protein concentration and
clearance.
PATIENT Correlation-S.Albumin Correlation-S.Albumin
GROUP and WGLF proteins and WGLF protein clearance
IgG Albumin al- AT IgG Albumin al-AT
CD -0.45 -0.39 -0.28 -0.46 -0.45 -0.15
(0.01) (0.02) (ns) (0.002) (0.003) (ns)
UC -0.48 -0.16 -0.30 -0.57 -0.31 -0.15
(0.02) (ns) (ns) (0.005) (ns) (ns)
figures in brackets = significance (p<) levels
42 patients in CD group, 23 patients in UC group
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TABLE 3.10
Serum Albumin, IgG, and al-AT in patients with CD and UC and controls (
median and range), and correlations with activity indices
IgG Albumin al-AT
g/1 g/1 g/1
CD 10.4 38 3.0
(42) (5.2-36) (27-45) (1.8-6)
CDAI 0.12 -0.61 0.53
CORRELATION (ns) (P<0.001) (P<0.001)
UC 10.4 41 3.0
(23) (5.5-15.6) (29-47) (1.5-5.1)
PTI -0.16 -0.54 0.20
CORRELATION (ns) (P<0.001) (ns)
CONTROLS 9.8 45 3.0
(17) (6.5-14.9) (39-49) (2.2-4.0)
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APPENDIX : CHAPTER 3
1. WGLF processing (Gaspari et al, 1988)
Reagents
All reagents are analar grade and obtained from Merck (BDH) unless otherwise
stated. All working reagents are kept at 4°C unless otherwise stated.
a. Phospate buffered saline: (PBS - Sigma) 1 tablet dissolved in 200 ml distilled water
to give pH 7.2.
b. Soy bean trypsin inhibitor: (SBTI - Sigma):Dissolve 0. lg per 100 ml PBS. Solid
kept at -20° C.
c. Disodium EDTA: Add 11 g to 100 ml distilled water. Dissolve to form a saturated
solution. Store at room temperature.
d. Phenylmethylsulplionylfluoride: (PMSF - Sigma) 0.1M in 95% ethyl alcohol.
e. Sodium Azide: 2g/100 ml distilled water.
f. New Born Calf Serum: (Heat inactivated - Sigma Chem Co,UK.)
Approximately 200-400mlWGLF is collected and filtered through cheesecloth into
50 ml polypropylene centrifuge tubes. SBTI was added to each tube to a final
concentration of 10% (v/v) followed by addition of 1.0M EDTA in PBS to 5% (v/v).
Tubes were centrifuged at 550g for 10 minutes.
The supernatant was transferred into another centrifuge tube and PMSF reagent
added to a final concentration of 1 %(v/v). Tubes were then centrifuged at 2200g for
30 minutes. The supernatant was transferred to another tube and PMSF again added
at 1 % (v/v) followed by the addition of sodium azide reagent to a final concentration
of 1%. After 15 minutes , 4% v/v heat inactivated calf serum was added. Samples
were divided into aliquots and stored at -70®C until assayed.
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2. WGLF processing by filtration
1. 2 x 25 ml samples of clearWGLF are collected from the patient.
2. 10 - 15 ml is filtered into a universal container, using Whatman GF/A 12.5 cm filter
paper. 10 ml is transferred to another universal container.
3. The following reagents are added with mixing between each addition:
1 ml SBTI, 0.56 ml Na EDTA, 0.24 ml PMSF, 0.12 ml sodium azide. (Leave for 2
minutes.) 0.6 ml new born calf serum. Mix, and dispense 6 x 1.5ml aliquots into 2 ml
microtubes with screw lids (Sarstedt, UK). Samples are stored at -70 ®C.
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3. WGLF albumin and al-AT
Chemicals and Reagents
a. Anti human albumin (sheep): SAPU - code S034-205.
b. Anti human al-AT (goat):PRU Central Antiserum Procurement Unit, Sheffield,
UK.
c. Polyethylene glycol 3350 (PEG 3350-Sigma Chem Co, UK)
d. Polyethylene glycol 6000 (PEG 6000-Biochemical Grade) Merck,UK.
e. Sodium Chloride (Analar) Merck,UK.
f. Standard - Human serum SPS-01 (Protein Reference Unit, Sheffield, UK)
g.Tris(hydroxymethyl)methylamine - TRIS (Analar) : Merck,UK.
h.Tween 20 ( Polyoxyethylene sorbitan monolaurate)(Sigma,UK)
Reagents
a.PEG 6000 reagent: 40g PEG 6000, 6g TRIS, 2g TWEEN 20 , and lg sodium azide
are dissolved in 800ml distilled water, adjusted to pH 7.0 with dilute hydrochloric
acid and made up to 1 litre volume with distilled water. Store at +4^C.
b.Antibody Reagent - al-AT. Dilute anti-human al-AT 1 in 40 with filtered PEG
6000 reagent just prior to analysis. Allow reagent to come to room temperature
before using.
c.Antibody Reagent - Albumin - Dilute anti-human albumin 1 in 40 with filtered PEG
6000 reagent just prior to analysis. Allow reagent to come to room temperature
before using.
d.Standard Diluent - Dissolve 9g sodium chloride, 48g PEG 3350, and lg sodium
azide in 1 litre solution distilled water.
e. Working Standards - Dilute standard serum with standard diluent to give standards
of 0,5,10,20,50,100,and 200ug/ml.
f. Sample blank - lavage solution processed as per WGLF.
Procedure
The procedure for both assays is essentially the same using the appropriate antibody
reagent.
a. Centrifuge processed lavage samples at 1500g for 10 minutes.
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b. Bring PEG 6000 reagent and standard diluent reagents to room temperature. Filter
sufficient PEG 6000 reagent through a 0.22u filter.
c. Using a Dilugil dispenser, dilute 0.05ml standards, blank and test samples with
0.95ml PEG reagent in 2ml polystyrene tubes (LIP,UK), in duplicate.
d. Repeat as for c with antibody reagent.
e. Leave tubes for 15 minutes at room temperature and read turbidity at 340nM using
a flow through spectrophotometer (PU8610 - ATI Unicam, Cambridge, UK).
f. After blank subtraction plot standard curve and read test concentration from
calibration curves.
Note: in practice the zero standard and sample blank give same values, with no cross
reaction between antibodies used and calf serum for either assay.
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4. WGLF al-AT by radial immune diffusion
Commercial plates supplied by Behring suitable for measuring low protein
concentrations (LC-Partigen) are used. Each plate has 12 wells, 3 for standardisation
and 9 for test samples. To use the plate remove the plastic container from the
aluminium sealed container, open the plate and leave at room temperature for 5
minutes to allow any condensation in the wells to evaporate. Using a Hamiltion micro
syringe add 20ul standards and samples to the wells taking care to avoid damaging the
agar-gel layer. After loading, allow the plates to stand open for about 10 - 20 minutes,
then close them with the plastic lid and leave them standing at room temperature.
Diameters ofprecipitates should be read off after 2-3 days. For standardisation the
diameters (in mm to the nearest 0.2 mm) are squared and plotted against ccl-AT
standard concentrations.
Standard used was SPS-01 diluted in standard diluent (method 3) to give standards of
10, 50, and 125 ug/ml.
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5. WGLF Albumin immunoturbidity - centrifugal analyser
Standard curve prepared: 12.8, 25.6, 51.3, 102.5, 164, 205 mg/1
Antibody - SAPU - anti-human albumin (Sheep) - SAPU.
Dilute 1 in 37.5 with 4% PEG
Assay run on Monarch Centrifugal analyser
Sample volume 40ul
Diluent volume = 26 ul
Antibody volume = 120ul
Temperature 37®C
Delay time 5 seconds
interval time 30 seconds
no of data points 10
filter 1 = 340 nm
filter 2 = 340 nm
run time 275 seconds
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6. Protease - non specific - Azacoll
Azacoll is a dye-derivatised collagen. Proteolytic enzymes release the blue dye from
this product which can be measured at 530nm.
Reagents
a. Phosphate buffered saline (PBS-0.01M pH7.0)
b. Azacoll reagent (Sigma Chem Co, Ltd) lOmg per ml PBS
Procedure
a. Add 0.05ml WGLF to 0.05ml Azacoll supension reagent in 2 ml polystyrene tubes.
Mix and incubate at 37°C for 15 minutes .
b. Stop reaction by placing reaction tubes in iced water for 2 minutes.
c. Add 1.5 ml PBS and centrifuge at lOOOg for 5 minutes to sediment residual
substrate.
d. Transfer 1.0 ml supernatant to similar tubes and read OD at 530nm.




The inactive precursor chymotrypsinogen is secreted by the acinar cells of the
pancreas and hydrolysed by trypsin in the small intestine to the active peptidase
chymotrypsin. (CT)
CT hydrolyses peptide links in which the carboxyl group is provided by an aromatic
amino acid and the amino group of any amino acid other than aspartate or glutamine.
Measurement is by the hydrolysis of a synthetic polypeptide labelled with p-
nitroaniline. The production of the p-nitroaniline is measured kinetically in a
spectrophotometer at 405nm.
a. Solvent - Boehringer Mannheim, UK contains 0.7% lauryl trimethylammonium
chloride, 0.5M sodium chloride, and 0.1M calcium chloride
b. Substrate and control are supplied with the kit in freeze dried ampoules,
reconstituted with 2 and 1 ml water respectively.
The chromogenic substrate is succ-ala-ala-pro-phe-p-nitroanilide.
Procedure
a. Switch on the spectrophotometer, check programme parameters and allow
temperature stabilisation.


















c. Assay water to check cycle function.
d. Add 20 ulWGLF to 1 ml substrate.
e. Aspirate into spectrophotometer.
f. Repeat for control and further test samples.
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The spectrophotometer printout gives the absorbance ofthe sample, the calculated
enzyme activity for each of the two cycles and the mean activity of the two cycles in
u/ml.
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8 IgG in WGLF
Principle of Method
Immunoglobulins are absorbed by class-specific antibodies bound to the solid phase
(ELISA plate). Then an enzyme-labelled anti-globulin conjugate (alkaline
phosphatase) is added and binds to the specific immunoglobulin required.
Instrumentation
Optical densities are read on a Dynatech microplate reader MR5000.





f.This will read the plate and hold the results, enabling you to see when the
standardard has reached the desired level.
g.When Standard has reached the desired O.D.press - START
h.TEST NUMBER = Type number desired e.g. 11 for Total IgG,
i.Lastly PLATE = you can type letters or numbers or a combination of the two.
j.The plate will now be read and the results passed on to the
printer.
This assay is carried out on IMMULON 1, flat-bottomed plates (DYNATECE1, UK).
Reagents
a.Carbonate/bicarbonate coating buffer: dissolve the contents of 10 capsules
(Sigma C-3041)in 1 litre of distilled water.
b.Coating antibodies used are:
Goat anti Human IgG Affinty purified.(Sigma 1-2136) Store at +4°C.
c.Elisa wash: 0.9% saline + 0.05% Tween 20 (0.5ml Tween 20/litre of saline. Store at
+4°C.
d. Elisa diluent: 0.9% saline + 0.05% Tween 20 + 1% adult bovine serum (filter
sterilised before adding) ie 0.5ml Tween 20/litre of saline and 10ml of filtered adult
bovine serum.
e. Alkaline phosphatase conjugate: goat anti Human IgG (Sigma A-3187. Store at
+4°C.
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f. Diethanolamine liquid (Sigma, UK). Store at room temperature.
Working diethanolamine reagent:
Diethanolamine 100 ml
Magnesium chloride(MgCl26H20) 0.102 g
Sodium azide (NaN3) 0.2 g
Distilled water 800 ml
Adjust pH to 9.8 with 6N HC1, and make up to 1 litre.
Store at 4°C
g. p-nitrophenyl phosphate (Sigma 104-105 Phosphatase substrate tablets) 5
mg/tablet. One tablet used per 5 ml of diethanolamine working reagent.
Standard
1. Standard SPS 01 (Protein Reference Unit,Sheffield, UK). Store at 4°C .
The starting concentration is adjusted to 1.0 ug/ml and a further 6 doubling
dilutions are made, giving a standard range of 1000 -15.6 ng/ml.
Procedure
a. Coat plates with 1/5000 dilution of IgG coating antibody in coating buffer, and
store at 4°C overnight in a moist box.
b. After overnight incubation plates are washed x3 with Elisa wash, then inverted and
tapped upside down on tissue to drain.
All wells are then filled with Elisa diluent and incubated at 20°C to block non¬
specific binding for 1 hour.
c. While plates are blocking make all standard, sample, and QC dilutions in Elisa
diluent. Lavage samples are diluted 1/25 for the measurement of IgG, and then double
diluted.
d. After at least 1 hour ofblocking, plates are decanted and drained upside down on
tissue.
e. Plates are loaded with the desired samples, standards, etc.(volume used in all wells
is 125pl.)
f. Incubate plates overnight at 4°C. in covered, moist box.
g. Next day plates are washed with Elisa wash x3, decanted and
drained on tissue.
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h. Conjugate is added to the plates at a dilution of 1/5000 for IgG to all wells, and
the plates covered, put in a moist box and incubated for 31irs at room temperature.
i. Plates are washed x3, drained and substrate added to all wells.
j. Allow plates to stand on the bench for about 3-4 mins, by which time colour
development of top standards, high samples and QCs will occur.
k. Place plates 011 the plate shaker - checking the OD ofthe top standard, via the
manual mode on the Elisa reader.
1. When OD has reached 1.000 , the plate is ready to read. (Test 11 for total IgG)
Programs will subtract background, read all wells, draw standard curve, and perform
regression 011 the results.
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9. Total Protein - Bio-Rad Protein Assay
Introduction
This is based on the Bradford dye binding proedure (Bradford, 1976) and is a simple
colorimetric assay for measuring total protein concentration. The standard assay is
used with samples having a protein concentration between 200 and 1400 ug/ml.
The assay is based on the colour change ofCoomassie brilliant blue G-250 in
response to various concentrations ofprotein. The dye binds primarily to basic
(especially arginine) and aromatic amino acid residues.
Reagents
The dye reagent is provided as a five fold concentrate, which should be diluted 1 in 4
with distilled water and filtered prior to use in the assay.
This can be stored in a glass container for up to 2 weeks at room temperature.
Standard
SPS-01 (Protein Reference Unit, Sheffield, UK) diluted with lavage solution to give
concentrations in the range 200-1400 ug/ml.
Test samples
Whole gut lavage fluid treated with PMSF (final concentration 2mM) and sodium
azide (final concentration 200mg/l)
Assay procedure
1. Place 0.05 ml of standards and samples in polypropylene tubes, and 0.05 ml lavage
solution in blank tube.
2. Add 2.5 ml diluted dye reagent.
3.Vortex (avoid excess foaming).
4. After a period of 5 minutes to 1 hour , measure OD at 595 nM versus reagent
blank.
5. Plot OD at 595nM versus concentration of standards (see Figure 3.8a).
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10. Development of Crohn's Disease Activity Index
This was undertaken by the National Cooperative Crohn's Disease Study group
(USA) in 1970. This group contained gastroenterologists from 13 universities or
university affiliated medical centres.
Their objective was to derive an index which satisfied the following requirements:
a. it should incorporate factors considered by most knowledgeable gastroenterologists
to be important indicators of disease activity.
b. it should utilise observations readily available at the time of a patient visit
c. it must weigh the component factors in an intuitively appropriate direction.
d.it should require only relatively simple computations.
e.it should demonstrate visit to visit changes consistent with the physician's overall
appraisal of changes in the patients condition.
f.it must correlate well with the physicians overall appraisal of disease activity.
g.it should weigh the component factors so as to optimise the accuracy with which it
predicts physicians overall appraisals.
Eight independent variables were coded in such a way that the expected value in a
normal individual was zero, and progressively larger positive values were expected to
reflect progressively greater activity of Crohn's disease.
Examples of such variables were : number of liquid or soft stools in a week;
abdominal pain; general well being;symptoms presumed related to Crohn's disease;
taking anti diarrhoeal drugs; body weight changes;hematocrit; abdominal mass.
Appropriate coefficients were determined which best predicted dependent variable
values using the eight independent variables.
Variables with a major contribution to the final index are stools, pain, well being, and
haematocrit; each of the others contributes less than 10%. Two of the variables are
purely subjective - pain and well being, and are recorded by the patient on a daily
basis; the objective variables are recorded by the physician.
In defining a limit between active and quiescent disease, one might select various cut
offvalues in the range 100-200. 150 has been chosen as a reasonable compromise.
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11. Powell-Tuck Index
This is used to assess disease activity in patients with ulcerative colitis.
This is a more simple index than the CDAI and is based on the following variables:
general health, abdominal pain, bowel frequency, stool consistency, blood in stool,
anorexia, nausea/vomiting, abdominal tenderness, other related lesions - eye
inflammation, arthralgia, oral ulceration, related skin lesions, body temperature,
sigmoidoscopy.
Scores varying between 0-10 are allocated based on the findings.
A total score ofgreater than 4 indicates active disease.,
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CHAPTER 4
INVESTIGATION OF MOLECULAR HETEROGENIETY OF ccl-
ANTITRYPSIN AND p-GALACTOSIDASE ACTIVITY IN
FAECES ANDWGLF OF SUBJECTSWITH ACTIVE IBD.
Introduction
Many proteins are secreted into the GI tract as a result of physiological and
pathological processes. Most of these undergo extensive degradation such that
measurement in faeces grossly underestimates their secretion rate. However al-AT
is resistant to extensive proteolysis and has been used to measure protein loss from
the gut. Mizon et al (1988) and Boege and Fischbach (1991) have recently
investigated the molecular heterogeniety ofal-AT in the GI tract, and have presented
evidence for partial degradation of this protein by enzymes which are secreted by gut
bacteria in healthy individuals.
Mizon et al (1988) apphed sodium dodecyl sulphate - polyacrylamide gel
electrophoresis and irnmunoblotting to analyse al-AT from healthy subjects and
patients with CD. A component with molecular weight 38 kD was identified in normal
faecal extracts as well as in six pathological samples. In these cases the CDAI was
170 (SEM 47). In contrast al-AT of 51 kD was detected in faecal extracts from eight
patients with very active CD (CDAI 287, SEM 39)
Mizon et al (1991) have sequenced the N-terminal end of the 38 kD al-AT, and
have shown that it differs from the native plasma form by the loss of 17 N-terminal
amino acids; carbohydrate analysis of this form demonstrated a total lack of neutral
sugars; in contrast the 51 kD al-AT is glycosylated, and an intermediate 44 kD
molecule is partially deglycosylated; furthermore analysis of 25 faecal extracts from
patients with CD demonstrated that the presence of the glycosylated form of al-AT
was related to the degree of inflammation, although some patients with raised CDAI
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have only the 38 kD al-AT; the author's interpretation of these findings was that in
active CD there is inhibition of the hydrolytic activity of some glycosidases.
This was confirmed by the same group (El Yamani et al, 1992) who showed
decreased exoglycosidase activity, especially (3-galactosidase (pG) in patients with
active CD with the 51 kD alAT.
Hoskins et al (1981) have shown that bacterial subpopulations, producing
glycosidases as extracellular enzymes, average about 1% of the viable faecal flora,
and once diluted in culture cease to produce the enzymes extracellularily; the
intracellular enzymes which are present in the majority of the bacteria have no
influence on the metabolism of luminal colonic glycoproteins.
Using concanavalin A detection El Yamani et al (1992) have further shown that
alterations in the deglycosylation process in some patients with CD could be extended
to all faecal glycoproteins. Subjects with faecal 51 kD al-AT in addition had several
other concanavilin A-reactive bands, which were not present in subjects with faecal
38 kD al-AT. Because of its particular resistance to proteolysis, it may be possible to
use faecal al-AT MW as a marker for assessing the deglycosylation process in the
gut.
In order to confirm and extend these studies I have a. measured MW distribution of
al-AT and PG activity hi WGLF and faeces from control subjects and patients with
active UC and CD; b. compared results inWGLF and faeces.
Principles of procedures used
1. Sodium dodecyl sulphate (SDS) polyacrylamide gel electrophoresis (PAGE):
A gel is formed by polymerising acrylamide and a suitable cross linking agent, N,N'-
methylene bisacrylamide. The polymerisation occurs rapidly at room temperature in
the presence of an initiator and catalyst and porosity of the gel can be adjusted by
varying the acrylamide concentration and degree of cross linking.
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Denaturing conditions are used for the PAGE. When a strongly ionic detergent is
used such as sodium dilauryl sulphate (SDS), proteins are denatured and combine
with a constant ratio (w/w) of SDS. The overwhelming negative charge provided by
the SDS coating makes any charge contributed by the protein negligible, and so
separation of such protein-SDS complexes by PAGE is almost entirely due to sieving,
and is therefore dependent on the molecular size of the protein.
The molecular sieving of the gel depends on the concentration of polyacrylamide. A
reasonably accurate value for the molecular weight of most proteins (except those
which are highly glycosylated) can be obtained by comparison of their electrophoretic
mobility with those of standard proteins ofknown MW.
The protein mixture is denatured and reduced (disulphide bonds split) by heating in
SDS with a reducing agent, prior to electrophoresis.
2. Transfer of proteins from gels to porous membranes (immunoblotting).
Protein blotting transfers the protein pattern generated in a gel to a porous membrane
(nitrocellulose) to produce a precise replica.
The purpose of this transfer is usually to facilitate binding of macromolecular ligands
(usually antibodies) to the proteins on the membrane. By this simple manipulation, a
ligand too large to penetrate the pores of a gel may now easily reach its target
proteins. When an antibody is used in this way the procedure is called immunoblotting
or Western blotting.
A typical immunoblotting experiment may be divided into five steps.
1. sample preparation and electrophoresis.
2. transfer to a membrane.
3. blocking (quenching) of the residual binding capacity of the membrane
4. incubation with probe (antibody)
5. detection ofbound ligand with secondary labelled reagents.
The reagents, equipment and procedure used are described in the appendix to this
chapter. The PAGE procedure is essentially that described by Laemmli (1970).
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3. (3-Galactosidase
P-nitrophenyl-galactoside was incubated with faecal extract or WGLF with release of
p-nitrophenol by (3G. The reaction was stopped by dilution with sodium carbonate
and p-nitrophenol measured at 405 nM.
Molecular weight marker standards
(Gibco BRL, Life Technologies Ltd, Paisley UK)
This contained proteins in the range 94-14 kD:
phosphorylase b (94), albumin (67), ovalbumin (44), carbonic anhydrase (29), trypsin
inhibitor (20), a-lactalbumin (14).The proteins were at a concentration of 1 mg/ml.
Also used was wide range MW marker (Sigma Chem Co, UK, M-4038). This
contained proteins in the range 205 - 6.5 kD:
myosin (205), (3-galactosidase (116), phosphorylase-B (97), fructose-6-phosphate
kinase, rabbit (84), albumin, bovine (66), glutamate dehydrogenase, bovine (55),
ovalbumin, chicken (45), glyceraldehyde-3-phosphate dehydrogenase, rabbit,(36),
carbonic anhydrase, bovine (29), trypsinogen, bovine (24), trypsin inhibitor, soybean
(20), a-lactalbumin, bovine (14), aprotin, bovine (6.5)
Patient samples investigated
Faecal homogenates were prepared from 17 patients ; nine with active CD, eight with
active UC, as assessed by raised WGLF IgG (>10ug/ml).
0.5 g faeces were suspended in 5 ml 0.9% sodium chloride and mixed on a rotornixer
periodically for 15 minutes. Samples were then centrifuged at 25,000g for 30 minutes
at 4°C in an MSE Superspeed 50 centrifuge. PMSF was added to a final
concentration of 2 mM to supematants before freezing at -70°C for subsequent
alAT MW distribution and PG activity measurements.
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WGLF samples (filtered, processed), were also investigated in 24 patients with active
IBD (15 CD, nine UC) for al-AT MW distribution and (3G activity.
These were filtered through 0.22 uM filters prior to assay for PG.
WGLF from nine control subjects were also assayed for PG.
In addition 0.1 ml human al-AT (1 mg/rnl PBS, Sigma Chem Co Ltd) was incubated
for 24 hours at 37°C with
a. 0.2 ml phosphate buffered saline (PBS).
b. 0.1 ml faecal suspension (one part faeces and four parts isotonic saline), and 0.1 ml
PBS.
c. 0.05 ml faecal suspension, 0.05 ml WGLF, and 0.1 ml PBS
d. 0.1 ml WGLF , and 0.1 ml PBS.
The faecal suspension and WGLF (filtered, processed) were prepared from a patient
with inactive CD.
Samples were then centrifuged as for faecal homogenates before electrophoresis and
blotting.
Results
The relative mobility of the MW markers were determined from the blots initially
stained with Ponceau S dye and plotted on semi-log graph paper against MW.
Relative mobilities were determined as a ratio of distance moved by band divided by
total length of electrophoretic run.
MWs ofal-AT bands revealed by blot probe were read from a calibration graph after
relative mobility calculations.
Plates 1,2 demonstrate blots of faecal and WGLF al-AT.
Plates 3,4 demonstrate a blot developed for WGLF al-AT (3) previously stained
with Ponceau-S dye (4)(photograph enlarged).
Plate 5 shows PAGE gel corresponding to plate 3 and 4 stained with coomassie blue.
Plate 6 shows the influence ofWGLF and faeces on native human serum al-AT.
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WGLF reduced the MW to 51 kD and faeces to 38 kD.
The calculation for MW is given in detail for plates 3 and 4 in table 4.1 and figure 4.1
(standard calibration).
Bands in the region 49 - 52 kD are reported as 51 kD, and in the region 36 - 38 kD
are reported as 38 kD.
Figures 4.2a and 4.2b give results for MW distribution ofa 1-AT in faeces and WGLF
ofpatients with IBD and corresponding (3G activities.
Figure 4.3 shows the correlation between WGLF and faecal (3G activities in patients
with active IBD. ( r=0.79, p<0.0002).
Tables 4.2 and 4.3 show results for individual patients with active CD or UC.
Four patients with active CD had al-AT with MW of 51 kD in both faeces and
WGLF with low (3G activity in both.
All other patients with either active CD or UC had al-AT MW of 38 kD in faeces.
One patient had al-AT MW of 44 kD hi addition to 38 kD in faeces.
More patients had al-AT of 51 kD in WGLF, which included 6 patients with active
UC who had 38 kD al-AT in faeces.
Four patients with CD and one with UC had 2 bands corresponding to 38 kD and 51
kD with a further intermediate band at 44 kD in 2 cases.
(3G activity was significantly lower in patients with 51 kD compared with 38 kD a 1-
AT for both faecal extracts (p<0.01) and WGLF (p<0.001).
WGLF (3G activity in nine control subjects who had no GI disease ranged from 0.1-
1.7 u/L
WGLF IgG and al-AT in patients studied with active EBD
Median (range) WGLF IgG for patients with active CD was 50(22 - 455) ug/ml.
Median(range) WGLF IgG for patients with active UC was 75(11 - 139) ug/ml.
Of the 4 patients with faecal 51 kD al-AT, WGLF IgG were 32, 50, 113, and 455
ug/ml.
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WGLF IgG were not significantly different between active UC and active CD
patients.
WGLF IgG were not significantly different between patients with active CD with 38
or 51 kD al-AT.
WGLF al-AT ranged from 17-92 (median 31) ug/ml in subjects with active IBD.
Discussion
Previous studies (Mizon et al, 1988,1991) have shown that the faecal form of al-AT
is related to the exoglycosidase (particularity (3G) activity in patients with active CD;
patients with active disease and 51 kD molecular form alAT had a significantly lower
glycosidase activity than patients with inactive or active CD and the 38 kD form.
In addition El Yamani et al (1992) have shown that the loss of (3G activity could not
be explained by destruction of the enzyme by protease activity since (3G activity was
resistant to faecal proteases for several hours at 37°C; neither could the low
exoglycosidic activity of the samples containing molecular form 51 kD be explained
by the presence of an inhibitor since mixing such an extract with another containing
molecular form 38 kD resulted in deglycosylation, and a (3G activity equal to the
theoretical enzyme activity calculated from that of the two mixed samples.
The results in my studies in patients with active CD agree with those of El Yamani et
al. 4/9 patients with active CD have both the 51 kD molecular form of al-AT and a
low (3G activity in faeces.
All patients with active UC studied had the 38 kD al-AT in faeces.
Faecal exoglycosidase activities have previously been studied in patients with CD and
UC and compared with healthy control subjects and amounts found to be widely
distributed; (3G activity was not different in patients and control subjects and was not
related to disease activity (Rhodes et al, 1985). Also if one of the exogtycosidase
enzyme activities was increased, the other activities were also elevated.
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In ray study control subjects had significantly greater faecal PG activity than subjects
with active UC, and active CD with al-AT 51 kD but were not different from
patients with active CD and al-AT 38 kD.
In WGLF the 51 kD molecular form of al-AT was present in patients with active
EBD to a greater extent than in faeces. This included six patients with UC all ofwhom
had low pG (0.2 - 1.7 u/1). All of these patients had 38 kD al-AT in faeces and PG
2-13 u/g.
Of the patients with CD the four subjects with low levels of PG in the faeces and 51
kD al-AT also had low PG in WGLF (0.2 - 0.8 u/1) and 51 kD al-AT.
The low exoglycosidic activity may be explained by changes in the intestinal bacterial
flora or its metabolic activity, resulting in a decreased secretion of these enzymes. The
combination of 51 kD al-AT in faeces and low PG activity was not found in patients
with active UC and appears to be specific for CD.
The greater degree of 51 kD alAT in WGLF compared with faecal extracts may have
been due to the rapid transit of proteins (less than two hours maximum) in WGLF
compared with faeces with less time being available for deglycosylation. Alternatively
the greater dilution of bacteria by liquid may have inhibited secretion of
exoglycosidase enzymes. However the relatively high activity of PG and the presence
of 38 kD al-AT in WGLF in some subjects with active EBD indicates the potential
for rapid deglycosylation and may indicate a mucosal site for these bacteria since the
majority ofbacteria in the lumen will be washed out by the WGL procedure.
Control values for PG activity in WGLF were similar to those for patients with 51 kD
al-AT and lower than those with 38 kD al-AT.
Control values for pG were much lower in WGLF than in faeces for control subjects
ie these did not parallel each other as seen in active IBD patients. The higher level in
faeces may relate to the longer transit time of these subjects compared with patients
with active IBD with PG possibly being more stable in faeces than other proteins
released into the gut - the longer the transit time the lower the total protein may
become thus artificially raising PG activity when expressed as u/g protein. In patients
with active IBD transit time is usually shorter and protein excretion greater.
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This highlights the advantage ofusing a standardised WGL procedure where controls
and test subjects are treated in a similar way.
Although previous studies have shown no difference between faecal (3G activities in
control and active IBD groups, there may be greater secretion of (3G by gut bacteria
in some patients with active IBD in response to loss of glycoproteins into the gut.
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1 2 3 4 5 6
Plate 1. Immunoblot - Faecal al-AT in active CD and UC
Lane 1,2- active UC (38 kD); Lane 3 - active CD (38 kD);Lane 4 - active CD (51 kD);
Lane 5 - human al-AT standard (54 kD);Lane 7 - active CD (38 and 44 kD);
Lane 10 - active UC (38 kD).
Plate 2: Immunoblot - WGLF and faecal al-AT (51 kD) in patients with active CD
Lane 1,2 - faecal and WGLF al-AT in CD (51 kD); Lane 3,6 - human al-AT standard (54 kD)
Lane 4,5 - faecal and WGLF al-AT in CD (51 kD).
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Plate 3
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66 kD
.—55 kD
Plate 4 45 kD
36 kD
5
Plate 3 : Immunoblot - WGLF in active CD
Lanes 1,9- human al-AT standard (54 kD); Lane 2-51 kD; Lane 4 - mixture 37-51 kD,
Lanes 3, 6,7 - 38 kD.
Plate 4: Ponceau S protein stain of immunoblot












Plate 5: PAGE separation corresponding to plates 3,4 showing proteins stained with coomassie
blue
Lane 5 : protein marker (MW)
Plate 6: Influence of incubation of human al-AT with WGLF and faeces (24 hour at 37°C)
Lanes 1,2 - human al-AT (54 kD); Lanes 3,4 - human al-AT incubated with faecal suspension
(38 kD); Lanes 5,6 - human al-AT incubated with faecal suspension and WGLF (38 kD);
Lanes 7,8 - human al-AT incubated with WGLF only.
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Table 4.1
Example of calculation ofmolecular size ofWGLF al-AT in active CD (plates 3-5).
Calculation ofMW ofprincipal bands.
distance relative MW
from origin mobility (kD)
(mm)
Lane 1 36 0.46 55 (human standard - 54 kD)
Lane 2 43 0.55 49
Lane 3 57 0.73 36
Lane 4 57 0.73 36
Lane 5 Composite Standard
Lane 6 58 0.74 35
Lane 7 55 0.71 37
Lane 9 36 0.46 55 (human standard 54 kD)
full distance - 78 mm
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TABLE 4.2
(3-Galactosidase activity and al-AT MW distribution in patients with active CD
Patient No al-AT MW (kD) P-galactosidase
WGLF FAECES WGLF(u/l) FAECES(u/g)
1 38 38 4.5 50
2 38 38 8.1 39
3 38 - 3.5 -
4 38 - 1.7 -
5 38-51 - 4.1 -
6 38-51 - 1.2 -
7 38-51 - 0.5
8 38-51 38, 44 2.3 2.0
9 51 51 0.8 0.2
10 51 38 1.6 17
11 51 38 1.1 9
12 51 51 0.2 0.1
13 51 51 0.6 2.2
14 51 51 0.6 2.0
15 51 0.1 -
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Table 4.3
P-Galactosidase activity and al-AT MW distribution in patients with active UC
Patient No al-AT MW(kD) p-Galactosidase
WGLF FAECES WGLF (u/1) FAECES (u/g)
1 38 38 3.0 8.0
2 38 - 6.2 -
3 38-51 38 2.0 12
4 51 38 0.4 3.2
5 51 38 0.4 13
6 51 38 1.3 7.1
7 51 38 1.1 12
8 51 38 1.7 2.1
9 51 38 0.2 2.5
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APPENDIX : CHAPTER 4
1. Poly Acrylamide Gel Electrophoresis and Immunoblotting - alAT.
Equipment
SE 250 - MIGHTY SMALL 11 SLAB GEL ELECTROPHORESIS UNIT (Hoeffer
Scientific Instruments,San Francisco, USA).
The SE 250 basic unit has upper and lower buffer chambers, lid assembly with cables,
alumina plates (notched), glass plates, red clamps, and celloseal to seal plates.
In addition SE 250-10A -.75 includes the above as well as a SE245 dual caster, 2x10
well combs and 4xT shaped spacers, 0.75 mm thick
This permits the preparation of 2 minigels approx 80 x 10 x 0.75 mm.
Reagents
Chemicals are from Sigma Chem Co Ltd, UK unless otherwise stated.
a. Acrylamide-bisacrylamide (30:0.8) dissolve 30 g acrylamide and 0.8g bisacrylamide
in 100 ml water (total volume). Filter through Whatman no 1 filter paper (BDH Ltd,
Merck, UK) and store at 4°C in a dark bottle. Prepare fresh every 1-2 months.
b. TEMED : used as supplied: store at room temperature.
c. Ammonium persulphate (1.5% w/v) dissolve 150 mg in 10 ml water on day of use.
d. Sodium dilauryl sulphate (SDS) (10% w/v) dissolve lOg SDS in water to 100 ml.
Heat in warm water to ensure dissolved before use.
e. Resolving gel buffer : 3.0M Tris/HCl (pH 8.8) 36.3 g tris and 48 ml 1.0M HC1 to
100 ml volume. Filter and store at 4°C.
f. Stacking gel buffer : 0.5M Tris/HCl (pH 6.8): Dissolve 6g Tris in 40 ml water,
adjust to pH 6.8 with 1M HC1 ( about 48 rnl) and bring to 100 ml volume. Filter and
store at 4°C.
g. Reservoir buffer : 0.25M Tris, 1.92M glycine, 1% SDS (pH 8.3). Dissolve 30.3 g
Tris, 144 g glycine, and 10 g SDS to 1 litre. Store at 4°C. Dilute 1:10 before use
with water.
h. Sample buffer: 6% SDS, and 6% 2-mercaptoethanol, 30% sucrose and 0.02%
bromophenol blue marker, in 0.15 M Tris HC1 pH 6.8.
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For 2 x 10% resolving gels mix:
10 ml acrylamide/bis
3.75 ml buffer
0.3 ml 10% SDS
14.45 ml water
Degas using water suction pump
add 1.5 ml ammonium persulphate and 0.015 ml TEMED and gently mix.
Cast gels, loading with a pastette.
Apply 1 ml 0.3% SDS solution to surface of the gels. Allow to set (20 - 30 minutes);
pour off 0.3% SDS.
For 2 stacking gels use:
2.5 ml acrylamide/bis
5 ml stacking gel buffer
0.2 ml 10% SDS
11.3 ml water
Degas using water suction pump
1.0 ml ammonium persulphate
0.015.ml TEMED.
Pour to the top and insert perspex comb before gel polymerises (from left to right).
Gel polymerises within 30 minutes.
Remove from casting block and clamp to electrophoresis tank after greasing rubber
seal. Pour reservoir buffer into top (cathode) above the level of the comb and check
for any leaks. Add reservoir buffer to lower compartment (anode). Remove comb and
add samples.
Sample preparation
Add sample buffer to sample (1 part buffer to 2 parts sample). Boil in eppendorfs for
3-5 minutes maximum at 100 °C.
Cool and apply samples (3 ul for MW marker and 1 uL for lmg/ml al-AT standard,
2 ul faecal supematants and lOul WGLF samples).
Attach lid assembly with cables to anode and cathode, and circulate cold water.
Run gels for 1 -2 hours at constant current (20 mA per gel)
Protein Transfer Blot
Equipment:
1. Milliblot - SDE Transfer system.
2. Consort E741 Power Supply.
Use a constant voltage supply; and do not allow initial voltage to exceed 100 volts
DC with a single layer of gels; with an 8 cm x 5.5 cm resolving gel the power supply
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adjusted to provide an initial current of 110 mA ( 2.5 x the area of gel). The normal
operating voltage should be between 10 and 100 volts at this current setting when
running one gel. (Voltages above 100 indicate the end of the electrodes usable life,
and must be replaced.)
The Mylar insulating matrix must be placed directly on top of the lower electrode to
prevent top electrode from touching lower electrode because of overtightening or
misalignment.
Transfers should be run for 30 minutes.
Reagents
a. Methanol
b. Anode buffer 1: (0.3M Tris, 10% methanol, pH 10.4). 36.3 g Tris, 100 ml
methanol in 800 ml with water and adjusted to pH 10.4 as required with 1M HC1
before adjusting to 1L volume.
c. Anode buffer 2: (0.025M Tris, 10% methanol, pH 10.4.) 3.03 g Tris and 100 ml
methanol in 800 ml water adjusted to pH 10.4 as required with 1M HC1 before
adjusting to 1L volume.
d. Cathode buffer: (.025M Tris, .04M glycine, 20% methanol, pH 9.4). 3.03 g Tris ,
2.52 g glycine and 200 ml methanol in 800 ml water and adjusted to pH 9.4 as
required with 1M HC1 before adjusting to 1 L volume.
e. Chromatography paper : grade 3MM CHR (Whatman, UK)
f. Nitrocellulose membrane: grade NCHAHY, 0.45um (Millipore, UK)
Procedure
a. Align the Mylar insulating matrix over the lower (anode) electrode.
b. Cut chromatography papers (x6) and nitrocellulose membrane to size of PAGE gel
(approx 8x6 cm).
c. Soak 1 layer of chromatography paper in anode buffer 1 and then allow excess
buffer to drain.
d. Place a drop of anode buffer 1 in the middle of the lower electrode surface, then
place the soaked filter paper on the lower electrode surface. Centre the paper and
smooth out to make a good contact.
e. Soak 2 layers of filter paper in anode buffer 2. Drain and place on top of the filter
paper already installed on the lower electrode surface. Roll a glass rod over the filter
paper to smooth the paper and remove trapped air bubbles.
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f Cut off a small corner of nitrocellulose membrane to mark. Wet with deionised
water for 5 minutes and rinse the membrane in anode buffer 2, before carefully
placing on top of the previous three layers of chromatography paper. Wear gloves
when handling membranes to avoid protein contamination.
g. Cut off a small comer of gel to mark. Centre the gel onto the membrane, and make
sure air bubbles are not trapped between the transfer membrane and the acrylamide
gel ; note : air will show up as white spots on the membrane and can be removed by
adding a few drops of cathode buffer to the gel. Ease out the bubbles with a gloved
finger or use a stirring rod dipped in cathode buffer to gently roll the trapped air out.
h. Place 3 layers of filter paper soaked in the cathode buffer on top of tbe acrylamide
gel.
i. Carefully place the lid over the 4 studs so that the top electrode (cathode) rests on
the trans unit sandwich, slip a knob over each of the 4 studs and then alternately
tighten each until a slight resistance is felt. Do not overtighten.
j. Attach the power cables to a Consort E741 power supply and set as follows: Switch
on at mains and instrument; comes up TEST, OFF. Press SET to set parameters as
follows : Time Down; End; constant voltage 20 volts; current 0.14 Amps ;0.5 (KVH);
power 300W.
k. Connect leads to power supply and transfer system and press RUN.
Electrophoresis will take place for 30 minutes at a current of 140 raA, with a
constant voltage of20V.
At the end of the run remove knobs and transfer gel to Coomassie blue stain for 1
hour to stain protein bands, and treat blot as below (wear gloves).
Immunoperoxidase staining of nitrocellulose blots.
Reagents
a. Ponceau S concentrate (protein stain - Sigma Chem Co, UK). Dilute 1 in 10 with
distilled water before use.
b. Tris Buffered Saline (TBS) : 10 mM Tris (1.21 g/1) and 140 mM NaCl (8.18 g/1)
adjusted to pH 7.4 wdtli 1M HC1.
c. TBS - Tween : TBS containing 0.1% (v/v) Tween 20.
Reagents 1 and 2 can be prepared and stored as xlO concentrates.
d. 5% lo fat milk (Asda) in TBS - Tween. Prepare fresh on day and store at 4°C.
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e. Goat anti human alpha-1-antitrypsin (PRU-Sheffield). Prepare just before use as a 1
in 100 dilution in 5% lo fat milk in TBS-Tween.
f. HRP labelled Anti-Sheep/Goat IgG (donkey) (SAPU code S084-201). Dilute 1 hi
500 with TBS-Tween just prior to use.
g. Substrate solution : Dissolve 18 mg 4-chloro- 1-naphthol in 6 ml methanol. Add 94
ml TBS and 0.025 ml 30% H2O2. Mix well and use immediately.
Procedure
a. Wash blot in TBS-tween for 2 minutes and transfer to Ponceau-S working reagent
for 5 minutes to highlight proteins. Decant reagent and measure mobility of marker
proteins.
b. Wash the blot in TBS Tween for 10 minutes, before blocking in 5% lo fat milk hi
TBS Tween for 1 hour on rocker.
c. Decant solution and wash x6 with TBS-Tween (5 minutes per wash) on rocker.
d. Add 20 ml antibody solution and place on mixer for 1 hour.
e. Decant and wash x6 in TBS-Tween as before.
f. Add 20 ml HRP-labelled antibody solution and place on rocker for 1 hour.
g. Decant and wash hi TBS-Tween x3, followed by TBS x3 as before.
h. Prepare substrate solution and use immediately. Place nitrocellulose membrane in
substrate and agitate gently on rocker. Purple spots develop and darken over 30
minutes.
i. Stop the reaction by washing the blot in several changes of distilled water for a
minimum of 10 minutes. Surface dry the nitrocellulose using filter paper and measure
mobility ofa 1-AT bands. Photograph ushig reflected fight. Store blots protected from
hght.
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2. Faecal and WGLF (3-GaIactosidase
Reagents
1. p-nitrophenyl (3-D-galacto-pyranoside (Sigma Chem Co, UK)
2. Phosphate Buffered Saline(PBS) pH 7.4 0.01M (Sigma Chem Co, UK)
3. 0.25M sodium carbonate (Merck,UK)
Procedure
The method used was that of Sharfman et al (1975).
P-nitrophenyl-galactoside (0.1 ml of 1 mg/ml in PBS) is incubated with faecal
supernatant or filtered/processed WGLF (0.05ml) at 37°C for 1 hour. The reaction is
stopped by addition of 0.25M sodium carbonate (1 ml), and OD of reaction product,
p-nitrophenol, read at 405 nM. Tests are read against faecal supernatant blanks where
sodium carbonate is added at time zero.
Calculation of (3-Galctosidase activity
Extinction coefficient ofp-nitrophenol at 405 nM is 18.8 x 10^
Therefore a 1 umole/litre solution has an OD at 405 nM of 0.018 OD units, and 1
umole in final reaction volume, 1.15ml, has an OD of 15.7 OD units
To express results in umols/min/g protein or units/g protein
a. divide by 60 to give OD/minute
b. divide by protein concentration in mg/ml (g/1)
c. multiply by 20 and 1000 since 0.05 ml sample is used and activity is per g protein
d. Divide by 15.7 since 1 umol in the final reaction volume has an OD of 15.7 OD
units.
This simplifies to change in OD/hour x 21.2/protein concentration in mg/ml.
ForWGLF calculation simplifies to OD/hour x 21.2 u/litre.
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3. Total protein
The assay used is the 'Pierce BCA Protein Assay' and is a highly sensitive method for
the spectrophotometric determination of protein concentration. Bicinchoninic acid
(BCA) in the form of its sodium salt is a sensitive , stable and highly specific reagent
for the cuprous ion. Macromolecular structure and the four amino acids (cystine,
cysteine, tryptophan and tyrosine) are responsible for the colour formation when
assayed with BCA. The purple reaction product formed by the reaction of two
molecules ofBCA with one cuprous ion, in an alkaline solution is water soluble and
exhibits a strong absorbance at 562 nM.
Reagents
a. Reagent A: 1000 ml of base reagent which contains sodium carbonate, sodium
bicarbonate, BCA detection reagent and sodium tartrate in 0.2N sodium hydroxide.
b. Reagent B: 25ml of 4% copper sulphate solution
c. Working Reagent: Mix sufficient reagents A and B hi the ratio 50:1 just prior to
use.
Procedure
a. Prepare a set of protein standards of known concentration by diluting the albumin
standard solution (2 mg/ml) provided with the kit in the same diluent as the unknown
samples.
b. Pipette 0.05 ml of each standard or unknown protein sample into the appropriately
labelled test tube (3 ml polystyrene). For blanks use 0.05 ml isotonic saline.
c. Add 2 ml working reagent to each tube and mix well.
d. Incubate all tubes for 30 minutes at 37°C
e. Cool all tubes to room temperature and measure absorbance at 562 nM against
water reference.
f. Prepare a standard curve by plotting net absorbance at 562 nM vs protein




MEASUREMENT OF HYALURONIC ACID IN WGLF IN GI
DISEASE
Introduction
Connective tissues are rich in the glycosatninoglycans (GAGs): chondroitin sulphate,
dermatan sulphate, heparin sulphate, keratan sulphate, and hyaluronic acid. These are
heteropolymers of an aminosugar and a uronic acid or a sugar plus a small proportion
of protein. These very large polyanions bind water and cations and form the ground
substance of connective tissue along with collagen and elastin.
Hyaluronic acid (HA) is an unbranched polysaccharide built from repeating
disaccharide units of D-glucuronic acid and N-acetyl-glucosamine linked by (3(1-3)
and (3(1-4) glycosidic linkages respectively, and the major MW component is in the
range of 400 kD - 1000 kD. Unlike the other GAGs, HA contains no sulphate and
less protein.
The main sites of production of HA arc the connective tissue and synovial
membranes. HA forms an important component of the tissue ground substance where
there is interaction with fibronectin, other GAGs and collagen, with the cytoskeleton
and with specific cell surface binding proteins.
Most HA is degraded in lymph nodes but a small amount diffuses from the tissues
and joint fluid to enter the circulation via the lymph and its concentration in blood is
10 - 100ug/ litre. Clearance from blood is rapid mainly as a result of uptake by
receptors on hepatic endothelial cells where it is degraded; studies in man using
labelled HA have shown a serum half life of 2.5 - 5.5 minutes.
Colombel et al (1989) and Lavo et al (1990) have reported increased jejunal secretion
of HA in patients with IBD and in coeliac patients when challenged with gliadin,
respectively. Concentrations ofHA in health and disease were much higher than could
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be explained by passive leakage from plasma. Farzad et al (1993) induced intestinal
epithelial denudation in rats by reversible ischaemia, and showed an increased HA
concentration in the jejunal perfusate with loss from the villous tips, and have
suggested that increased denudation of epithelial cells due to inflammatory or toxic
responses will result in increased release ofHA from the exposed lamina propria to
the intestinal lumen.
WGLF proteins such as IgG and albumin have been measured as indices of protein
leakage from plasma as a result of inflammatory changes in the intestinal mucosa. HA
has now been measured in WGLF hi control subjects and in subjects with IBD and
colon cancer as a possible direct measure of leakage from the lamina propria in small
and large bowel disease.
1. Experiments investigating measurement of HA in WGLF
HA was measured using a radioimmunometric kit supplied by Pharmacia, Uppsala,
Sweden (Chapter 5, appendix).
The calibration curve for HA is shown in Figure 5.1
a. Comparison of processed and unprocessed WGLF samples for HA
measurement
Three samples from control subjects, and three samples from patients with IBD were
measured for HA using a. unfiltered unprocessed samples b. filtered processed
samples. See table 5.1
Results were significantly higher for ah unprocessed, unfiltered samples compared
with their respective samples processed with protease inhibitors. This may indicate a
positive interference in the unfiltered, unprocessed samples or a quenching of HA
measurement in processed samples.
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b. Recovery of standard HA from WGLF
0.04 ml 500ug/l HA standard was added to two patient samples of processed WGLF
(0.1ml). Samples were then assayed for HA.
See Table 5.2
Quantitative recovery ofHA from processed WGLF indicated no interference causing
reduction in HA measurement in these samples.
c. Investigation of interfering compound using unfiltered unprocessed samples.
A sample ofWGLF was treated in four different ways in order to attempt to identify
the source of the interference.
The sample was assayed a. unfiltered and unprocessed, b. unfiltered and processed c.
filtered and processed and d. filtered through a 0.22u filter and unprocessed.
See Table 5.3
These results on this single sample indicate that removal of bacteria has no influence
on the results, whilst processing with protease inhibitors significantly lowered the
results.
d. Influence of time delay on filtering and processing samples
A sample ofWGLF was divided into three and filtered and processed at time zero and
subsequently after +60 and +120 minutes at 37^C.
The HA concentrations for time 0, +60, and +120 minutes before processing were 58,
60 and 56 ug/1; it can be concluded that there is no increase or decrease in HA
concentration caused by delay in protease inhibition.
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e. Influence of pancreatic enzyme preparations on HA assay
Two different pancreatic enzyme preparations were treated as WGLF and assayed
before and after filtering and processing.
The enzymes used were a.chymotrypsin and b. collagenase and were obtained from
Sigma Chem Co Ltd, UK. Both were used at a concentration of 0.5 mg/ml
Chymotrypsin gave a value for measured HA in excess of 500 ug/1 before processing,
whilst collagenase gave a value of 12 ug/1; processing of both samples led to a
significant reduction in the HA in the chymotrypsin sample to 15 ug/1 whilst the
collagenase value remained the same.
It was concluded that chymotrypsin was interfering with the HA assay in the
unprocessed samples. It may do this by partial proteolysis of the labelled HA binding
protein making this less available for reaction with HA or with the HA-Sepharose
binding reagent thus reducing the 'bound counts' and increasing the apparent
concentration ofHA in the sample.
2. WGLF HA in patients with active IBD and colon cancer
HA was measured in 20 control subjects, 19 patients with active CD, seven patients
with active UC, five patients with colon cancer, and in seven other patients with
miscellaneous GI disease. Significant differences were determined using a Mann
Whitney test for non parametric data.
WGLF HA was correlated with WGLF IgG for all subjects (n=58)
Results
Results are shown in Figure 5.2a and Figure 5.2b.
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Median (range) for the different groups was as follows: controls 24(4 - 608), active
CD 159 (6 - 620), active UC 301(14 - 740), CRC 43 (19 - 123).
There was a significant difference between control subjects and patients with active
CD (p<0.001) and active UC (p<0.02) but no significant difference between controls
and patients with colon cancer. There was a weak but significant correlation between
WGLF HA and WGLF IgG (r=0.46, p<0.002). However there was considerable
scatter ofpoints and some patients with high HA had a normal IgG and vice versa.
A single patient in the control group had a very high HA concentration (608 ug/1).
The protease and chymotrypsin activity of this sample was found to be low as
expected in processed samples, and so this could not explain the raised value. A
subsequent sample taken on this patient gave an HA concentration of 36 ug/1.
Discussion
In the small bowel HA can be observed in large quantity in the loose connective tissue
of the villi and lamina propria of human jejunum using a histochemical procedure with
biotin labelled protein binding to the HA and identification with avidin enzyme and
substrate (Gerdin and Hallgren,1991). It has been concluded that the accumulation of
HA in the subepithelial layer of the jejunal mucosa indicated that the high jejunal
secretion ofHA in normal subjects is due to passive diffusion from the subepithehal
interstitium.
HA has physicochernical properties promoting a high ability to bind water and create
microenvironments where macromolecules are excluded (Laurent, 1987). A
considerable proportion of HA (about 60%) can be readily mobilised from the
interstitium by enhanced interstitial fluid flux (Reed et al,1992). This is substantiated
by the HA concentration in intestinal lymph, which is considerably higher than that
found in lymph from other regions of the body (Tengblad et al,1986). During
intestinal absorption intestinal lymph flow increases as does lymphatic HA
concentration probably as a result of release of HA from jejunal lamina propria. The
decreased interstitial concentration of HA could be expected to have important
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implications for interstitial exclusion of macromolecules as well as for transport of
water and protein.
Colombel et al (1989) and Lavo et al (1990) have reported jejunal secretion ofHA in
both normal subjects and patients with IBD and coeliac disease. Increased jejunal
secretion of HA was observed in the disease groups and this may be indicative of
enhanced connective tissue response due to inflammation, reduced lymphatic
drainage, or direct leakage through denuded epithelial cells.
In the present study the difficulties of measuring HA in the presence of proteolytic
enzymes has once more been identified and a direct effect of chymotrypsin on the
assay observed. This difficulty has previously been identified by Engstrom-Laurent et
al (1985) who observed that other authors using proteolytic digests of serum had
obtained unusually high values when measuring serum HA.
The increased WGLF HA of patients with active IBD is in agreement with previous
jejunal perfusion studies.
Ahrenstedt et al (1992) in a study ofpatients with CD of the terminal ileum perfused
the proximal jejunum and observed increased secretion of HA from 'uninvolved'
jejunum compared with controls and patients with inactive disease. This is compatible
with a subclinical alteration in the connective tissue of macroscopically unaffected
mucosa in active CD. They suggest that a reasonable mechanism for the access of
HA to the intestinal lumen is through the many denuded villous tips which are formed
during the continuous turnover of the villous epithelium. This has also been suggested
by Farzad et al (1993). Colombel et al (1992) have shown that elemental diets cause
an increase in leakage of plasma proteins albumin, and IgG and also stimulate
secretory immunity (IgA) but have no effect on the secretion ofHA from the jejunum,
which highlights the different mechanisms resulting in the appearance of these
proteins.
This has further been observed with this study in WGLF where the relationship
between plasma leakage (IgG) and interstitial leakage (HA) is only weakly significant.
The reference values for HA in WGLF (median of 24 ug/1 with an average perfusion
rate of 20 ml per minute) would appear to be higher than those from the jejunal
perfusion studies. Ahrenstedt et al (1992) obtained control values of mean (SD) of
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42 (23) at a flow rate of 3 ml pr minute, and Colombel et al (1989) obtained control
values of mean (SEM) of 12 (2) at a flow rate of 10 ml per minute
Preliminary values for patients with active UC show some high values and the normal
colonic mucosa may contribute significantly to baseline WGLF HA values.
A single sample of human gastric aspirate gave a value of 150 ug/1. HA from sources
within the GI tract other than the small and large bowel may influence the WGLF









1 control 1 >500 8
2 control 2 350 9
3 control 3 350 14
4 IBD 1 >500 114
5 IBD 2 >500 180
6 IBD 3 >500 35
Table 5.2
Recovery of HA from WGLF samples
WGLF WGLF + added Recovery
HA ug/1 HA ug/1
1. 116 240 112%
2. 42 163 92%
Table 5.3
Processing procedure for WGLF prior to analysis
Treatment HA ug/1
a. unfiltered unprocessed 650
b. unfiltered processed 30
c. filtered processed 28
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Meaurement of WGLF Hyaluronic Acid
Principle of Test Procedure:
This is a radiometric assay which is based on the use of specific hyaluronic acid
binding proteins, isolated from bovine cartilage ( Pharmacia Diagnostics AB, Uppsala,
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Sweden). The hyaluronic acid in the patient sample reacts with HABP- I in
solution. The unbound HABP-125! is then quantified by incubating with HA covalently
coupled to sepharose particles of small size and low density. Separation is performed
by centrifugation followed by decanting. The radioactivity bound to the particles is
measured in a gamma counter and the response is inversely proportional to the
concentration ofHA in the sample.
Reagents:
1. HA standards: 10, 25, 75, 200, and 500 ug/1. Store at 2 - 8°C.
2. Sample diluent and zero standard.
3. HABP-125I, 200 Kbq: Dilute 1/30 in tracer diluenteg. 200ul HABP -125I in 6 ml
tracer diluent. Prepare weekly.
4. Tracer diluent (blue) 15 ml : ready for use.
5. HA-Sepharose Ready for use; store at 2 - 8°C.
6. Decanting suspension 220 m! Ready for use ;store at 2 - 8°C.
Procedure:
a. Pipette 100 ul of standards, processed WGLF samples, and WGLF sample blank
consisting ofprocessed lavage solution in duplicate.
b. Add 200 ul ofHABP-'25I solution.
c. Incubate for at least 60 minutes at 8 - 10°C
d. Add 100 ul ofHA-Sepharose. Resuspend thoroughly before use.
e. Incubate for 45 minutes but not more than 60 minutes at 8 - 10°C.
f. Mix decanting suspension and add 2 ml to each tube.
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g. Centrifuge for 10 minutes at 1500g. Decant the tubes immediately in one
movement and let the tubes stand for 30 seconds inverted on absorbent paper. Tap
the tubes x2 against the absorbent paper to get rid of residual drops. The precipitate
is firmly packed and will not be lost even if the tubes are tapped vigorously.
h. measure the radioactivity in gamma counter.
Results:
a. Express the counts (B) for standards and unknowns as a percentage of the mean
counts of the 0-standard (B0)
% activity bound = B/B0 x 100.
b. Plot the percentage values of the standards against the HA concentration on a lin-
log paper and construct a standard curve.
c. Read the concentration of the unknown samples from the standard curve.
d. Subtract the WGLF sample blank result fromWGLF sample test results.
e. Results are multiplied by 1.24 to correct for dilution when processing samples.
Interference:
There is no measureable interference of chondroiton sulphate at concentrations





An appraisal of the whole gut lavage procedure for diagnosis of blood and
protein loss from the gut
The WGL procedure which is routinely earned out as a bowel preparation prior to
clinical investigations has provided a novel opportunity for investigating blood and
protein loss from the gut. My work has shown that this type of test is highly relevant
to patient management and to further research in clinical gastroenterology. The
procedure has many advantages when compared with the more traditional
investigative methods such as those involving faecal collections, but there are also
some disadvantages.
The WGL procedure involves the administration of an isotonic solution which is not
absorbed from the gut, is safe and well tolerated by patients, clears the gut of faecal
debris and leads to the production of a clear fluid per rectum within three to four
hours. The procedure is non-invasive and only involves passing tubes in a minority of
patients who have a low tolerance for the oral lavage procedure. There are no
substrates in the lavage solution which may be metabolised to explosive gases, (when
mannitol solution is used as a bowel preparation solution it is fermented and produces
hydrogen), so subsequent patient investigations such as diathermy are completely
safe. In contrast as the WGL procedure is commonly used prior to colonic
examination, collection, processing and analysis of the resultant fluid does not require
further patient involvement or inconvenience. The fluid can be processed, for example
, as serum and urine are processed; thus, filtration, centrifugation, or direct addition
ofpreservatives into solution are all easily accomplished; these procedures are much
less easily done with faecal specimens, which cannot be immediately dealt with in
these ways.
After adequate treatment with protease inhibitors WGL fluid can yield valuable
information in both healthy and diseased subjects by measurement of endogenous
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secretions present in the WGL solution. Since the whole gut is perfused during the
procedure, inflammatory lesions in areas which are difficult to investigate by direct
access such as the ileum yield products that can be detected.
It has been confirmed by sequential analysis ofWGL samples for different proteins
that there is a steady state perfusion once the clear fluid is obtained. This however
does require monitoring of the patient by trained nursing staff to maintain the correct
fluid intake. Measurements of fluid intake rate and concentration of analyte in WGLF
can allow quantitative determination of the daily output and additional knowledge of
the blood or serum concentration of the substance permits calculation ofblood or
serum clearance of the analyte. This eliminates the need for 24 hour faecal collections.
Quantitative faecal measurements are not easily made, because the discipline required
of the patient and staff and the necessary facilities of an investigative metabolic unit
are not generally forthcoming or available.
Often in studies where pathological faecal samples are compared with controls, the
pathological samples may be of a different form (diarrhoea) from the controls and this
itselfmay introduce a physiological difference as highlighted by Strygler et al (1990).
Since a standard WGL procedure is used for controls and patients any such sample
differences are eliminated when WGLF samples are studied.
A further advantage ofWGLF compared with faeces in investigative work is the
elimination of dietary interference by substances that may give false readings . For
example a dietaiy component such as red meat can make a significant contribution to
the measurement of faecal haemoglobin, thus reducing the specificity and sensitivity
of the assay.
Some physicians perceive the WGL procedure as being veiy invasive and
impractical; however it is well tolerated, and has been successfully used in a wide
range of subjects from children to the elderly; it is much less invasive than tests that
might give equivalent information but which involve passing tubes; the patient has
more control and in this sense the procedure is much less disturbing.
The acknowledged disadvantages and potential disadvantages of the WGL procedure
merit consideration:
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1. The WGL procedure induces an osmotic diarrhoea, a non physiological state which
may lead to altered gut losses compared with normal.
2. Since the whole gut is perfused, pathological areas are not specifically located as
hi closed loop studies. Accordingly it is not possible to link protein measured in
WGLF to intestinal cell or tissue type and so such investigations require to be
combined with studies ofbiopsies or imaging ; however WGL here provides an extra
dimension similar to the sugar permeability tests which give diagnostic information
complementary to that ofjejunal biopsy hi patients with malabsorption.
3. Some proteins such as albumin are labile and are still degraded to some extent
during the lavage procedure, despite the prompt addition of protease inhibitors when
the fluid is collected. The amount of degradation will depend on the site ofprotein
secretion and activity of the patient's proteases, with more proximal protein secretion
being more affected.
4. Patients on average pass samples every 10-20 minutes once clear lavage fluid is
being produced per rectum and so gut losses are measured only during this time
period; ie only continuous loss ofprotein or blood is measured by this procedure;
occasionally patients with active UC have been observed to be passing fresh blood per
rectum, have subsequently undergone the WGL procedure, and have been found to
have a normal WGL haemoglobin.This highlights the difference between continuous
ooze and acute intermittent bleeding which may stop completely between episodes.
Little is known about the intermitteucy ofprotein loss although reassuringly,
sequential samples show little variation.
Blood Loss in WGLF in GI disease
WGLF haemoglobin concentration is not subject to the variations of faecal
haemoglobin concentration caused by natural and pathological variation of stool
weight and diet differences and has been shown to be a more sensitive index ofblood
loss. A condition known to be associated with GI bleeding was present in more than
97% ofpatients in whom WGLF Hb was above the reference range.
Three groups of patients were studied in more detail with regard to GI blood loss.
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a. Patients with inflammatory bowel disease:
Anaemia in these patients was unrelated to GI blood loss, and GI blood loss was not
a consistent feature of active inflammation. There was a weak relationship between
disease activity as measured byWGLF IgG and GI blood loss, but only in patients
with active UC was there a relationship between fall in blood haemoglobin and WGLF
IgG. Other factors such as duration of illness, malabsorption and poor diet may
contribute to anaemia in these patients.
b. Patients with unexplained Fe deficiency anaemia:
Most studies in the past have identified GI lesions which are assumed to bleed and be
the cause ofFe deficiency anaemia; this has usually not been confirmed by blood loss
measurement. In the present study there were 73 clinical, dietary, or iatrogenic factors
recorded in 42 iron-deficient patients all ofwhich could contribute to Fe deficiency
anaemia. However the WGLF haemoglobin test detected only eight patients who
were losing more than two ml ofblood per day, including all six patients with lesions
generally recognised to be important causes of occult bleeding, - four with colonic
cancer, one with diffuse gastric vascular ectasia, and one with severe ulcerative
oesophagitis. Although the WGLF haemoglobin measurement may miss intermittent
bleeding, it seems likely that in many instances, GI lesions detected in Fe deficiency
patients by standard investigations are coincidental and are not bleeding. In these
patients iron deficiency is likely to be due to poor diet, malabsorption, chronic blood
loss from a site other than the gut, or a combination of these.
c. Patients with colon cancer:
Occult tests for GI blood loss have mainly been used hi the detection of colon cancer.
However it is now generally accepted that a substantial percentage ofpatients with
colon cancer are not detected with 'Haemoccult screening' either for technical
reasons and lack of sensitivity of the test, or because the tumours are not bleeding.
In my series, 19 of 20 patients with colon cancer had elevated WGLF Hb
concentrations. 1 am now extending this work by studying a much larger series.
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Practical consequences of this test of occult blood loss have arisen in at least two
situations 1. patients may have raised WGLF Hb levels with no apparent disease; in
my series there were two cases with raised WGLF haemoglobin had reportedly
normal barium enemas but were each subsequently shown to have a cancer at
colonoscopy (earned out because ofthe positive WGLF Hb result).
2. As discussed at (b) above where patients with Fe deficiency have normal WGLF
Hb levels, deficient diet and malabsorption should be considered as the cause and
treated appropriately.
Protein Loss in GI disease
In healthy control subjects the mean clearances of IgG and al-AT were four and
38 ml per day respectively; albumin is affected by proteolysis but in patients with
cystic fibrosis who are deficient in pancreatic enzymes, there was a mean clearance of
14 ml per day (Croft et al, 1995). Hiis might indicate that clearance in controls may
relate directly to MW size: al-AT (54 kD), albumin (66kD), and IgG (166kD).
Alternatively the higher clearance of the smaller MW al-AT in controls and patients
with IBD may be influenced by osmotic diarrhoea ( Strygler et al 1990). The osmotic
diarhoea may lead to greater release ofal-AT winch has been shown to be present in
epithelial cells in both normal and diseased subjects.
IgG determination in WGLF shows a strong relationship with CDAI in active IBD.
Raised IgG and albumin levels in WGLF were seen in active but not inactive IBD.
al-AT was raised in WGLF from some patients with inactive as well as active IBD.
This may be due to the permeability of smaller MW al-AT in damaged but not
inflamed tissue as has been shown in other studies where al-AT was raised in
inactive as well as active IBD.
Tissue inflammation may be required to allow significant leakage of the higher MW
IgG and then in states of inflammation, clearances may become independent of
molecular weight. The low rate of leakage for IgG in controls may enhance the
sensitivity ofWGLF determinations of IgG as an index of active IBD when
hyperaemia and inflammation result in leakage from plasma. It is worth noting that
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patients with abnormal X-ray findings may have no current inflammation; on the other
hand, patients with normal X-ray findings can be very ill despite having no strictures
or fistulae but still having active microsopic inflammation which cannot be readily
seen on X-Ray. These considerations indicate the importance of tests such as WGLF
IgG and other proteins and mediators, that provide objective indices of IBD activity;
accordingly our group is continuing to extend this work.
Determinations ofWGLF proteins can not be used to make a diagnosis of IBD as
these are merely indices ofprotein exudation into the gut which occurs in other
diseases including intestinal neoplasia. Similarily normal values ofWGLF proteins do
not exclude IBD as these are normal in most patients in the quiescent phase of their
illness.
Patients with lymphangiectasia ( only two seen to date) appear to lose more al-AT
relative to IgG and albumin, which indicates a different mechanism than that seen
with inflammation with al-AT being preferentially lost through dilated lymph vessels.
Studies ofhyaluronic acid (HA) which is thought to be secreted into the gut
transepithelially, have demonstrated only a weak relationship between WGLF IgG and
WGLF HA concentrations; this suggests a different mechanism for loss of these
proteins, IgG mainly being derived from plasma and HA directly from exposed sub¬
mucosal tissue.
The selectivity ofprotein transport into the gut may have different mechanisms or
combinations ofmechanisms for different types ofmucosal inflammation and disease
and this whole topic requires further close scrutiny.
It has previously been shown using faeces that al-AT appears in different MW sizes
in patients with CD. I have been able to assess this point in much detail, using WGLF.
In some patients with active CD the 5 I kD form was present and this appeared to
relate to deficient levels of P-galactosidase. In contrast no patients with active UC
studied had 51 kD al-AT in faeces. Reduced deglycosylation ofproteins in patients
with CD may influence response to treatment of this group ofpatients with certain
drugs which require to be metabolised into active forms by bacterial enzymes prior to
being therapeutic. In addition changes in the metabolism of commensal bacteria as
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indicated by reduction in protein deglycosylation may contribute to either
exacerbations of, or predispose to, CD.
Current perspective on the use of whole gut lavage in diagnosis and research
Initially the WGL procedure was set up in our department to measure intestinal
antibodies, and it was observed incidentally that there was protein loss of albumin
and IgG in IBD. Subsequently this has been further explored and the phenomenon is
now used by clinicians as a diagnostic test to monitor protein loss in LBD. The
procedure was then exploited further to measure blood loss in IBD and to elucidate
other conditions notably unexplained Fe deficiency anaemia and colon cancer.
More recently, assays for granulocyte elastase ( a measure ofneutrophil migration
into the gut), growth factors, and cytokines have been set up and used in attempts to
gain further insight into disease mechanisms in IBD. Combinations of these tests have
been used to investigate colon damage hi patients with cystic fibrosis and after
radiotherapy.
A clinical trial of a new steroid used in the treatment of CD is underway and this will
be supported by WGLF studies along lines developed to monitor IBD. We are also
developing protocols for studies of intestinal inflammation in patients with tropical
diarrhoeas.
There is a need to separate protein 'loss' into (a) protein delivered physiologially into
the gut; (b) protein leaked into the gut;and (c) protein elaborated in the gut. This may
require investigation of immunoglobulin subclasses (eg of IgG) which are sometimes
present in very low concentrations.
There are many technical problems that still confront us. WGLF contains a large
concentration ofPE 3350 (59g/l) and so it is difficult to concentrate further when
small concentrations of analytes are to be measured. A research colleague within the
laboratory has investigated various approaches to reduce or eliminate this problem.
Different physical methods have been used to eliminate PEG fr om the solution prior
to further analysis ofproteins. Ammonium sulphate precipitation, dialysis, gel
filtration, and ion exchange chromatography have been used to separate PEG from
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proteins, with varying degrees of success. Both anion exchange chr omatography and
ammonium suplrate precipitation separated PEG from proteins. Affinity
chromatography, using media to selectively extract proteins, has also been used to
look at specific groups ofproteins eg using thioplrilic (T) gels to extract
immunoglobulins fr om WGLF. Now, methods are being explored to examine degrees
of degradation of immunoglobulins using SDS/PAGE/ Western blotting techniques
and ELISAs for total and specific Ig antibodies.
Exfoliated cells present in the fluid are currently being harvested for DNA extraction
in patients with colon cancer and their family members ; recruitment ofpatients for
this molecular study will provide abundant material for my investigation ofpatients
with polyps and colon cancer and the issue as to whether polyps/cancers bleed or
not can be further investigated ; also other proteins lost in association with blood loss
eg a I-AT, or more specific proteins secreted by polyps or carcinomas can also be
measured.
The use ofWGLF has added a new dimension to research into gut pathology. We feel
that it merits continuing exploitation and that it promises to yield a rich harvest of
material for the further elucidation of intestinal disease mechanisms and for the
clinical diagnosis and management ofpatients.
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Relative specificity for active inflammatory bowel
disease of plasma-derived proteins in gut lavage fluid
W. Gordon Brydon, Chintamaneni P. Choudari and Anne Ferguson
Objective: Whole gut lavage with isotonic non-absorbable fluid is essentially a whole
gut perfusion; whole gut lavage fluid (WGLF) can be used for clinical evaluation of
intestinal immunity. High concentrations of WGLF immunoglobulin (Ig) G, albumin and
cc-1-antitripsin (A1AT; probably reflecting plasma leakage) are characteristics of active
inflammatory bowel disease. We aimed to establish reference values for concentrations
of these proteins in WGLF and to assess the extent of high concentrations in conditions
other than active inflammatory bowel disease.
Methods: Cut lavage was performed on 63 immunologically normal patients or
volunteers and on 254 occasions in patients with gastrointestinal symptoms or disease.
After filtration and addition of protease inhibitors, WGLF content of IgG was assayed
by enzyme-linked immunosorbent assay; albumin and A1AT by immunoturbidimetry.
Results: Normal ranges were established: IgG < 1-10 pg/ml; albumin <1—26|ig/ml
and A1AT <1-19|tg/ml WGLF. In 102 tests on patients with inflammatory bowel
disease of varying activity, high concentrations of WGLF IgG were present in 64%,
of albumin in 52% and of A1AT in 36%. High concentrations of one or more
proteins were present in 15 out of 152 patients with other conditions. In the majority,
the existence of gastrointestinal protein loss was consistent with the clinical picture
(one lymphangiectasia, seven colorectal cancers, one gut lymphoma, one perforated
diverticulitis, one pouchitis and one lymphocytic colitis).
Conclusion: Studies of gut lavage fluid proteins provide a new approach to screening
of clinically complex patients with inflammatory bowel disease and other ulcerating
and inflammatory lesions. This simple technique offers an alternative to faecal isotope
excretion in the diagnosis of protein-losing enteropathy.
European Journal of Gastroenterology & Hepatology 1993, 5:269-273
Keywords: Ulcerative colitis, Crohn's disease,
gastrointestinal protein loss, measure of disease activity.
ltroduction
fliole gut lavage is a relatively new technique for
eansing the bowel prior to barium enema or colono-
:opy. Whole gut lavage fluid (WGLF), essentially a gut
erfusate, is an excellent source of material for clinical
ivestigation and research concerning intestinal immu-
ity and inflammation [1-6]. By using appropriate im-
lunoassay and biochemical techniques, WGLF can be
sed to investigate intestinal immunoglobulin and anti-
ody production, locally produced immunoregulatory
/tokines and occult gastrointestinal bleeding.
'e have also observed that patients with active inflam-
latory bowel disease have high concentrations of
GLF immunoglobulin (lg)G, albumin and a-l-anti-
ypsin (A1AT) and in a prospective study, we found
tatWGLF protein concentrations correlated well with
irious clinical indices of inflammatory bowel disease
activity [2,7,8]. It seems likely that a test based on
gut lavage fluid (probably measuring plasma leakage
across inflamed mucosa) would have many applica¬
tions as a safe, inexpensive and objective measure of
inflammatory bowel disease activity.
With a view to the introduction of this new test into
clinical practice, we have examined WGLF from a
series of patients to determine reference values for
WGLF protein concentrations and to establish whether
abnormally high values are found in diseases other
than inflammatory bowel disease.
Methods
Patients and volunteers
Gut lavage was performed on 317 occasions. The
reasons were bowel preparation for barium enema,
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colonoscopy or colorectal surgery; a treatment for in¬
tractable constipation, and in volunteer members of
staff and patients as part of a research project on se¬
cretory antibodies to food proteins.
Patients and volunteers drank 4 litres of isotonic
non-absorbable polyethylene glycol-based lavage fluid
(Golytely) at a rate of 250 ml every 10-15min. Within
2h, solid then liquid faeces were passed followed
by several large volume, virtually clear fluid 'stools'.
An aliquot of the first completely clear specimen was
collected for analysis.
Processing of whole gut lavage fluid
In the first phase of our work, specimens were pro¬
cessed as described by Gaspary et al. [ 1 ]. An aliquot
of 200ml lavage fluid was filtered through gauze
into 50ml polypropylene tubes. Specimens were cen-
trifuged twice and treated with a series of reagents to
inhibit proteolysis, and with calf serum which provides
an alternative substrate for any remaining proteases.
Further experiments showed that the fluids could be
clarified by filtration as efficiently as by centrifugation
and a simpler method for specimen preparation has
been developed.
The fluid (20ml) was filtered through GF/A (What¬
man, Maidstone, UK) glass fibre filters. The follow¬
ing reagents were added to 10ml of the filtered fluid
(final concentrations in brackets): protease inhibitor
which comprised soya bean trypsin inhibitor in PBS
(80gg/ml), sodium ethylene diamine tetracetic acid
in PBS (15mmol/0, phenyl methyl sulphonyl fluo¬
ride in 95% ethanol (2 mmol/1), preservative: sodium
azide (1 mmol/1), and newborn calf serum (5% v/v).
Aliquots of processed WGLF were then stored at
— 70°C for later analyses.
Analytical methods
Sample analysis for IgG was by enzyme-linked im¬
munosorbent assay (ELISA) [2] using affinity-purified
goat anti-human IgG (North East Laboratories) and hu¬
man reference serum from the Protein Reference Unit
(PRU), Royal Hallamshire Hospital, Sheffield, UK. The
between run coefficient of variation of the assay was
15.5%.
The technique we used previously for albumin detec¬
tion had a lower limit of 18pg/ml. Therefore, we de¬
veloped a more sensitive, immunoturbidimetric pro¬
cedure for assaying albumin; a similar method was
used for A1AT. Anti-human albumin was supplied by
the Scottish Antibody Production Unit and anti-human
A1AT was obtained from from the PRU. WGLF was
diluted by polyethylene glycol (PEG) 6000 reagent
in tris buffer (pH 7) with and without antibody. It
was then incubated for 15 min and the turbidity was
measured at 340 nmol/1 in a flow-through spectropho¬
tometer (PU8610, Philips, Cambridge, UK). Standard
plots of albumin and A1AT values over 0-200 gg/ml
were prepared from Human Reference Serum which
had been diluted in 0.9% NaCl containing 48g/l PE(
3350. Between run coefficients of variation for thes
assays were 11% for albumin and 6% for A1AT.
Results
Technical aspects
The data presented below relate to 70 specimens pre
cessed by the centrifugation method and 246 by filtn
tion. Experiments in a separate group ofWGLF spec
mens, with duplicates processed both by centrifug;
tion and filtration techniques, showed no significar
differences in residual protease activity (n = 10), i
immunoglobulin concentrations (n = 11) or in th
concentration of a representative secretory antibody
IgA anti-gliadin antibody (n = 8).
Normal values for whole gut lavage fluid proteins
Gut lavage was carried out in 63 individuals whor
we classified as 'normal'. There were 20 men (ag
range 15-80 years, mean 44.1 years) and 43 wome
(age range 24-88 years, mean 51.4 years).
There were seven healthy volunteers, 19 patients wit
simple constipation, 11 with small benign coloni
polyps, 18 who had had minor gastrointestinal symj;
toms in whom no abnormality had been found an
eight patients with minor, non-inflammatory gastrc
intestinal conditions. All were on a normal diet an
none was being treated with immunosuppressive c
non-steroidal anti-inflammatory drugs.
Values forWGLF IgG, albumin and A1AT had a skewe
distribution (Figs 1-3) which was not normalized fc
using transformed data. Since only the upper limit c
normal is relevant in relation to a diagnosis of activ
inflammatory bowel disease, we have taken the uppc
and lower values which include 95% of the results [S
as the working normal ranges: < 1-10 pg/ml forWGL




WGLF IgG concentration (ug/ml)
Fig. 1. Concentration of immunoglobulin (Ig) C in whole gi
lavage fluid (WCLF) from 63 immunologically normal patients ar
volunteers.
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. 2. Concentrations of albumin in whole gut lavage fluid (WCLF)
ti 63 immunologically normal patients and volunteers.
mber of
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. 3. Concentrations of a-1-antitrypsin in whole gut lavage fluid
CLF) from 63 immunologically normal patients and volunteers.
hole gut lavage fluid proteins in a further series of
munologically normal subjects
ice these reference ranges were established, gut
rage has been performed in a further 44 patients
nsidered to be immunologically normal with dia-
oses of constipation, benign polyp or with mi-
>r gastrointestinal symptoms. In all cases, values for
3LF proteins were within the reference ranges stated
ove.
hole gut lavage fluid proteins in patients with
lammatory bowel disease
vages were performed in patients with inflammatory
iwel disease (71 with Crohn's disease and 31 with ul-
rative colitis), heterogeneous with respect to disease
stribution, activity and treatment. Abnormally high
ncentrations of WGLF IgG were present in 64%
these (44 with Crohn's disease and 21 ulcerative
litis), of albumin in 52% (35 with Crohn's disease
d 19 ulcerative colitis) and of A1AT in 36% (28 with
ohn's disease and nine with ulcerative colitis; Figs
6).
hole gut lavage fluid proteins in patients with
lorectal cancer
lart from inflammatory bowel disease, colorectal
ncer was the only diagnostic category for which a
bstantial number of patients had abnormal results,
ita were available for 10 patients and one or more



















Fig. 4. Concentrations of immunoglobulin (Ig) C in whole gut
lavage fluid (WGLF) from patients with Crohn's disease, ulcera¬




Fig. 5. Concentrations of albumin in whole gut lavage fluid (WCLF)
from patients with Crohn's disease, ulcerative colitis or colorectal
cancer.
ofWGLF IgG was high in four cases, albumin high in
six and A1AT high in two (Figs 4-6).
Whole gut lavage fluid proteins in other diseases
Details of the diagnoses and WGLF results in 98 pa¬
tients with other conditions are given in Table 1.
Small bowel disease
Only four out of 29 patients with small bowel dis¬
ease had a high value for one or more of the WGLF
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Table 1. Proteins in whole gut lavage fluid (WGLF).
Abnormal WGLF proteins (|ig/ml)
No. of lavages No. of patients with
performed normal WGLF proteins IgG Albumin A1AT
coeliac disease 4 4
bacterial overgrowth 4 4
ileal resection 3 3
lymphangiectasia 1 - 14 36 195
giardiasis 1 1 1 3 21
idiopathic diarrhoea 15 13 2 5 31
enteropathy-associated T cell lymphoma 1 - 41 70 19
Other benign colorectal disease
colonic diverticulosis (uncomplicated) 10 10
perforated diverticulitis 1 - 85 18 10
eosinophilic colitis 1 1
microscopic colitis 1 1
ischaemic colitis 1 1
collagenous colitis 1 1
lymphocytic colitis and common variable 1 - 18 68 29
immuno-deficiency radiation proctitis (treated) 3 3
solitary rectal ulcer 2 2
rectal prolapse 1 1
pelvic ileal reservoir 4 4
pelvic ileal reservoir with pouchitis 1 - 120 34 27
Other significant disease
gastrointestinal 27 27
systemic 15 14 18 48 V

















Fig. 6. Concentrations of a-1-antitrypsin (A1AT) in whole gut
lavage fluid (WCLF) from patients with Crohn's disease, ulcera¬
tive colitis or colorectal cancer.
patients; a man with lymphangiectasia and protein-los¬
ing enteropathy and a coeliac man with enteropathy-
associated T cell lymphoma, which was extensively ul¬
cerated with local perforation and an abscess cavity
communicating with the gut. Two out of eight patients
with idiopathic diarrhoea (i.e. severe watery diarrhoea
with no diagnosis reached after investigation had hi
values for A1AT (21 and 31 pg/nil, respectively),
Colorectal disease
Three out of 27 patients with various non-malign;
colorectal diseases had high values for WGLF prote
concentration. These were a young man with immi
odeficiency, several auto-immune diseases and ly
phocytic colitis whose diarrhoea is steroid-responsf
a patient with pouchitis, and an 81-year-old worn
with severe diverticulitis, local perforation, peri-div
ticular abscess and a colovesical fistula.
Other diseases
WGLF protein concentrations were normal in 41 c
of 42 patients with various other gastrointestinal a
systemic disorders; the exception was a woman w
lung cancer and widespread abdominal metastases.
Discussion
Our finding of increased concentrations of IgG
WGLF from patients with Crohn's disease was
chance as we were merely evaluating the use of ELI
techniques for immunoglobulin and antibody me
urements which had originally been developed 1
saliva [2]. Since then, we have conducted a prospect
study ofWGLF protein concentrations in 53 inflamn
tory bowel disease patients and found a remarkal
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>se correlation between the concentration ofWGLF
ateins, particularly IgG and albumin, and various
rreral measures of activity in inflammatory bowel
;ease [8]. This study also showed that WGLF pro-
n measurements cannot be used to screen for the
ssence or absence of inflammatory bowel disease,
irmal results were obtained in several patients with
ictive disease but who still had striking radiological
pathological changes such as ulceration and stric-
es.
this series, when cases judged to be immunologi-
ly normal are excluded, there were 98 examina-
ns in patients without inflammatory bowel disease.
15 of these, a positive result was obtained for one
more of the assays performed. In the majority of
>es, and in all those with multiple abnormal re-
Its, the existence of gastrointestinal protein loss was
keeping with the clinical picture; one patient with
nphangiectasia, seven with malignant colorectal tu-
)urs, two with intra-abdominal abscesses communi-
ang with the gut, one with pouchitis and one with
usual lymphocytic colitis. Plasma leakage detected
WGLF protein assays (presumably gastrointestinal
Dtein loss) clearly can occur in a range of clinical
nations although the majority of positive results are
inflammatory bowel disease patients.
isease activity' in inflammatory bowel disease is a
her nebulous entity but well recognized by clini-
ins in their overall clinical assessments which rely
avily on subjective factors such as general well¬
ing and presence or absence of abdominal pain
3,11]. Objective tests such as erythrocyte sedimen-
ion rate, platelet count and blood concentrations of
Lite phase proteins provide supportive evidence in
me patients, and the present clinical and laboratory
ihniques of assessment of inflammatory bowel dis-
se activity are satisfactory in 80 to 90% of patients,
iwever, we suggest that a direct approach to the
lasurement of active intestinal inflammation will be
eful from time to time in inflammatory bowel disease
tients. For example, there are patients with Crohn's
;ease in whom blood parameters of inflammation
2 negative yet active disease is suspected. This is of-
l the case in patients with duodenojejunal disease
with recurrent small bowel disease after procto-
lectomy. Our tests may also allow an assessment
the relative contribution of primary inflammatory
>wel disease activity to overall disability in patients
10 also have pyogenic complications such as wound
urinary tract infections, or inflammatory diseases of
tier systems such as ankylosing spondylitis.
gut lavage is now widely used for bowel prepara-
m prior to endoscopy, radiology and surgery, WGLF
r laboratory analysis can often be obtained in the
urse of a standard clinical workup. Lavage fluid, coi¬
ned as described above, is aesthetically acceptable to
moratory staff, resembling urine rather than faeces
and specimens can be stored at — 70°C for several
months without deterioration. We suggest that this
new and direct approach to clinical investigation of
gut immunity will prove useful in many clinical and
research situations, including the analysis of illness
and of response to treatment in some complex in¬
flammatory bowel disease patients. We have had the
opportunity to study a single patient with an estab¬
lished disease of chronic protein-losing enteropathy,
lymphangiectasia, but our experience suggests that
protein assays in WGLF could replace the tedious
isotope-based techniques traditionally used to detect
and monitor this condition.
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Gut Lavage Fluid Protein Concentrations: Objective Measures of
Disease Activity in Inflammatory Bowel Disease
CHINTAMANENI P. CHOUDARI, SEAMUS O'MAHONY, GORDON BRYDON, OBEDY MWANTEMBE,
and ANNE FERGUSON
Gastro-lntestinal Unit, Western General Hospital and University of Edinburgh, Edinburgh, Scotland
Background: Fluid obtained by whole gut lavage nor¬
mally contains traces of immunoglobulin (Ig) G, albu¬
min, and a-1-antitrypsin; higher concentrations have
been found in patients with inflammatory bowel dis¬
ease (IBD). Methods: In a prospective study, 53 la¬
vages were performed in 45 IBD patients (27 Crohn's
disease, 18 ulcerative colitis), in whom disease activ¬
ity was simultaneously assessed by Crohn's Disease
Activity Index or Powell Tuck index. Concentration of
IgG in lavage fluid was measured by enzyme-linked
immunosorbant assay, and of albumin and a-l-anti-
trypsin by immunoturbidimetry. Results: For IgG, con¬
centrations in lavage fluid correlated closely with activ¬
ity indices; in Crohn's disease, r = 0.723 (P <
0.0001), in ulcerative colitis, r = 0.714 (P < 0.0001).
Results for albumin and a-1-antitrypsin concentra¬
tions were similar to those for IgG, but they were less
sensitive in detecting active disease. However, this
method cannot be used as a diagnostic test for IBD;
normal results were obtained for IgG in 6 (all inactive)
cf 42 lavages in patients who had unequivocal radiolog-
cal or endoscopic abnormalities. Conclusions: Assay
cf protein concentrations in gut lavage fluid is a simple,
abjective means of grading disease activity in patients
with IBD; its potential uses are likely to be in the evalua¬
tion of complex cases and in clinical trials.
The Crohn's Disease Activity Index (CDAI), devel¬oped in the 1970s,1 has proved a reliable and re¬
markably reproducible measure of health status in pa¬
rents with Crohn's disease (CD). In theory, the CDAI
is vulnerable to criticism because it is heavily weighted
ay subjective factors ofgeneral well-being and abdomi¬
nal pain, and investigators have argued that the CDAI
s not so much a measure of disease activity as of gen¬
eral disability. Many factors apart from intestinal in-
lammation will contribute to the index, including
nfection, obstruction, malnutrition, psychological
dysfunction, and the side effects of drugs. Neverthe-
ess, the CDAI and similar indices for ulcerative colitis
TJC) activity, such as the Powell-Tuck index (PTI),2
provide standards for the assessment of any new ap¬
proach to the measurement of disease activity in IBD.
Whole gut lavage is now widely used as a bowel
preparation for barium enema, endoscopy, or colorec¬
tal surgery.3 The clear fluid passed after initial colonic
cleansing is essentially a gut perfusate. It contains se¬
creted immunoglobulins (Ig) and antibodies and, after
appropriate processing, provides ideal material for the
clinical investigation of intestinal humoral immu¬
nity.4'5 Normally, whole gut lavage fluid (WGLF)
contains only trace amounts of IgG, but in two sepa¬
rate groups of 10 and 44 patients with active IBD we
found concentrations of IgG that were significantly
higher than those of controls.5,6 We also found high
concentrations of WGLF albumin with a positive
correlation between lavage IgG and albumin content,
suggesting that these tests are measuring plasma leak¬
age across inflamed mucosa.6
In the present prospective study, gut lavage has been
performed on 53 occasions in 45 well-characterized
patients with CD or UC, and WGLF concentrations of
IgG and of two plasma-derived proteins, albumin and
a-1-antitrypsin (A1AT), were measured. At the same
visit the CDAI or PTI as appropriate was calculated,
blood was taken for measurements of erythrocyte sedi¬
mentation rate (ESR), platelet count, and C-reactive
protein (frequently used, single indices of activity),
and the physician's global assessment was quantified
by using a visual analogue scale (VAS) of 0-120.
We aimed to establish whether assay of WGLF pro¬
teins could be used as a diagnostic test for IBD and to
assess to what extent concentrations of proteins in
WGLF parallel the global indices, CDAI and PTI. Do
the results of this investigation make it possible to
Abbreviations used in this paper: A1AT, alpha-l-anti-trypsin;
ELISA, enzyme-linked immunosorbant assay; ESR, erythrocyte sedi¬
mentation rate; PRU, Protein Reference Unit; PTI, Powell-Tuck index;
VAS, visual analogue scale; WGLF, whole gut lavage fluid.
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grade severity within "active" disease or to detect min¬
imal abnormalities in patients with CDAI of <150 or
PTI of <4 (i.e., classified as inactive)? Does this ap¬
proach offer any advantage over conventional clinical
tests (ESR, C-reactive protein, platelet count) or a
physician's global assessment (recorded on a VAS for
the purpose of this investigation)?
Material and Methods
Subjects
A total of 45 patients with IBD were studied, 27
with CD (11 male, 16 female) and 18 with UC (8 male, 10
female). The diagnosis and disease extent in all patients were
confirmed by"histology, endoscopy, and radiology. Full de¬
tails are given in Table 1. The patients were classified into
various subgroups by the nature of previous resections and
current macroscopic disease. Five CD patients and 1 UC
patient were studied twice, and 1 man with UC was studied
three times. In 44 of the 53 studies, gut lavage was being
performed as bowel preparation for colonoscopy or barium
enema examination; in 4 cases lavage was performed as prep¬
aration for surgery; and in 5 cases it was performed to empty
Table 1. Clinical Details of 45 Patients With IBD
























































the gastrointestinal tract before treatment with an elementa
diet.
Clinical Assessments
Patients completed a diary card of symptoms for th<
week preceding the lavage. Haematological and biochemica
indices included haemoglobin, platelet count, ESR, C-reac
tive protein, total protein, and albumin and serum Igs. A1
patients were clinically assessed by one of us (C.P.C.), anc
the CDAI or PTI was calculated in the standard fashion. Ir
addition, the physician's assessment of overall disease activ
ity for the day of lavage was recorded on a VAS, this being
based on symptoms, signs, and results of the blood tests.
The study was approved by the Medicine Subcommittei
of the Lothians Area Ethics of Research Committee.
Lavage Protocol
Patients drank 4 L of isotonic nonabsorbable poly
ethylene glycol-based lavage fluid (Golytely; Braintree Lab
oratories, Inc., Braintree, MA) at a rate of 250 mL ever
10-15 minutes. Usually within 2 hours solid feces wen
passed followed by liquid feces, which were followed b1
several large-volume, virtually clear fluid "stools." An ali
quot of the first completely clear specimen was collected fo
analysis. The procedure was supervised by an experiencet
nurse and performed either in a general in-patient ward o
in the gastrointestinal out-patient investigation suite.
Processing of Whole Gut Lavage Fluid
Specimens were processed within 10 minutes of col
lection. Fluid, 20 mL, was filtered through a GF/A (What
man Scientific Ltd., Kent, England) glass fibre filter. Th<
following reagents were added to 10 mL of the filtrate, witl
mixing after each addition (final concentrations in brack
ets): soya bean trypsin inhibitor in phosphate buffered salim
(80 |lg/mL); sodium ethylenediaminetetraacetic acid ii
phosphate buffered saline (15 mmol/L); phenyl methyl sul
phonyl fluoride in 95% ethanol (2 mmol/L); sodium azidi
(1 mmol/L); and newborn calf serum (5% volume).
Aliquots of processed WGLF were then stored at —70°C
Analytical Methods
Sample analysis for IgG was by enzyme-linked im
munosorbant assay (ELISA),5 using affinity-purified goa
anti-human IgG (North East Laboratories) and, as stan
dard, human reference serum from the Protein Refereno
Unit (PRU), Royal Hallamshire Hospital, Sheffield.
Albumin and A1AT were assayed by immunoturbidimet
ric procedures. Anti—human albumin was supplied by th<
Scottish Antibody Production Unit, and anti—human A1A1
was obtained from the PRU. WGLF was diluted in PEC
6000 reagent in tris buffer pH7 with and without antibod'
and incubated for 15 minutes. Turbidity was measured a
340 nmol/L in a flow-through spectrophotomete
(PU8610, Phillips). Standard plots of albumin and A1A7
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values over the range 0-200 |Xg/mL were prepared from
Human Reference Serum (PRU), diluted in 0.9% NaCl con¬
taining 48 g/L PEG 3350.
Statistical Analysis
Correlation coefficients were calculated by using the
Spearman Rank Correlation test.
Results
The patients studied were heterogeneous in dis¬
ease distribution and in their previous and current
treatment. In CD, the CDAI range was from 24 to 321;
24 lavages were in patients with CDAI of >150 (de¬
scribed below as having active disease) and 8 in pa¬
tients with a CDAI <150 (in remission). In patients
with UC, the PTI ranged from 0 to 13; 13 lavages were
in patients with active disease (PTI of >4), and 8 were
in patients in remission with a PTI of <4.
Whole Gut Lavage Fluid Protein
Concentrations
Reference ranges for WGLF IgG, albumin, and
Ad AT have previously been established by studies of
33 immunologically normal subjects: 20 men, age
"ange 15—80, and 43 women, age range 24—88, who
were all taking a normal diet without being given im¬
munosuppressive or anti-inflammatory drugs. Normal
/alues are for IgG <10 (Ig/mL, for albumin <26 |lg/
riL, and for A1AT <19 (Xg/mL.7
Values for WGLF protein concentrations in pa-
dents with CD and UC are shown in Figure 1 and are
slotted against CDAI or PTI as appropriate.
Diagnostic Potential of Whole Gut Lavage
Fluid Tests
The possibility that WGLF protein concentra-
ions are always high when there is overt intestinal
mucosal inflammation (on radiological or endoscopic
visualization) would provide a means of screening pa¬
rents for the presence or absence of IBD. This issue
tas been considered by analysis of the results for
iVGLF IgG. High values for IgG concentration were
tresent in only 24 of the 27 lavages performed in pa-
ients who had unequivocal macroscopic small bowel
tr colonic CD and in 13 of the 15 lavages in patients
vith UC who had positive radiograph or endoscopic
indings. There was also one patient with microscopic
:vidence of colonic CD and no macroscopic disease;
towever the WGLF IgG concentration was high.
Whole Gut Lavage Fluid Proteins and
Disease Activity
IgG, Crohn's disease. In 32 lavages from pa-
ients with CD, values for WGLF IgG concentration
were normal in 9. Seven of these were in patients in
remission, and 1 was in an 18-year-old man with a
borderline CDAI of 168. He had ankylosing spondyli¬
tis, and his anorexia and high ESR shortly after right
hemicolectomy for CD were thought to reflect activity
of arthritis rather than of CD. There was one patient
with WGLF IgG concentration of 10 (Xg/mL and
CDAI of 185.
Abnormally high concentrations of WGLF IgG
were present in 23 patients of whom 22 had active
disease. A 13-year-old boy with perianal CD and unex¬
plained abdominal pain had a CDAI of 119 and a
WGLF IgG concentration of 20 JXg/mL. During the
next 6 months his growth stopped and pain became
worse; both problems have resolved with systemic ste¬
roid therapy.
IgG, ulcerative colitis. In 21 lavages from pa¬
tients with UC, values for WGLF IgG concentration
were normal in 8 patients (of whom 7 were in remis¬
sion) and high in 13 patients (12 with active disease).
Both discrepant cases were patients who had had un¬
equivocally active disease two weeks before and were
in the early stages of Sulphasalazine or oral corticoste¬
roid treatment respectively.
Albumin. In 32 lavages from patients with CD,
values for WGLF albumin concentration were normal
for 15 patients (8 of these patients were in remission
and CDAI in the others ranged from 168-283). Albu¬
min concentration levels were high in 17 patients, all
of whom had active disease.
In 21 lavages from patients with UC, values for
WGLF albumin concentration were normal for 12 pa¬
tients (of whom 8 were in remission) and were abnor¬
mally high in 9 patients, all of whom had active dis¬
ease.
A1AT. I n 32 lavages from patients with CD,
values for WGLF A1AT concentration were normal
for 17 patients (of whom 7 were in remission) and
were high in 15 patients (14 with active disease). In 21
lavages from patients with UC, values for WGLF
A1AT concentration were normal in 14 patients (of
whom 7 were in remission) and high in 7 patients (6
with active disease).
Correlation of Lavage Proteins
Concentrations With Activity Indices in
Active and Inactive Disease
Correlation coefficients for WGLF protein
concentrations against activity indices are detailed in
Table 2. For both CD and UC and for all three proteins
studied, there was a highly significant positive correla-


































































Figure 1. Concentrations of IgG, albumin, and A1 AT in WGLF taken from patients with CD and UC and plotted against CDAI and PTI, respectively.
tion between activity index and WGLF protein con¬
centration, with rvalues ranging from 0.439 to 0.723.
Because, as shown clearly in Figure 1, the relation¬
ship between activity index and lavage protein con¬
centration is not linear but biphasic, correlations were
separately calculated for cases with active and inactive
disease (as defined by CDAI and PTI). Calculations
were also performed for the subsets of CD patients
with active colonic and active small bowel disease.
The results (Table 2) show that there are significant
correlations only in active disease; that the highest r
values were found for IgG vs. CDAI in active CD (r =
0.821), particularly in the subset with active small
bowel CD (r = 0.970); and that in active UC, although
there was good correlation between WGLF IgG con¬
centration and the PTI (r = 0.740), the other two pro¬
teins did not show significant correlation with the
PTI. In inactive CD and UC, WGLF protein concen¬
trations were independent of activity indices.
Conventional Laboratory Indices of
Disease Activity
For the purposes of this analysis, patients with
CD who had a CDAI of > 150 and those with UC who
had a PTI of >4 have been designated as having active
disease. The numbers of cases with abnormal and nor¬
mal values for ESR, C-reactive protein, and platelet
count in the active and remission groups are given in
Table 3. This table also includes, for comparison, num¬
bers with normal and abnormal WGLF IgG, albumin
and A1AT values, and the physician's overall assess¬
ment based on a VAS.
The three blood indices were normal in most pa¬
tients with inactive disease. However, they were also
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lavages r P r P r P
rohn's disease
All 32 0.723 <0.0001 0.588 <0.0001 0.439 <0.01
Active 24 0.821 <0.0001 0.547 <0.01 0.293 NS
Inactive 8 0.217 NS -0.352 NS 0.160 NS
Active colonic 8 0.778 <0.05 0.507 NS 0.468 NS
Active small bowel 10 0.970 <0.0001 0.547 NS 0.359 NS
Icerative colitis
All 21 0.714 <0.0001 0.701 <0.0001 0.527 <0.02
Active 13 0.740 <0.01 0.610 <0.05 0.600 <0.05
Inactive 8 -0.318 NS -0.378 NS -0.041 NS
OTE. P > 0.05.
S, not significant.
ormal in many patients with unequivocally active
isease, and this was particularly so in the group of 13
isessments in active UC; ESR was normal in 8 cases,
-reactive protein was normal in 10, and platelet
aunt was normal in 8.
Discussion
The degree of illness in a patient with IBD is
ot directly related to the length of bowel grossly af-
:cted. Factors such as the severity of local inflamma-
on and nonspecific "disease activity" are also rele-
ant. There is an urgent need for simple and objective
idices of these separate components of overall disabil-
y for use in clinical practice and research.
There have been many attempts to develop a single
idex of illness in IBD1'2'8"13 by combining a few clini-
il and/or laboratory criteria, and claims have been
lade for the significance of single laboratory determi-
ations in some situations.14-18 We have been exploit-
ig the relatively new method of bowel cleansing by
hole gut lavage and have reported that whole gut
vage fluid (WGLF), appropriately processed, has
considerable potential as a source of material for clini¬
cal evaluation of intestinal immunity and inflamma¬
tion.5
In an initial technical appraisal of ELISA as applied
to WGLF, we found high concentrations of IgA but
only trace amounts of IgG (<5 (Ig/mL) in fluid from
control subjects, whereas there were significantly
higher IgG concentrations in WGLF from 10 patients
with active CD.5 This was confirmed in a separate
cohort of patients with active CD who also had sub¬
stantial amounts of albumin in WGLF, indicating that
these tests may be detecting plasma leakage into the
gut.6 In further work, assay of A1AT has been in¬
cluded in the protocol because fecal A1AT concentra¬
tion and clearance are widely accepted as indices of GI
protein loss.
With a view to the introduction of this new test into
clinical practice, we also carried out a retrospective
review of results for 140 lavages in symptomatic pa¬
tients7 to establish whether concentrations of these
proteins in WGLF are high in conditions other than
active IBD. Assays of WGLF obtained on 102 occa-
ible 3. Presence of Normal or Abnormal Values for Conventional Laboratory Indices of Disease Activity, Global Assessment,
WGLF IgG, Albumin, and A1AT Concentrations in Patients With CD and UC Arbitrarily Subdivided Into Active or









No. of Normal High Normal High Normal High Normal High Normal High Normal High
lavages (<20) (>20) (< 1 -5) (>1.5) Normal High (0-60) (61-120) (^10) (>10) (<26) (>26) (<19) (>19)
ihn's disease
Active (CDAI > 150) 24 5 19 8 16 6 18 1 23 2 22 7 17 10 14
nactive (CDAI < 150) 8 5 3 8 0 7 1 7 1 7 1 8 0 7 1
erative colitis
Active (PTI > 4) 13 8 5 10 3 8 5 2 1 1 1 12 4 9 7 6
nactive (PTI < 4) 8 8 0 8 0 7 1 6 2 7 1 8 0 7 1
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sions from 95 patients with IBD of varying activity
revealed high concentrations of IgG in 65 (64%), of
albumin in 53 (52%), and of A1 AT in 37 (36%). High
WGLF IgG concentrations were present in a patient
with lymphangiectasia, in 1 of 5 patients with non-
IBD forms of colitis, and in only 1 of 32 patients with
other conditions (a value of 11 pg/mL). These results
and comparable findings for albumin and A1AT sup¬
ported the view that high WGLF protein concentra¬
tions are relatively specific markers of active IBD.
We now report a prospective study based on 53 la¬
vages in patients with UC or CD fully characterized
with regard to anatomical distribution of disease and
investigated for various single and composite activity
indices at the time of the lavage. The aims of this study
were to determine whether assay of WGLF proteins
can be used as a diagnostic test for IBD and whether
this completely objective procedure can substitute for
or complement currently used clinical tests and indices
of disease activity. We have used the best currently
available index, the CDAI, as the reference measure of
disease activity in CD and a similar index for UC, the
PTI.
The present study shows that WGLF protein con¬
centrations, particularly IgG, discriminate well be¬
tween active and inactive IBD and, within the subsets
of patients with active disease, closely parallel disease
activity as defined by CDAI and PTI. Furthermore,
these sensitive tests were completely normal in most
patients with CDAI <150 and PTI <4, strongly sup¬
porting the present clinical trials practice whereby
such values are taken as successful end points, indicat¬
ing that remission has been achieved.
However WGLF protein assays cannot be used as
screening or diagnostic tests for IBD. Although high
values are found in many patients, the data in this
paper clearly show that values are normal in clinically
inactive disease, even when there are unequivocal ra¬
diological or endoscopic features of IBD such as cob¬
blestone ulcers and long, stringlike strictures. Never¬
theless in our clinical practice we are finding that assay
of WGLF IgG is a valuable aid to diagnosis in some
clinical situations, e.g., in patients with microscopic
CD, when IBD coexists with severe diverticular dis¬
ease, and in separating the effects of intestinal and joint
disease in IBD patients with ankylosing spondylitis.
There is abundant evidence to implicate IgG in the
pathological lesions of IBD, particularly CD: immuno-
histochemistry reveals an excess of IgG-containing
cells deep in the mucosa19'20; isolated intestinal mono¬
nuclear cells from IBD patients spontaneously secrete
high amounts of IgG21'22; and there are differences in
intestinal plasma cell IgG subclass distribution be
tween controls, UC and CD patients.23 Thus, when w
first noted the presence of IgG in WGLF, we consic
ered that it was probably derived from the abundar
IgG cells in diseased mucosa. However, the findings c
high concentrations of two plasma proteins, albumi
and A1AT, in lavage fluid from patients with activ
IBD suggests that at least some of the IgG is plasmt
derived. Furthermore, all three protein concentration
were low in WGLF from some inactive CD patieni
who have extensive chronic ulceration of the intestin
(diseased tissues known to be replete in IgG cells).
It could be argued that these sensitive tests at
merely measuring plasma proteins entering the gut k
men as a result of bleeding. However, in active IBL
when abundant amounts of the three proteins are pre:
ent in WGLF, their relative concentrations differ sut
stantially from those in plasma. The three proteir
differ in molecular weight (IgG, 150,000 daltons; a
bumin, 69,000 daltons; A1AT, 45,000 daltons), an
we suggest that there is a selective increase in mucost
to-lumen permeability in active IBD operating eithe
at the level of the capillary or the epithelial basal larr
ina.
We have also considered whether analytical factoi
could explain the different results for the three pre
teins studied in relation to discrimination between ac
tive and inactive disease. Although the technique
used differ, co-efficients of variation, between-rur
and within-run, are similar for the three assays £
10%—15%.7 Although fluids are processed within mir
utes of collection, proteins leaking proximally into th
gut lumen will have been exposed to pancreatic an
bacterial proteases during the transit of fluid along th
gut (1-2 hours). Ex vivo experiments show that £
37°C, degradation of albumin by unprocessed WGL
is significant (loss of 10%—40% of measured albumi
in 1 hour), whereas IgG and A1 AT are relatively resi:
tant to such proteolysis. This could explain the diffei
ences in results for IgG and albumin in active disea:
but not the relative insensitivity ofWGLF A1AT cor
centrations.
Various scientific approaches to the measuremer
of disease activity in IBD have recently been n
viewed.24'25 Laboratory tests such as ESR, platele
count, acute phase proteins, are useful. However the
may be normal in active IBD, particularly in UC an
in small bowel CD (e.g., Table 3) and will be positiv
in situations of active inflammation or infection witl
out gut involvement. Other techniques, such as labele
leucocyte studies26'27 and measures of GI protein lo:
by A1AT clearance,28"30 have advantages and disac
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antages, which have been fully discussed else¬
where.6'24,25 In general, they have been developed and
pplied without being subjected to prospective evalua-
ion against the carefully developed standard activity
ndices such as CDAI. Furthermore, labeled leucocyte
tudies are expensive, involve exposure to radioactiv-
ty, and depend on complete fecal collection. The find-
ngs with these tests relate to events in macroscopically
fFected gut and thus differ with those obtained with
he gut lavage technique, which appears to measure a
more diffuse phenomenon.
There may be problems in interpretation of isotope-
'ased or A1 AT clearance studies if the treatment used,
uch as elemental diet therapy, changes intestinal tran-
it rate or otherwise influences defecatory function;
his could either mask or mimic changes resulting
rom specific anti-inflammatory effects of the test
reatment. Because the standard protocol for collec-
ion of whole gut lavage fluid is not influenced by
oncurrent dietary or pharmacological treatment, this
aethod should lend itself to clinical trials.
Because gut lavage is now widely used for bowel
reparation before endoscopy, radiology, and surgery,
CGLF for laboratory analysis can often be obtained in
he course of a standard clinical work-up. Lavage fluid,
ollected as described above, is aesthetically acceptable
a laboratory staff, resembling urine rather than feces,
nd specimens can be stored at — 70°C for several
aonths without deterioration. Concentration of IgG
t WGLF assayed by ELISA discriminates very well
etween active and inactive IBD and accurately grades
ae degree of activity. We suggest that this new and
irect approach to clinical investigation of gut immu-
ity will prove useful in the analysis of illness and of
jsponse to treatment in some complex IBD patients
nd has considerable potential in clinical trials of anti-
iflammatory and immunomodulatory regimens.
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Fecal Occult Blood Testing Will Fail to
Detect Colonic Polyps
Dear Sir:
In the June 1993 issue ofGASTROENTEROLOGY, an original report'
and an editorial3 debate at length the evaluation of fecal occult blood
(FOB) tests for the detection of colorectal neoplasia. Improvements
in the screening or case finding of tumors by this approach will
require not only refinements in specimen collection, handling, and
analytical techniques, but also assume that the lesions to be detected
are, in fact, bleeding.
When gut lavage with polyethylene glycol-based solutions is used
for bowel cleansing, the clear gut lavage fluid passed at the end of
the procedure, whole gut lavage fluid (WGLF), is essentially a gut
perfusate and can be used for immunological, biochemical, and cyto-
logical studies. For research purposes, the lavage is supervised by an
experienced nurse with a defined protocol for fluid ingestion and is
administered at a gut perfusion rate of around 20 mL/min.
In relation to the investigation of gastrointestinal bleeding, we
have found that hemoglobin (Hb) can readily be assayed in WGLF
by using the HemoQuant technique; this allows detection and quanti¬
fication of chronic bleeding from any level of the gastrointestinal
tract without interference in the analysis by dietary constituents and
uninfluenced by patient-related variables such as intestinal transit
time. We have already reported our preliminary experience of the
application of this approach*; our further data are relevant to the
debate on the potential values of FOB testing.
Reference values for WGLF lib, based on results in 43 normal
individuals, are 2.50 ± 1.13 flg/mL (mean ± SD; range, 1-5.4 fJg/
mL).
In the course of immunological research, we have collected WGLF
from a series of unselected hospital inpatients (to use as "diseased
controls"; these include 25 patients with colorectal tumors). Values
for WGLF Mb were abnormally high in all of 12 patients with
colorectal cancer (198 ± 313; range, 13.6-990 fig/mL). There were
13 patients with benign colorectal polyps. In the 5 cases with small
polyps (<2 cm) and in 6 of 8 with larger polyps, WGLF Mb concen¬
tration was in the range 1-4 flg/mL, i.e., completely normal. The
two patients with high values were a woman with multiple sessile
polyps (WGLF Mb, 6.3 Jig/mL) and a man with three polyps, one of
which (4X4 cm) had areas of moderate dysplasia (WGLF Mb, 20
Pg/mL).
These data show that colorectal cancers diagnosed in general clini¬
cal practice have a high frequency (in this small series, 100%) of
occult bleeding, but only a minority of benign polyps bleed. A screen¬
ing strategy based on FOB testing is entirely rational for cancer
detection but will miss the majority of benign colorectal polyps.
GORDON BRYDON, B.Sc., M.R.C.Path.
ANNE FERGUSON, FRCP., F.R.C.Path., F.R.S.E.
Gastrointestinal Unit
University of Edinburgh and Western General Hospital
Edinburgh, Scotland EH4 2XU
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Reply. My colleagues and I thank Drs. Brydon and Ferguson for
their comments on our report.1 Their data based on MemoQuant
assay of whole gut lavage fluid suggests that blood loss is normal in
most patients with large adenomas. There are several reasons why we
would challenge that conclusion. First, it is not clear whether blood
loss measured in lavage fluid equates with blood loss in "real life,
and their assays presumably were performed on single samples, not
on samples collected over several days as is usual with fecal occult
blood testing.
Second, despite the precision of the assay,2 HemoQuant is not the
best method for detection of low grade bleeding from the large bowel;
immunochemical tests that detect only hemoglobin and guaiac tests
that detect only hemoglobin and heme provide better discrimination
between normal subjects and those with low-grade bleeding.1'* Al¬
though we found considerable overlap in MemoQuant estimates of
blood loss between patients with adenomas and normal subjects, mean
blood loss was higher in the patients with adenomas.5
Perhaps the most compelling evidence comes from the randomized
controlled trials of occult blood testing for colorectal cancer, in which
the yield of large adenomas exceeds that of small adenomas in subjects
with positive Hemoccult tests.4 If detection of adenomas was caused
by serendipity, the reverse would be expected. The high yield of large
adenomas supports the view that the positive Hemoccult tests were
indeed produced by low-grade bleeding from the adenomas.
D. JAMES B. ST. JOHN, M.B.B.S., F R C P., F.R.A.C.P.
Department of Gastroenterology
The Royal Melbourne Hospital
Melbourne 3030, Australia
1. St. John DJB, Young GP, Alexeyeff MA, Deacon MC, Cuthbertson
AM, Macrae FA, Penfold JCB. Evaluation of new occult blood tests
for detection of colorectal neoplasia. Gastroenterology 1993; 104:
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Use of whole gut perfusion to investigate
gastrointestinal blood loss in patients with iron
deficiency anaemia
























Iron deficiency anaemia may be due to
occult bleeding into the gut. However,
although clinical investigations may show
a high frequency of gastrointestinal tract
disease in these patients, the cause-effect
relationship between the lesions detected
and anaemia remain uncertain. This
study aimed to establish whether lesions
detected by endoscopy or imaging of the
gastrointestinal tract in patients with
unexplained iron deficiency anaemia are
bleeding continuously. Routine clinical
tests were performed in 42 patients with
unexplained iron deficiency anaemia
referred to this unit. Whole gut lavage and
assay of haemoglobin in the gut perfusate
were also performed. The main outcome
measures were clinical diagnoses (by
imaging and endoscopy of the upper
gastrointestinal tract and colon); the con¬
centration of haemoglobin in whole gut
lavage fluid; and the calculated gastro¬
intestinal blood loss per day. There were
73 clinical, dietary, or iatrogenic factors of
possible aetiological importance in the 42
patients - poor diet (10), gross gastro¬
intestinal abnormality (34 in 28 patients),
malabsorption (14), coagulation problems
(6), and NSAID use (9). The gut lavage
test showed, however, that at the time the
test was performed, only eight patients
were losing more than 2 ml blood daily
into the gut, including all four with colonic
cancer, one with diffuse gastric vascular
ectasia, and one with severe ulcerative
oesophagitis. It is concluded that occult
gastrointestinal bleeding sufficient to
cause anaemia was evident in only 19% of
42 patients. There was a high frequency of
other potential causes of iron deficiency in
the remainder, suggesting that most of
the gastrointestinal diseases and lesions
detected in them were probably coinci¬
dental. Factors other than blood loss
should be considered and treated in
patients referred for anaemia assessment.
{Gut 1996; 38: 120-124)
Keywords: occult gastrointestinal bleeding, colon
cancer detection, whole gut perfusion, dietary iron
deficiency, iron malabsorption.
Iron deficiency anaemia may be the only
clinical manifestation of ulcerative oesopha¬
gitis, benign or malignant gastric ulcer,
duodenal ulcer, large benign colonic polyps, or
colonic cancer. Thus, it is normal clinical
practice to examine the upper and lower
gastrointestinal tract by x ray or endoscopy,
or both, in patients with unexplained iron
deficiency. High detection rates for lesions
capable of causing blood loss are reported - for
example, 57%, 60%, and 70% respectively in
recent series from the USA,1 Australia,2 and
England.3 Accurate measurements of the
amounts of blood lost into the gut in these
patients have not been performed, however,
and so the cause-effect relationships between
the lesions detected and the anaemia remain
uncertain.
We have recently reported that when peroral
gut lavage with a non-absorbable fluid is used
for bowel cleansing, the clear fluid passed per
rectum at the end of the procedure (whole gut
lavage fluid, WGLF) is essentially a gut
perfusate.4 For research purposes the lavage is
supervised by an experienced nurse with a
defined protocol for fluid ingestion, to give a
gut perfusion rate of around 20 ml per minute.
Blood loss during the test, from any level of the
gastrointestinal tract, can be detected and
measured by assay of haemoglobin (Hb) in
WGLF.5 We have used this new test in a series
of patients with iron deficiency anaemia in
order to assess which of the gastrointestinal
lesions detected are chronically and




Forty two patients referred to gastrointestinal
physicians with unexplained iron deficiency
anaemia were investigated over an 18 month
period. Twenty six were women aged between
40 and 85 years (median 66) and 16 were men
aged between 43 and 86 years (median 72).
Entry criteria were a low blood Hb concentra¬
tion (<130 g/1 in men, <115 g/1 in women)
together with two of the following: low mean
cell volume (<76 fl), low serum ferritin (<10
peg/I), low serum iron (<14 |xmol/l), and
reticulocyte response with rise in Hb after oral
iron treatment.
In order to establish reference values for the
WGLF Hb concentration, assays were per¬
formed in WGLF from 22 healthy volunteers
and 15 patients with simple constipation or
trivial, functional gastrointestinal symptoms;
there were 23 men and 14 women, median age
32 years, range 19-86.
Reproducibility of the technique was
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assessed indirectly, by examining results of
WGLF Hb measurements in pairs of samples
which had been collected from 40 patients or
healthy volunteers in the course of other
research projects, or as part of their routine
clinical care, including 10 pairs of specimens
from patients with active inflammatory
bowel disease, before and after initiation of
treatment.
CLINICAL ASSESSMENT
As part of the initial clinical interview and
examination, we recorded not only gastro¬
intestinal symptoms and clinical signs but also
the quality of the diet and current or recent use
ofNSAIDs, aspirin, or anticoagulants.
Upper gastrointestinal endoscopy, rigid
sigmoidoscopy, and barium enema or colono¬
scopy, or both, were performed in 40 patients.
In two patients, when the first endoscopy
examination showed a carcinoma (one gastric,
one colonic) other booked investigations were
cancelled. These patients have not been
excluded from the series since examination of
the gastrointestinal tract was completed at
laparotomy. Although the planned protocol
included endoscopic duodenal biopsies for the
diagnosis of coeliac disease, these were, in fact,
obtained from only 25 patients, and a further
three had a Watson capsule biopsy of the
jejunum.
GUT LAVAGE PROCEDURE
Gut lavage was performed as preparation for
barium enema or colonoscopy examination.
Supervised by a research nurse, patients drank
isotonic lavage fluid (Klean-Prep, Norgine
Ltd, UK), at a rate of one glass (200 ml) every
10-15 minutes, until clear fluid was being
passed per rectum. A sample was collected and
stored at —70°C.
ASSAY OF HAEMOGLOBIN AND CALCULATION OF
BLOOD LOSS
Haemoglobin in WGLF was assayed by the
Hemoquant technique, which measures bacte-
rially degraded as well as intact Hb.6 The
blood Hb concentration was measured in a
sample taken on the day of lavage and gastro¬
intestinal blood loss per day was calculated as:
WGLF Hb concentration (|xg/ml)X28-8
=ml blood lost/d
Blood Hb concentration (g/1)




Initial Hb values in the 16 men ranged from
61-119 g/1 (mean 90 g/1), and in the 26 women
they ranged from 45-114 g/1 (mean 85 g/1).
Many patients had symptoms of anaemia such
as tiredness, lethargy, and breathlessness but
few had significant gastrointestinal symptoms.
One woman developed dysphagia while
being investigated; five patients reported
dyspepsia, three heartburn, one constipation,
and two diarrhoea.
There were 10 patients whose diet was
clearly deficient in iron-containing foods (as
judged at clinical interview by one of us (AF,
AW, or MM); formal dietary assessment was
not performed. Nine patients had been taking
NSAIDs when the anaemia was diagnosed but
at the time of their gastrointestinal investiga¬
tions the drugs had been withdrawn from eight
of the nine. Four patients had been on long
term anticoagulant therapy, which had been
stopped in one case. There was a further
patient with a bleeding diathesis due to
idiopathic thrombocytopenic purpura and one
woman with alcoholic liver disease also had
abnormal coagulation.
MALABSORPTION
Twelve patients had a gastric abnormality
likely to lead to iron malabsorption. Seven of
the 12 had had a partial gastrectomy for peptic
ulcer disease many years previously and the
other five had atrophic gastritis.
Small bowel biopsy tissue from one woman
with no gastrointestinal symptoms and a diet
deficient in iron showed pathology typical of
coeliac disease. Coeliac disease was probable
in one other patient with an oesophageal
carcinoma. She had old rickets and gave a
history of macrocytic anaemia with a normal
Schilling test 25 years ago; unfortunately the
endoscopist had not taken a duodenal biopsy
but ELISAs were positive for serum IgA and
WGLF IgA antibodies to gliadin.7
OTHER GASTROINTESTINAL DISEASES
DETECTED
Standard x ray and endoscopic investigations
produced many positive results, including six
carcinomas (Table I). Indeed there were only
seven patients in whom no lesion was found:
TABLE I Gastrointestinal diseases and other factors of




Partial gastrectomy without gastritis 4


















Previously anticoagulated now stopped 1
Idiopathic thrombocytopenic purpura 1
Alcoholic liver disease 1
Drugs:
Previously taking NSAID 8
Current on NSAID 1
Poor diet:
Iron deficient diet 10







Figure 1: FVesence ofgastrointestinal (Gl) diseases and of other aetiological factors in 42
patients with iron deficiency anaemia. In 28 patients, one or more gastrointestinal disease
was detected by imaging or endoscopy, or both; in 10 the diet was judged by an experienced
clinician to be deficient in iron; and 14 patients had diseases associated with iron
malabsorption. As shown, there was significant overlap between these groups and with the
presence of other relevant factors such as use of non-steroidal anti-inflammatory drugs
(NSAIDs) or coagulation abnormality.
two of these had iron deficient diets, one had
alcoholic liver disease, one had previously
taken NSAIDs, leaving only three of the 42




Values for WGLF Hb in the 37 volunteers and
patients with a normal gastrointestinal tract,
ranged from 1-0-5-4 p.g/ml (mean 2-50, SD
1-13). We have therefore set the reference
range for this measurement as 1-5 p,g/ml.
Thirty sets of duplicate samples were from
individuals with normal values for WGLF
Hb at the first test. In all cases the value for
the second sample was also normal; mean
table ii Concentrations of IgG (reflecting disease
activity) and of haemoglobin, in whole gut lavage fluid
(WGLF) from a series ofpatients with inflammatory bowel
disease who had gut lavage performed twice within a four
week period






Crohn's 55 24 10 5
disease 93 60 22 9
144 82 162 145
137 54 58 14
27 9 12 9
216 41 15 9
44 34 9 8
101 11 14 4
Ulcerative 254 102 151 25
colitis 188 2 23 4
difference in duplicate values was 0-96 p,g/ml
(range 0-3). There were 10 pairs of specimens
from patients with inflammatory bowel
disease, one sample collected in relapse, and
one after a variable clinical improvement on
treatment. A shown in Table II, concentrations
of IgG and of Hb in WGLF parallelled disease
activity: Hb concentrations were lower in the
specimen collected after treatment, but in most
cases the values were still above the reference
range.
Twenty five of the 42 patients with iron
deficiency had values for WGLF Hb within the
normal range. There were a further seven
patients with marginally raised concentrations
(6-8 p.g/ml, calculated daily gastrointestinal
blood losses 1-2-1-7 ml/d), including two
patients with malignant disease (gastric cancer,
6 |xg/ml, 1 -2 ml/d, oesophageal cancer 6 pg/ml,
1-3 ml/d). Two patients had WGLF Hb con¬
centrations of 10 and 12 |xg/ml, with
calculated blood losses of borderline clinical
significance at 2-0 and 2-1 ml/d, and there were
only eight patients with unequivocally high
values (taken as WGLF Hb >10 p,g/ml, and
calculated blood loss >2 ml/d during the
lavage procedure) (Fig 2). This group included
all four patients with colon cancer (blood
losses 5-132 ml/d).
Discussion
In view of the very high rates of detection of
gastrointestinal diseases in anaemic patients, it
has been entirely reasonable to assume that
chronic blood loss from the gut is the com¬
monest cause of iron deficiency anaemia in
men and in postmenopausal women.8 Lack of
correlation with positive faecal occult blood
test has generally been attributed to deficien¬
cies in the guaiac based faecal occult blood
methods, which are relatively insensitive and
preferentially detect blood loss from the
distal gastrointestinal tract. A further factor
is that bleeding may occur in the form of
multiple intermittent episodes, rather than as a
continuous ooze.
The accurate measurement of bleeding into
the gut requires a suitable assay for Hb or some
other component of red blood cells, applied to
a specimen representative of gut luminal
contents - ideally a complete five or seven day
faecal collection or several separate faecal
samples. Problems associated with tests on
faeces include not only the resistance to collec¬
tion and handling of faecal specimens by
patients, nurses, and laboratory staff, but also
the potential interference in analyses by
residues of meat and other dietary con¬
stituents. Patient-related variables such as
intestinal transit time and faecal bulk are also
relevant. The Hemoquant method is a highly
sensitive analytical technique, which measures
both intact and bacterially metabolised
haemoglobin7; when this is used to test a timed
specimen of faeces collected after a period on a
meat free diet, it can detect and quantify blood
loss from the proximal or distal gut. We have
previously reported that this method can also
readily be used with WGLF.5 Use of gut
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Figure 2: Distribution (within the classification shown in Figure 1) and diagnosis, for the eight patients in whom
gastrointestinal blood loss (based on the whole gut lavage fluid test) was estimated to be more than 2 ml daily.
perfusion fluid as an assay material overcomes
the need for dietary restrictions and unpleasant
faecal collections, and specimens can be
obtained when peroral gut lavage is being used
to cleanse the bowel before colonic investiga¬
tions. The reference range for WGLF Hb
concentrations, 1-5 |xg/ml, equates to daily
blood losses of around 0-2-1 ml/d. The main
theoretical disadvantage of this new test of
gastrointestinal bleeding is that the sampling
time is limited to a few hours; further experi¬
ence, and comparisons between WGLF and
five day faecal collections, should show how
frequently occult bleeding is discontinuous,
and in what time frame.
Review of the results of WGLF Hb
measurements highlights the complexity of
possible aetiologies in the 42 iron deficient
patients studied. Altogether 73 clinical,
dietary, or iatrogenic factors were recorded -
poor diet (10), gross gastrointestinal abnor¬
mality (34 in 28 patients), malabsorption (14),
coagulation problems (6), and NSAID use (9).
However, out test of gastrointestinal bleeding
detected only eight patients who were losing
more than 2 ml blood daily into the gut,
including all six patients with lesions generally
recognised to be important causes of occult
bleeding - four with colonic cancer, one with
diffuse gastric vascular ectasia, and one with
severe, ulcerative oesophagitis.
There are several possible explanations for
the findings. In some patients with low or
normal values for WGLF Hb, gastrointestinal
bleeding may be intermittent rather than a
continuous ooze, as discussed above. The
lesion responsible for blood loss might have
healed in the interval between diagnosis of
anaemia and investigation. This may well have
been the case in NSAID treated patients, eight
of whom had the drugs stopped as soon as
anaemia was recognised. It seems likely,
however, that in many instances, the
gastrointestinal lesions detected by standard
investigations were simply not bleeding, and
the anaemia was the result of some other
cause. In the patients with calculated daily
blood loss of less than 2 ml/d, based on the
WGLF test, there was a high frequency of
other conditions which might lead to iron
deficiency, such as poor diet or malabsorption.
Regrettably, in developing the protocol for the
study we did not arrange a formal assessment
of dietary iron intake, but a general appraisal of
the diet was made by an experienced and
nutritionally aware clinician. Nevertheless, this
is an example of how the emphasis which we
and others have placed on the development of
better tests for gastrointestinal bleeding leads
to relative neglect of these other clinically
important features.
Absorption and bioavailability of dietary
iron, and iron malabsorption, are partly inter¬
related. The amount of inorganic iron which is
absorbed is greatly influenced by the nature of
other foods taken at the same time.10 A much
higher proportion of haem iron than inorganic
iron is absorbed,11 12 and malabsorption syn¬
dromes may affect one and not the other - for
example, in coeliac disease there is malabsorp¬
tion of ferrous but not of haem iron.13 Optimal
inorganic iron absorption requires healthy
gastric and small bowel mucosae, and so will
be compromised after gastric surgery, and
probably also in patients with atrophic gastritis
and hypochlorhydria. There were seven (17%)
patients in our series who had had a
partial gastrectomy many years before. Coeliac
disease may be expressed as a single nutrient
deficiency, and some form of small bowel
biopsy should be included in the investigation
of all iron deficient patients. Free iron loss
into the gut in association with high rates of
epithelial cell proliferation and loss, is another
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potential factor in patients with coeliac disease
or gastritis.14
In iron deficient patients reported recently,
serious diseases detected vary somewhat
because of different aims of the studies, entry
criteria, age, and sex. However, in all reports,
a significant minority of patients with
unexplained anaemia is found to have
completely asymptomatic colonic cancer -
9-5% of our 42 patients - a good yield of
potential curable, serious disease. There is no
reason to change current clinical practice;
patients with unexplained iron deficiency
should have colorectal endoscopy or imaging,
and probably upper gastrointestinal endoscopy
at the same time. But in the majority who do
not have colorectal cancers, more attention
needs to be paid to the completion of the
diagnostic process - separate recognition of
bleeding and non-bleeding lesions, or dietary
iron deficiency, and of iron malabsorption due
to hypochlorhydria or coeliac disease.
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providing a source of the deficient complement protein,
allowed generation of the membrane-attack complex, thus
causing bacterial lysis and endotoxin release. Serum from
two C6-deficient patients showed impaired bactericidal and
endotoxin-releasing activity in vitro. Thus, whereas C6-
deficient serum has no intrinsic bactericidal or endotoxin-
releasing activity, addition of normal plasma or purified C6
reconstitutes this activity by allowing assembly of the
membrane-attack complex. These data suggest that,
compared with immunocompetent patients, patients with
a terminal-complement-component deficiency show a
reduction in endotoxin release during gram-negative
infection coincident with an inability to generate the
membrane-attack complex and cause bacterial lysis.
Therefore, although unable to deal effectively with
the organism, terminal-complement-component-deficient
patients may have a decreased morbidity because they are
not exposed to the sudden release of endotoxin that can
occur after meningococcal infection.
Evidence that deficiency of the terminal complement
component may offer a selective advantage comes from a
study from the Cape area of South Africa. Among families
with a history of neisserial infection, Orren and colleagues9
found more C6-deficient individuals than expected. They
reasoned that C6-deficient individuals show an exclusive
susceptibility to neisserial infections. However, tissue
damage after all gram-negative infectionsmay be less severe,
suggesting a biological advantage in having a terminal-
complement-component deficiency. Decreased endotoxin
release could account for the limited tissue damage, and our
in-vitro studies with E coli suggest that the mechanism for
limiting endotoxin release may operate for gram-negative
organisms other than neisseria.
The administration of FFP to complement-deficient
patients may be hazardous because of the possibility of
provoking acute endotoxin release.
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Haemoglobin in gut lavage fluid as
a measure of gastrointestinal
blood loss
W. Gordon Brydon Anne Ferguson
To detect and measure occult gastrointestinal
bleeding, we have measured haemoglobin
concentrations (by HemoQuant) in the clear fluid
obtained after whole-gut lavage. In subjects with
healthy gastrointestinal tracts, lavage-fluid
haemoglobin concentrations were 0-5-5-1 mg/L,
equivalent to daily blood loss of 0-1-1-1 mL. High
concentrations were found for patients with
colorectal cancer, severe diverticular disease, and
rectal varices, in seven of sixteen patients with active
inflammatory bowel disease, and in four patients
with iron-deficiency anaemia thought to be due to
gastrointestinal bleeding. In these four patients,
estimated blood loss ranged from 2-6-24-5 mL per
day. This method could have various research and
clinical applications.
Lancet 1992; 340: 1381-82.
Available methods for the detection and quantification of
gastrointestinal bleeding are accompanied by such
difficulties as interference by dietary constituents, dilution
by faecal bulk, sensitivity too high or too low, inability to
detect bleeding from the upper gastrointestinal tract, the
need for complete faecal collections over several days, and
the use of radioactive tracers.1 Whole-gut lavage is used to
cleanse the bowel for barium enema or colonoscopy, and the
lavage fluid is useful for clinical investigation and research in
intestinal immunity.26 We tried to find out whether
measurement ofhaemoglobin in whole-gut lavage fluid was
a feasible approach to detection and quantification of
gastrointestinal blood loss in clinical practice.
Whole-gut lavage was done as bowel preparation for barium
enema, colonoscopy, or colonic surgery, in the treatment of severe
constipation, and in healthy volunteers for research purposes. A
diagnosis was assigned to each patient after review of the case notes
several weeks after the lavage procedure, by a physician unaware of
the lavage fluid test results. Patients with inflammatory bowel
disease were judged to have active disease if the IgG concentration
in whole-gut lavage fluid was greater than 10 mg/L.5
Subjects drank 4 L isotonic non-absorbable polyethylene-glycol-
based lavage fluid (Golytely, Seward Medical, London, UK), 250
mL every 10-15 min. Solid then liquid faeces were passed, within
2 h in most patients, followed by several large volumes of virtually
clear fluid. The first volume of completely clear fluid was collected













Healthy IBD Acute Potentially Probable
subjects upper Gl bleeding occult Gl
bleeding colonic bleeding
disease
Concentrations of haemoglobin in whole-gut lavage fluid.
IBD = inflammatory bowel disease (0 = active; d = inactive).
Gl = gastrointestinal. A = benign colonic polyp; ■= colorectal cancer;
X = rectal varices; ▲ = severe diverticular disease.
for analysis; a sample was stored at — 70°C, without filtration or
other processing.
Lavage-fluid haemoglobin was measured by the HemoQuant
method, in which haemoglobin is converted to fluorescing
polyphyrins; the reported sensitivity is less than 10 mg/L.7 A
three-step purification process eliminates any interfering
fluorescent material, and fluorescence of the acid extract is
measured at 600 nm in a spectrofluorimeter. The haemoglobin
standard used was a simulated lavage fluid, containing 100 mg/L
human haemoglobin in 60 g/L polyethylene glycol 3350, 0-9%
sodium chloride, and 0 02% sodium azide.
Haemoglobin concentrations in lavage fluid from eleven
subjects diagnosed as having healthy gastrointestinal tracts
ranged from 0-5 to 51 mg/L. The rate of fluid passage along
the gut during lavage is about 0 02 L/min, so the estimated
24 h haemoglobin loss into the gut is 14—147 mg. The daily
blood loss (in mL) is equal to 28-8 times the lavage-fluid
haemoglobin concentration divided by the blood
haemoglobin concentration (taken as 140 g/L).
Seven of sixteen patients with active inflammatory bowel
disease (six Crohn's disease, one ulcerative colitis) had high
concentrations of haemoglobin in gut lavage fluid, whereas
concentrations were normal or borderline in patients with
inactive disease (figure). Four patients who had lately bled
acutely from gastric lesions had normal haemoglobin
concentrations in lavage fluid, as did six of seven patients
with benign colonic polyps; the exception was a womanwith
a polyp of 2 cm diameter, who was on long-term
anticoagulant therapy. High concentrations were also found
in patients with colorectal cancer, portal hypertension and
rectal varices, severe diverticular disease of the colon, and
iron-deficiency anaemia thought to be due to occult
gastrointestinal bleeding. In the last group, the calculated
daily blood losses were 2-6 mL (von Willebrand's disease),
5-3mL (severe oesophagitis, on aspirin treatment), 11-8mL
(previous gastric surgery and stomal ulcer), and 24-5 mL
(radiation proctitis and a symptomless gastric ulcer). Of
twenty-four other patients with no clinical features to
suggest gastrointestinal bleeding, twenty-two had normal
lavage-fluid haemoglobin concentrations and two
borderline concentrations (8-8 mg/L in a man with coeliac
disease and lymphoma and 8-9 mg/L in a man with
pemphigoid).
Whole-gut lavage is safe and simple. After completion of
bowel cleansing, the clear fluid passed per rectum can be
used for various clinical investigations and research
techniques. Lavage fluid usually contains 0-5-2 0 mg
protein per mL (unpublished) of which 20-30% is IgA.2"4
There are trace amounts of plasma-derived proteins in
lavage fluid from healthy subjects, and gastrointestinal
protein loss is greatly increased in active inflammatory
bowel disease.5 This study shows that gut losses of
haemoglobin can be detected and measured by means of
whole-gut lavage. The estimated daily blood loss among our
normal subjects is similar to values calculated from studies
with radiolabeled red cells.8,9
The HemoQuant method detects blood loss from the
proximal gastrointestinal tract as well as from the colon.
Thus it could be used to measure daily blood loss, in
accurately timed faecal collections taken with the patient on
a meat-free diet, as an alternative to studies with
radiochromium-labelled red cells. Whole-gut lavage offers
many practical and aesthetic advantages over faecal
collections, and preparative and analytical laboratory
methods are simpler.
Since gut lavage is now widely used before endoscopy,
radiology, and surgery, lavage fluid for laboratory analysis
can often be obtained without additional cost or patient
discomfort. Measurement of lavage-fluid haemoglobin
could have applications in the investigation of patients with
iron-deficiency anaemia and suspected occult
gastrointestinal bleeding and in assessing the importance of
blood loss in patients, such as those with inflammatory
bowel disease, in whom poor diet and malabsorption may
also contribute to chronic iron-deficiency anaemia.
Research studies based on this method should define the
frequency and magnitude of gastrointestinal bleeding in
patients taking anticoagulants or non-steroidal anti¬
inflammatory drugs and those with bleeding disorders and
will establish whether colorectal polyps and cancers bleed
into the gut.
We thank the nursing staff of the Clinical Investigation Suite for their help
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Hospitals Endowments Research Trust and the National Association for
Colitis and Crohn's disease.
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